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ABSTRACT 
 Huntington’s disease (HD) is a devastating, genetic, neurodegenerative 
disease for which there is currently no effective therapy.  The polyglutamine 
(polyQ) expansion that causes HD is in the first exon (HDx1) of huntingtin (Htt). 
However, other parts of the protein, including the 17 N-terminal amino acids 
(AAs) and two proline (polyP) repeat domains, modulate the toxicity of mutant Htt 
(mHtt). The role of the P-rich domain that is flanked by the polyP domains has 
not been explored. Using highly specific intracellular antibodies (intrabodies; 
iAbs), we tested various epitopes for their roles in mHDx1 toxicity, aggregation, 
localization and turnover. Three domains in the P-rich region (PRR) of HDx1 are 
defined by iAbs: MW7 binds the two polyP domains, and Happs 1 and 3, two new 
iAbs, bind the unique, P-rich epitope located between the two polyP epitopes. In  
cultured cells, we find that the three PRR-binding iAbs, as well as VL12.3, which 
binds an epitope in the N-terminal 17 AA segment, decrease the toxicity and 
aggregation of mHDx-1, but they do so by different mechanisms. The PRR-
binding iAbs have no effect on Htt localization, but they cause a significant 
increase in the turnover rate of mHtt, which VL12.3 does not change. In contrast, 
expression of VL12.3 increases nuclear Htt. These results suggest that the PRR 
domain regulates mHtt stability and toxicity. Thus, compromising this pathogenic 
epitope by iAb binding represents a novel therapeutic strategy for treating HD.  
 We have tested this hypothesis by delivering both VL12.3 and Happ1 to 
the brains of HD model mice using an AAV2/1 viral vector with a modified CBA 
promoter.  VL12.3 treatment, while beneficial in a lentiviral model of HD, has no 
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effect on the YAC128 HD model and actually increases severity of phenotype 
and mortality in the R6/2 HD model.  In contrast, Happ1 treatment confers 
significant beneficial effects in assays of motor and cognitive deficits as well as in 
the neuropathology found in the lentiviral, R6/2, N171-82Q, YAC128 and BACH 
models of HD.  These results indicate that increasing the turnover of mHtt using 
AAV-Happ1 gene therapy represents a highly specific and effective treatment 
possibility for HD.  
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Chapter 1 
Introduction 
  Huntington’s disease is an autosomal dominant, progressive, 
neurodegenerative disorder that results from the expansion of a polyglutamine 
(polyQ) tract in HDx-1 (Huntington's disease collaborative research group,1993). 
At least nine other neurodegenerative diseases are caused by the expansion of a 
polyQ tract, including several types of spino-cerebellar ataxia (Orr et al., 1993; 
Kawaguchi et al., 1994; Imbert et al., 1996; David et al., 1997), dentatorubral 
pallidoluysian atrophy (Koide et al., 1994), and spino-bulbar muscular atrophy 
(Spada et al., 1991). In each case, the polyQ expansion is in a different protein, 
and although the mutant protein is expressed widely, only a specific subset of 
neurons, unique to each disease, die.  Although expression of pure polyQ is 
sufficient to cause toxicity (Marsh et al., 2000; Yang et al., 2002), it is the protein 
context surrounding the polyQ expansion that makes particular neurons 
susceptible in each disease.  In HD, the mutant protein, mutant huntingtin (mHtt), 
exhibits toxic gain of function, which includes aggregation, sequestering of 
important cellular proteins, aberrant protein-protein interactions, disruption of the 
ubiquitin proteasome, and dysregulation of axonal transport, transcription, and 
mitochondrial metabolism (Ramaswamy et al., 2007; Rosas et al., 2008).  This 
leads to chorea, dementia, weight loss and loss of striatal medium spiny neurons 
(MSNs) as well as some cortical neurons (Nakamura and Aminoff, 2007).  
 The simple genetic nature and autosomal dominant transmission of HD 
should facilitate therapy development.  Unlike Alzheimer’s and Parkinson’s 
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diseases (AD and PD), which are predominately idiopathic and not diagnosed 
until significant neuronal loss has occurred, there is an opportunity for reliable 
pre-symptomatic treatment of HD. This allows for neuroprotective strategies 
rather than more complicated restorative strategies such as fetal graft 
transplantation or strategies for coping with existing neuronal loss such as L-
Dopa treatment for PD. Surprisingly, the therapies currently available to HD 
patients are aimed at symptom management rather than disease process.  
These include SSRIs and atypical anti-psychotics for psychiatric disturbances 
and tetrabenzine for chorea (recently, the first drug to be approved by the FDA 
specifically for the treatment of HD)(Huntington Study Group, 2006).  Though HD 
has a single genetic cause, it has a very complex pathology with detrimental 
effects on a wide variety of cellular processes. As a result, a wide variety of 
therapies aimed at downstream events have been investigated in both pre-
clinical and clinical trials. 
 Pre-clinical experiments involve the use of animal models.  In the case of 
HD there are C. elegans, Drosophila, rodent, sheep, and non-human primate 
(NHP) models available.  These models are generated by neurotoxic lesion or 
genetically by viral delivery or germline manipulation.   
The short experimental time frame of C. elegans and Drosophila models is 
well suited to high throughput screening and proof of principal studies.  However, 
the simplicity of the C. elegans nervous system and the absence of higher brain 
structures and endogenous Htt in Drosophila lessen the impact of therapeutic 
trials using these models. 
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Despite the large number of available HD mouse models, no one model 
completely recapitulates the human disease (Ehrnhoefer et al., 2009). 
Transgenic mice expressing N-terminal mHtt fragments (which are much more 
toxic than full-length mHtt), such as the R6/2 and N171-82Q lines, exhibit rapid 
onset of progressive motor and cognitive deficits, weight loss, Htt inclusion 
formation, and striatal atrophy accompanied by ventricular enlargement, but no 
loss of MSNs (Mangiarini et al., 1996; Carter et al., 1999; Lione et al., 1999; 
Schilling et al., 1999).  These models are also limited to therapeutic strategies 
directed at the N-terminus of mHtt, so they cannot be used to study modifiers of 
mHtt toxicity with sites of action outside of this area such as caspase-6 cleavage 
(Graham et al., 2006). Given its rapid symptom onset, the R6/2 line is widely 
used for preclinical testing, but the drawbacks are that it more closely resembles 
a model of juvenile onset HD and its very severe symptoms may be more difficult 
to treat with candidate therapies.  
The N171-82Q model provides a compromise between adult symptom 
onset and a tractable experimental time frame. However, unlike most HD 
transgenic models, which are under the control of the human or mouse Htt 
promoter, transgene expression in the N171-82Q line is driven by the prion 
protein promoter. While the Htt promoter drives evenly distributed, ubiquitous 
expression, the prion protein promoter results in ~8-fold higher transgene 
expression in the cerebellum, leading to cerebellar inclusion formation at a much 
younger age than forebrain inclusion formation (Harper et al., 2005). Thus, 
cerebellar pathology could underlie some of the motor deficits in these mice.  
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Full-length Htt transgenic models, such as the YAC128 and BACHD lines, 
exhibit more human-like, slower, progressive cognitive and motor deficits along 
with striatal atrophy, ventricular enlargement and some selective loss of MSNs at 
later stages. However, their motor deficits are quite mild compared to those seen 
with the N-terminal fragment models, making it difficult to achieve statistically 
significant therapeutic effects and, unlike in the human disease, the YAC128 and 
BACHD mice gain, rather than lose, weight during disease progression (Slow et 
al., 2003; Van Raamsdonk et al., 2005; Gray et al., 2008). The background strain 
of these models, the FVB/N line, is also subject to retinal degeneration 
confounding late stage behavior testing (Taketo, 1991). 
Models of HD induced by viral vectors coding for mHtt, such as the 
lentiviral model, exhibit the striatal neuron loss characteristic of human HD, which 
makes these models very attractive for studying this key aspect of the HD 
phenotype. However, these animals show only mild motor deficits and no change 
in body weight (De Almeida et al., 2002; Regulier et al., 2003).  
Rat models are limited, including neurotoxin and lentivirus-induction 
models (De Almeida et al., 2002) and a single transgenic with onset at greater 
than 12 months (von Hörsten et al., 2003).  All of the rodent models have the 
drawbacks that brain size is too small to employ gene therapy delivery 
techniques valid to human HD, as well as the lack of separation of the caudate 
and putamen, as is the case in humans. 
The newly developed sheep transgenic model has the benefits of being a 
fairly inexpensive genetic model with brain size and morphology much more 
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similar to humans than rodents (Snell et al., 2008). However, the lack of 
established sheep behavioral tests and facilities for the care of late stage disease 
make this model most appropriate for histological studies of the pre-symptomatic 
and early disease stages. Reduction of dopamine- and cyclic AMP-regulated 
phosphoprotein (DARPP-32) immunostaining, a marker of healthy MSNs that is 
diminished in the striatum of HD postmortem brains (Rudnicki et al., 2008), has 
been observed in these animals prior to motor symptoms. The founders have not 
yet reached symptomatic onset, so the extent or existence of motor deficit and 
neurodegeneration is unknown. 
Non-human primate models obviously share the most morphological and 
behavioral homology with humans. However, studies with NHPs are expensive 
and, until very recently, only neurotoxin and viral-induction models of HD were 
available.  Neurotoxin models are not useful for therapies directed at the mHtt 
protein rather than downstream non-specific effects of toxicity. Viral-induction 
models are spatially and temporally limited, thus incapable of fully recapitulating 
human HD.  Thus, it is important that a NHP transgenic model is currently being 
developed.  Preliminary studies indicate behavior and neuropathology similar to 
human HD (Yang et al., 2008). This model has the potential to be very 
informative and predictive for pre-clinical trials. 
 There are many cellular aspects of mHtt toxicity. For instance, it disrupts 
transcriptional regulation, an example of which is dysregulation of CBP, a protein 
that acetylates histones (Steffan et al., 2001). Treatment with histone deacetyase 
(HDAC) inhibitors induces postitive effects in cell culture, Drosophila and 
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transgenic mouse HD models (McCampbell et al., 2001; Ferrante et al., 2003). 
However, toxicity of broad-spectrum HDAC inhibitors has previously limited their 
therapeutic potential.  Recently, isotype-specific HDAC inhibitors, which should 
have fewer side effects, have been validated in Drosophila and transgenic mouse 
HD models (Pallos et al., 2008; Thomas et al., 2008).  A phase I clinical trial of an 
isotype-specific HDAC inhibitor for the treatment of cancer showed safety and 
tolerability (Siu et al., 2008).  
Another example of transcriptional dysregulation in HD is repression of 
brain derived neurotrophic factor (BDNF) expression.  BDNF is produced by 
cortical neurons and is required for striatal neuron survival (Zuccato et al., 2001).  
Over-expression of BDNF or glial derived neurotrophic factor (GDNF) in the rat 
brain is neuroprotective in an excitotoxic HD model (Kells et al., 2004). 
Upregulating BDNF in HD mice with ampakine treatemnt, a positive modulator of 
AMPA receptors, rescues synaptic plasticity and improves long-term memory 
deficits (Simmons et al., 2009). Interestingly, cystamine, a transglutaminase 
inhibitor originally thought to reduce mHtt-induced toxicity by preventing cross-
linking of expanded polyQ molecules, increases BDNF secretion in the brain of 
HD model mice and in the serum of mouse and non-human primate models 
(Borrell-Pagès et al., 2006). A phase I clinical trial of cysteamine treatment, the 
FDA-approved, reduced form of cystamine, shows safety and tolerability 
(Dubinsky and Gray, 2006). 
 mHtt also disrupts glutamate uptake (Behrens et al., 2002), N-methyl-D-
aspartate receptor (NMDAR) signaling (Zeron et al., 2002), and mitochondrial 
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regulation and metabolism resulting in excitotoxicity and oxidative damage. 
NMDAR antagonist treatment improves survival and body weight in HD mice, but 
not motor symptoms (Schiefer et al., 2002). Combinatorial treatment with an 
NMDAR antagonist and a mitochondrial anti-oxidant, coenzyme Q10, improves 
survival, motor deficit and ventricular enlargement of HD model mice (Ferrante et 
al., 2002). However, a phase I clinical trial showed no effect on disease 
progression (Huntington Study Group, 2001), further supporting the idea that 
beneficial results in a single mouse model of HD are not a valid predictor of 
clinical efficacy. Other mitochondrial modifiers such as minocycline, which 
decreases mitochondrial permeability, and creatine, which increases 
mitochondrial stability, have neuroprotective effects (Ferrante et al., 2000; 
Andreassen et al., 2001; Wang et al., 2003b). Both were safe and tolerated in 
clinical trials and modest beneficial effects were reported (Bonelli et al., 2004; 
Hersch et al., 2006). A recent high throughput screen for small molecules that 
inhibit mHtt-induced neuronal death showed that inhibition of mitochondrial 
functions, including electron transport but also coupling and general metabolism, 
is sufficient to rescue cell death (Varma et al., 2007). Mutant Htt represses 
transcription of PGC-1α, a regulator of mitochondrial metabolism, which when 
delivered by lentivirus to the striatum of transgenic HD model mice, prevents 
neuronal atrophy (Cui et al., 2006).  
 There may be advantages in terms of specificity and efficacy in directing 
therapy towards the most upstream HD targets. An obvious approach of this type 
is to reduce the level of mHtt protein itself, either by gene silencing or through 
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increased clearance. RNAi silencing of mHtt with shRNAs or siRNAs can knock 
down mHtt expression and improve HD phenotype in three different transgenic 
HD mouse models (Harper et al., 2005; Rodriguez-Lebron et al., 2005; DiFiglia et 
al., 2007). Both viral-mediated delivery of RNAs and direct neuronal uptake of 
cholesterol-conjugated RNAs have been reported.   One caveat of this approach 
is that current RNAis cannot distinguish between expanded and normal polyQ 
stretches and therefore do not differentiate between wild type (wt) and mHtt.  
They can, however, target human Htt versus mouse Htt. As a result, endogenous 
wtHtt is not silenced in these models although it would be in human HD 
applications. Conditional knockout of wtHtt in adult mice results in progressive 
neurodegeneration (Dragatsis et al., 2000), indicating that silencing of wtHtt may 
not be tolerated. A new study reports that reduction of mouse wtHtt levels by up 
to 80% for up to four months has no negative effects while this same reduction in 
mHtt levels has dramatic beneficial effects (Boudreau et al., 2009), arguing that 
non-allele-specific silencing of Htt in human HD would therefore be a viable 
strategy.  
The general resistance to Htt-associated neurodegeneration in the mouse 
brain should also be considered, however.  If sensitivity to Htt-associated 
neuropathology were similar between mice and humans, heterozygous knock-in 
HD mice with polyQ lengths equivalent to those seen in patients would model 
human HD fairly closely.  In actuality, these mice have no HD-related phenotype 
(White et al., 1997), and in order to model human HD in mice, polyQ expansions 
lengths well above those seen in humans are used, often in the context of a 
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highly toxic N-terminal fragment. For this reason, development of allele-specific 
RNAi is preferable.  This could be accomplished using single nucleotide 
polymorphisms (SNPs), as has been demonstrated for spinocerebellar ataxia 
type 3 (Miller et al., 2003). However, this method would likely require generation 
of custom siRNAs for each patient based on SNP composition. A recent report 
indicates that a large percentage of HD gene positive individuals could be treated 
using a small panel of SNPs that are significantly enriched in HD patients of 
European descent (Warby et al., 2009). However, this approach, still in its 
infancy, would not be useful for a large number of patients. 
A different strategy for reducing mHtt levels involves induction of 
autophagy.  Autophagy is a non-specific degradation process for long-lived and 
mis-folded cytoplasmic proteins.  Induction of autophagy by rapamycin, valproate 
or trehalose results in accelerated clearance of mHtt and subsequent therapeutic 
benefit in fly and mouse HD models (Ravikumar et al., 2004; Sarkar et al., 2007). 
Though wtHtt levels are not affected by this strategy, it is not specific to Htt and 
could potentially have off-target effects.  Ideally, therapeutic action should be 
specific to the mHtt protein. This is why we are exploring the use of an antibody-
based approach. 
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Chapter 2 
 
Intrabodies binding the proline-rich domains of mutant 
huntingtin increase its turnover and reduce neurotoxicity 
 
Southwell AL, Khoshnan A, Dunn DE, Bugg CW, Lo DC, Patterson PH 
J Neurosci. 2008, 28(36): 9013-20. 
 
INTRODUCTION 
The first exon of Htt consists of 17 N-terminal amino acids (AAs) followed 
by the polyQ tract, the PRR, which consists of two polyP stretches that are 
separated by a P-rich domain, and 13 additional AAs (Fig.1A).  The non-polyQ 
domains in HDx-1 are known to modulate the toxicity of the mutant protein, 
although the mechanisms by which this occurs are not well understood 
(Duennwald et al., 2006). Understanding how these non-polyQ domains 
contribute to the toxicity and cellular specificity of mHtt could lead to new 
therapeutic strategies.   
 Classically, the function of a protein domain would be studied by removal 
of that domain followed by functional testing.  Although a great deal of knowledge 
has been acquired through such methods, the deletion of a domain may cause 
altered folding of the remaining protein or otherwise generate effects not related 
directly to the function of the missing domain.  Perturbation of a protein domain 
by intrabody (iAb) binding is a more specific method for exploring function.  
Intrabodies are intracellular, recombinant, single chain antibody fragments (scFv) 
that contain the heavy and light antigen-binding domains (VH and VL) connected 
by a linker. Alternatively, single domain antibody fragments consist of either VH or 
VL. Intrabodies are highly specific reagents that can be targeted to sub-cellular 
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compartments, distinct protein conformations, post-transcriptional modifications, 
as well as to non-protein targets such as oligosaccharides (Biocca and Cattaneo, 
1995; Stocks, 2005; Messer and McLear, 2006; Lo et al., 2008).  Intrabodies 
therefore have great potential to increase our understanding of the functions of 
individual protein domains in living cells.  
 We sought to use iAbs to investigate the role of the PRR of Htt in 
HD pathology, and to explore their efficacy as possible HD therapeutics. The 
PRR is known to be important for mHtt toxic gain of function (Passani et al., 
2000; Steffan et al., 2000; Modregger et al., 2002; Khoshnan et al., 2004; Qin et 
al., 2004), and although a number of PRR binding partners, including WW 
domain-containing proteins, vesicle-associated proteins, P53, and IKKγ, have 
been identified, the mechanism of the modulation of mHtt toxicity by the PRR 
domains remains unclear. To investigate the role of the polyP stretches of the 
PRR domain we used MW7(Ko et al., 2001), a scFv iAb that binds polyP. MW7 
reduces mHtt-induced aggregation and promotes cell survival in culture 
(Khoshnan et al., 2002). It also inhibits mHtt-induced neurodegeneration in a 
Drosophila HD model (Jackson et al., 2004).  However, the specificity of this iAb 
for pure polyP could allow binding to other cellular proteins containing a polyP 
domain, although there is no evidence of the latter binding to date using 
immunoblotting.  To characterize the role of the P-rich stretch of the PRR, we 
produced novel iAbs (Happs) against the P-rich domain of Htt. Happ1 and 3 are 
single domain, light chain iAbs (VLs) that bind mHtt in a PRR-dependent manner.  
We then tested the Happs, MW7 and VL12.3, a single domain light chain iAb that 
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binds the 17 N terminal AAs of Htt (Colby et al., 2004b), for efficacy in blocking 
mHDx-1 aggregation and toxicity in dissociated cell culture as well as in brain 
slice cultures. We also examined their effects on the level of mHDx-1 and its sub-
cellular localization. The most striking findings are that both the anti-polyP and 
anti-P-rich iAbs reduce toxicity by increasing mHtt turnover and lowering mHtt 
level, while the anti-N-terminal iAb appears to reduce mHtt toxicity by a different 
mechanism. 
 
RESULTS 
Isolation of Happ intrabodies.  Novel iAbs against the PRR domain were 
selected in a two-stage protocol. First, a non-immune, human, recombinant scFv 
phage library (Griffin.1)(Griffiths et al., 1994) was used and clones were selected 
that bind a unique, P-rich sequence between the two polyP domains in mHDx-1.  
The second stage involved three rounds of selection using mHDx-1Q50 
(Scherzinger et al., 1997).  Following the second stage, individual clones were 
analyzed for inserts containing open reading frames (ORFs).  Although the 
Griffin.1 library consists of full scFv fragments, the two clones selected had only 
the VL ORFs. A control VL that does not bind Htt (CVL) was also isolated from the 
library. These three VLs (Happ1, Happ3 and CVL) were then inserted into a 
mammalian expression vector for cell culture and brain slice studies. To verify 
the specificity of these iAbs, they were expressed as glutathione-s-transferase 
(GST) fusion proteins and used as primary antibodies to stain lysates of 293 cells 
transfected with HDx1 or HDx1ΔPRR.  The lysates of non-transfected cells were 
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used to test for binding non-Htt cellular proteins (Fig. 1B).  As expected, MW7 
and the Happs bind only to HDx1 containing the PRR, while VL12.3 binds both 
forms of HDx1.  None of these iAbs bind the non-transfected lysates.  These 
results confirm that the Happs require the Htt PRR epitope for binding.   
The intrabodies reduce mHDx-1 aggregation and toxicity.  Each of the 
iAbs was tested at various ratios to mHDx-1 (0.5:1, 1:1, 2:1, 3:1, and 4:1) for 
effects on mHDx-1 toxicity by counting ethidium homodimer-2 (EthHD-2)-positive 
dead cell nuclei (Fig. 2A), and aggregation by counting green foci of the HDx-1-
green fluorescent protein (GFP) fusion protein (Fig. 2B). While VL12.3, Happ1 
and Happ3 reduce aggregation in a dose-dependent, saturable manner, MW7 
displays a threshold effect, requiring a 4:1 ratio to mHtt for effect.  This may be 
the result of its specificity for pure polyP.  As there are two polyP stretches that 
can each likely accommodate binding of two iAb molecules, reduction of 
aggregation by polyP binding may require complete blockade of these epitopes.  
As with aggregation, VL12.3 is also the most effective iAb in reducing toxicity, 
with an optimal ratio to mHDx-1 of 1:1.  MW7 is optimal at a ratio of 4:1, while 
Happ1 and 3 each show an optimal ratio of 2:1, with significant beneficial effects 
at 1:1. Similar effects on mHDx-1-induced toxicity are seen when measuring 
lactate dehydrogenase (LDH) activity released into the culture supernatant (data 
not shown). These results confirm previous findings with iAbs against the N1-17 
AA epitope (Colby et al., 2004b), and further demonstrate that the PRR also 
modulates HDx1 toxicity. As expected, CVL has no dose-dependent effects on 
mHtt-induced toxicity or aggregation. 
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The anti-Htt intrabodies reduce mHDx-1-induced neurodegeneration 
in a cortico-striatal brain slice model of HD.  Rat brain slices, which preserve 
much of the intrinsic circuitry, were biolistically co-transfected with yellow 
fluorescent protein (YFP), mHDx-1-cyan fluorescent protein (CFP) and an iAb. 
Four-5 days after slice preparation and transfection, the number of 
morphologically healthy, transfected MSNs in the striatum of each slice was then 
assessed using YFP fluorescence as an independent reporter of cell type and 
vitality (Fig. 3).  The number of healthy MSNs per brain slice was compared 
between iAb controls (brain slices transfected with YFP + CVL and slices 
transfected with YFP + mHDx-1 + CVL), a negative control (transfected with YFP 
+ mHDx-1 + vector backbone DNA), and the test condition transfected with YFP 
+ mHDx-1 + anti-Htt iAb).   Compared to transfection with YFP + CVL, co-
transfection of mHDx-1 with CVL, results in a significant reduction in healthy 
MSNs. In contrast, co-transfection of mHDx-1 with VL12.3 or Happ1 results in 
numbers of healthy MSNs that are similar to slices transfected with YFP + CVL 
(Fig. 3A). Co-transfection of slices with mHDx-1 + MW7 yields intermediate 
results, with significantly greater numbers of healthy MSNs than with mHDx-1 + 
CVL, but fewer than with YFP + CVL (Fig. 3B).  These results extend the findings 
from 293 cells to MSNs in a semi-intact milieu.  
VL12.3 alters cytoplasmic vs. nuclear localization of mHDx-1. To 
evaluate the effect of the iAbs on HDx-1 intracellular localization, ST14A striatal 
neuronal precursor cells (Cattaneo and Conti, 1998) were co-transfected with 
mHDx-1-GFP and iAb and incubated for 48 hours. Cells were fixed, stained for 
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both iAb and nuclei, and then analyzed by confocal microscopy.  GFP 
fluorescence intensity was used to compare levels of mHDx-1 in the whole cell 
vs. the nucleus (Fig. 4).  The anti-PRR iAbs do not alter the cytoplasmic/nuclear 
mHDx-1 ratio, while VL12.3 causes a significant increase of nuclear Htt (Fig. 4B).  
In terms of localization of the iAbs themselves, VL12.3, Happ1 and Happ3 display 
a slight preference for the nucleus while MW7 is slightly more cytoplasmic (Fig. 
4C). This could be the result of the larger size of the MW7 scFv compared to the 
single domain iAbs.  No significant differences are seen between VL12.3, Happ1 
and Happ3, and the slight preference of VL12.3 for the nucleus is too small to 
account for the increased nuclear HDx-1 in the presence of VL12.3, indicating 
that this change in localization is not the result of the iAb itself targeting the 
nucleus. Thus, iAb binding to the N-terminus of Htt disrupts cytoplasmic vs. 
nuclear trafficking of Htt, which may influence its nuclear functions.  Since the 
amount of nuclear mHtt correlates with toxicity (Truant et al., 2007), this result 
suggests that VL12.3 may not be ideal as a therapeutic iAb despite its clear 
effects on blocking mHtt toxicity.   
The intrabodies differentially alter the level of soluble mHDx-1.  To 
determine the effects of the intrabodies on mHDx-1 levels, 293 cells were co-
transfected with iAb and either wtHDx-1 or mHDx-1, using each iAb at its optimal 
ratio to HDx-1, and incubated for 48 hrs. Soluble and insoluble cell fractions were 
then assayed for HDx-1 by immunoblotting and densitometery (Fig. 5). Each of 
the iAbs dramatically reduces the level of insoluble mHDx-1. However, the three 
anti-PRR iAbs (MW7, Happ1, Happ3) also significantly reduce the level of 
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soluble mHDx-1, while VL12.3 has no significant effect on soluble mutant or 
wtHDx-1 levels.  From a therapeutic standpoint, it is important that only a slight 
reduction of wtHDx-1 protein is seen, indicating that anti-PRR iAbs are selective 
for the mutant form.  Although these iAbs bind wtHDx-1, their preference for the 
mutant form is not unexpected as the interaction of endogenous Htt PRR-binding 
partners with Htt is known to increase with increasing polyQ repeat length 
(Passani et al., 2000; Holbert et al., 2001). 
The anti-PRR intrabodies increase mHDx-1 turnover.  To further 
investigate the reduction of soluble mHDx-1 a SNAP tag fusion labeling 
experiment was performed (Jansen et al., 2007). A traditional pulse chase 
experiment was not used because mHDx-1 is known to affect transcriptional 
regulation.  This property of mHDx-1 could conceivably be altered by iAb binding 
leading to variable transcription rates of HDx-1 in the presence of the various 
iAbs. Traditional pulse-chase experiments require equal transcription and 
translation of the target protein in all conditions within the labeling period.  The 
SNAP tag fusion system allows labeling of all pre-existing HDx-1.  By measuring 
the amount of Htt at the time of labeling and again at a later time point, we are 
able to measure a rate of turnover independent of transcription or translation 
rate. This system also offers greater specificity as only the SNAP tag fusion 
protein is labeled as opposed to all cellular proteins translated during the labeling 
period as with traditional pulse-chase experiments.   
To investigate HDx-1 turnover using the SNAP tag fusion system, 293 
cells were co-transfected with iAb and HDX-1 fused to the SNAP tag. Twenty-
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four hours post-transfection, HDx-1 was labeled using a fluorescent, cell 
permeable SNAP substrate.  This substrate undergoes a covalent binding 
reaction with the SNAP tag and remains fluorescent until the SNAP-tag fusion 
protein is broken down.  Some cultures were immediately examined for HDx-1 
levels while others were incubated for 48 hours post-transfection to allow 
turnover of labeled HDx-1.  Fluorescence intensity of HDx-1-SNAP was used to 
determine the percentage of HDx-1 labeled at 24 hours that is still intact at 48 
hours (Fig. 6).  Cells transfected with HDx-1-SNAP alone were used to determine 
a baseline level of turnover.  While the percentage of mHDx-1 remaining in the 
presence of VL12.3 is equivalent to that in the control, this percentage is 
significantly reduced in the presence of MW7, Happ1 or Happ3, indicating an 
increase in the rate of mHDx-1 turnover specifically in the presence of anti-PRR 
iAbs (Fig. 6B).  The lack of effect of VL12.3 provides a convenient control for non-
specific effects of iAb binding to mHDx-1. Although the mechanism by which this 
increase in mHtt turnover occurs is not yet clear, the levels of iAb protein are 
increased in the presence of mHtt (data not shown), suggesting that mHtt is not 
broken down as a part of a complex with iAb.  This novel ability of anti-PRR iAbs 
to increase turnover of mHtt suggests that this region of the protein is important 
for stability.  Further evidence of the specificity of the iAb effects is shown by the 
fact that none of the anti-Htt iAbs significantly changes the rate of wtHDx-1 
turnover (Fig. 6C). 
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DISCUSSION  
While anti-N-terminal and anti-PRR intrabodies ameliorate the negative 
effects of mHtt in cell culture and brain slice models of HD, they do so with 
different efficacy and by different mechanisms.  These different mechanisms 
offer clues to the specific functions of their target domains.        
The VL12.3 intrabody was isolated from a yeast surface display library and 
initially required a 5:1 ratio to mHtt to reduce aggregation (Colby et al., 2004a).  It 
was then re-engineered, including removal of the disulfide bonds, which do not 
form in the reducing environment of the mammalian cytoplasm (and can cause 
mis-folding of intrabodies (Biocca et al., 1995)), and mutated for greater binding 
affinity to Htt (Colby et al., 2004b). In addition to inhibiting mHtt-induced toxicity 
and aggregation, we find that VL12.3 also alters cytoplasmic vs. nuclear 
trafficking of HDx-1.   
Modulation of Htt intracellular targeting by the N-terminus has been 
recently characterized. Removal of this amphipathic alpha helix causes an 
increase in the level of nuclear Htt, indicating that it functions as a cytoplasmic 
retention signal (Rockabrand et al., 2007). Mutation of hydrophobic residues, or 
the introduction of a helix breaking proline residue in the N-terminal domain 
results in increased nuclear Htt, suggesting that cytoplasmic retention by the N-
terminus is the result of association with organelle and vesicle membranes (Atwal 
et al., 2007). Although the N-terminus is not a dimerization domain, disruption of 
the helical structure also prevents the aggregation of mHtt, which is accompanied 
by an increase in the toxicity of the protein.  Thus, the N-terminus of Htt is 
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required for cytoplasmic localization and the formation of aggregates.  The effect 
on toxicity seen in these experiments may be related to the prevention of 
aggregation, since mHtt-expressing neurons without aggregates exhibit more 
toxicity than those with aggregates (Arrasate et al., 2004).  Toxicity related to the 
N-terminus may also involve altered Htt localization, as the addition of a nuclear 
localization signal to mHtt increases its toxicity in both cell culture and mouse 
models of HD (Peters et al., 1999; Schilling et al., 2004).  Interestingly, while 
removal or mutation of the N-terminus results in increased toxicity, VL12.3 
binding results in reduced toxicity, suggesting that VL12.3 may inhibit formation of 
a toxic conformation or an oligomerization seed molecule. Thus, this intrabody 
may ameliorate toxicity regardless of mHtt localization or aggregation state.   
The polyP and P-rich domains of mHtt are implicated in a number of 
aberrant protein interactions. These domains are required for mHtt binding to, 
and sequestering of, several SH3 domain-containing proteins, including proteins 
associated with vesicle function (Modregger et al., 2002; Qin et al., 2004).  The 
PRR of Htt is required for interaction with WW domain-containing proteins (Staub 
and Rotin, 1996; Faber et al., 1998). These include transcription factors, and 
these interactions are enhanced with increased polyQ repeat length (Passani et 
al., 2000; Holbert et al., 2001). These domains are the site of interaction with 
IKKγ, a regulatory subunit of the IκB kinase complex.  Activation of this complex 
is known to promote aggregation and nuclear localization of mHtt (Khoshnan et 
al., 2004). The PRR of Htt is also the site of P53 interaction and is required for 
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transcriptional repression of P53-regulated genes (Steffan et al., 2000).  Again, 
this interaction is enhanced by increased polyQ repeat length. 
 MW7, an intrabody recognizing pure polyP, reduces mHtt-induced 
aggregation and toxicity in cell culture and in Drosophila models of HD 
(Khoshnan et al., 2002; Jackson et al., 2004).  We find that it is also effective in 
an acute brain slice model of HD, and that it increases the turnover of HDx-1, 
with greater effect on the mutant than the wild type form.  We also produced 
novel intrabodies, Happ1 and 3, which recognize the unique, P-rich epitope 
between the two polyP domains of Htt.  The Happ intrabodies exhibit beneficial 
properties similar to those of MW7 such as preferential effects on the mutant 
form of Htt and increasing turnover without altering localization, but the Happs 
are effective at lower ratios to Htt than MW7.  We found no evidence that the 
anti-PRR intrabodies bind to previously aggregated mHtt, suggesting that the 
observed reduction in aggregation is the indirect result of increased turnover of 
the soluble form of the protein, causing a shift away from the aggregated state.  
The increased turnover of mHDx-1 in the presence of either anti-polyP or anti-P-
rich intrabodies suggests that this effect is a direct result of blocking these 
epitopes and therefore that this domain has a role in modulating stability of the 
mutant protein.   
Disruption of mHtt stability by Happ binding could have therapeutic 
potential.  The success of RNAi experiments show that reduction of mHtt levels is 
an effective therapeutic strategy (Harper et al., 2005; Rodriguez-Lebron et al., 
2005; Machida et al., 2006).  Unlike RNAi however, these intrabodies can 
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distinguish between the wt and mutant forms of Htt, which is preferable, as the 
loss of normal Htt function can have negative effects (Dragatsis et al., 2000; 
Leavitt et al., 2001; Zuccato et al., 2001).  The ability of the Happ intrabodies to 
increase turnover of mHtt may ameliorate the disruption of the ubiquitin 
proteasome seen in HD, although it is presently unclear if this increased turnover 
occurs through a ubiquitin-dependent pathway.  As the levels of intrabody protein 
are increased in the presence of Htt, it is likely that the intrabodies direct the 
breakdown of mHtt without themselves being degraded. Moreover, the Happs, 
although significantly more effective than the original intrabody isolated and 
matured to become VL12.3, have yet to undergo any re-engineering and could 
potentially be improved by removal of disulfide bonds and mutation for greater 
Htt binding affinity. In addition, the present results with the Happ intrabodies 
highlight the importance of the unique, P-rich domain in mHtt toxicity. 
 
MATERIALS AND METHODS 
Cell culture.  HEK 293 (ATCC, Manassas, VA) or ST14A striatal 
precursor cells (Cattaneo and Conti, 1998) were grown in DMEM (Invitrogen, 
Carlsbad, CA.) supplemented with 10% heat-inactivated fetal bovine serum 
(FBS), 2 mM glutamine, 1 mM streptomycin and 100 international units of 
penicillin (Invitrogen). Cells were maintained in 37oC (293) or 33oC (ST14A) 
incubators with 5% CO2 (unless otherwise stated).  Transfections were 
performed using lipofectamine 2000 transfection reagent (Invitrogen) according 
to the manufacturer’s protocol. 
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Immunoblotting. Protein concentration was determined using a BCA 
assay (Pierce, Rockford IL.).  Seventy five μg total protein/sample in a volume of 
30 μl was combined with 6 μl 6X protein loading buffer (Ausubel F.M., 1993), and 
boiled for 5 minutes.  Samples were separated by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS/PAGE) using 4-20% criterion pre-cast 
gels (Biorad, Hercules, CA.) and precision plus protein kaleidoscope molecular 
weight standard (BioRad).  Samples were then transferred overnight to 
nitrocellulose membranes for immunoblotting.  Appropriate primary and 
horseradish peroxidase (HRP)-conjugated secondary antibodies were then 
applied as described in (Ausubel F.M., 1993).  Super signal west dura (Pierce) 
substrate was applied to membranes according to the manufacturer’s protocol.  
Chemiluminescence was detected and densitometry was performed using a 
Fluorchem 8900 (Alpha Innotech, San Leandro CA.) gel doc system.   
Selection of clones from phage display library for binding to P-rich 
epitope of Htt.  Intrabodies were selected from the Griffin.1 human recombinant, 
scFv phage display library (Griffiths et al., 1994). One well of a six well plate was 
coated with a synthetic peptide (200 μg /ml) derived from the P-rich epitope of Htt 
(PQLPQPPPQAQP) located between the two poly P stretches by incubating at 
4oC overnight. Following the provider’s instructions, the coated well was then 
used to select phage expressing intrabodies specific for this epitope.  After the 
fourth round of selection, the phage pool enriched for binding to P-rich peptide 
was purified by PEG/NaCl precipitation and suspended in 2 ml phosphate 
buffered saline (PBS).  
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Generation of bait peptide for isolation of Happ intrabodies.  A 
plasmid encoding mHDx-1Q50-GST (Scherzinger et al., 1997) was transformed 
into XL-10 gold ultra-competent bacteria (Stratagene, La Jolla, CA) according to 
the manufacturer’s protocol.  Cells were grown to an OD of 0.6 at 600 nm and 
induced with 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) for 4 hours.  
Bacteria were collected by centrifugation, and GST fusion proteins were isolated 
in 1 ml 50% glutathione-Sepharose bead slurries containing bound peptide 
(Ausubel F.M., 1993).  Twenty-five μl of each bead slurry was added to 10 μl 
protein loading buffer, boiled for 5 minutes and separated by SDS/PAGE.  
Peptide expression was verified by Coomassie staining of PAGE gels and the 
sizes compared to a protein molecular weight marker (data not shown).   
Selection of Happ intrabodies from P-rich-specific phage display 
library.  One ml of the pre-selected, P-rich-specific phage pool was selected with 
mHDx-1Q50-GST as described in the library provider’s instructions. Briefly, GST-
fusion bait peptide bound to glutathione-sepharose beads was incubated with 
replication deficient phage displaying pre-selected, P-rich scFvs and then 
washed in PBS with 0.1% triton X-100 to remove unbound phage particles.  
Bound phages were allowed to infect log phase bacteria. To repeat selection, 
M13 helper phages, which do not display scFvs but enable the replication of scFv 
displaying phages from pre-infected bacteria, were used to recover selected 
phages. This selection was repeated an additional two times.  After the final 
round of selection, individual clones were screened for inserts by the polymerase 
chain reaction (PCR)(Griffiths et al., 1994). Six clones with inserts were identified 
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(Happ1-6).  Inserts were sequenced and analyzed for open reading frames 
(ORFs).  Three clones were found to contain ORFs, two of which were 
redundant.  The two unique ORFs (Happ1 and 3) were amplified by PCR using 
primers designed to add both appropriate restriction sites and a C-terminal 
hemaglutinin (HA) epitope tag, and cloned into the AAV (adeno-associated virus) 
genome plasmid (Stratagene) mammalian expression vector for characterization 
in cell culture, and also into the pGEX-6p1 GST fusion (Amersham Biosciences, 
Piscataway, NJ.) bacterial expression vector for protein purification.  A control 
intrabody that does not bind HDx-1 (CVL) was also isolated from the library and 
cloned into these vectors. Cloning was performed according to the Invitrogen 
One-shot top 10 competent cell protocol.   
Htt aggregation and toxicity assays.  HEK 293 cells were co-
transfected with mHDx-1Q103-GFP and intrabody (iAb) in poly-D-lysine-coated 
24 well plates at ~60% confluency.  Each well received 0.2 μg mHDx-1 DNA in 
pcDNA3.1 vector and iAb (VL12.3, MW7, Happ1, Happ3, or CVL) DNA in AAV 
vector at various ratios to HDx-1 (0.5:1, 1:1, 2:1, 3:1, 4:1).  DNA levels were 
normalized to 1 μg per well using CVL in AAV vector.  Non-transfected wells were 
used as a negative control, and each condition was performed in triplicate.  
Cultures were moved to a 33oC incubator 8 hours post-transfection to slow cell 
division and maintain a monolayer.  At 40 hours post-transfection, cells were 
incubated in medium containing 1 mM EthD-2 (Invitrogen) for 15 min at 33oC for 
detection of dead cell nuclei.  Cells were then fixed in 4% paraformaldehyde 
(PFA) at 4oC for 30 minutes and permeabilized with PBS containing 0.1% triton 
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for 15 minutes. For detection of all nuclei, cells were treated with PBS containing 
0.5 μg/ml DAPI.  Fluorescence microscopy was used to visualize dead cells (red 
channel), large Htt aggregates (green channel), and total cell number (blue 
channel).  Three representative microscope fields were analyzed for each well (9 
per condition).  Dead cells and aggregates were counted for each field and 
normalized to the total cell number.  P values were computed using two-way 
analysis of variance (ANOVA) and Bonferroni post-hoc test. 
Brain slice neurodegeneration assay.  All animal experiments were 
performed in accordance with the institutional Animal Care and Use Committee 
and Duke University Medical Center Animal Guidelines.  Brain slice preparation 
and biolistic transfection were performed as previously described (Lo et al., 1994; 
Khoshnan et al., 2004).  Briefly, brain tissue was dissected from euthanized 
postnatal day 10 (P10) CD Sprague-Dawley rats (Charles River Laboratory, 
Raleigh, NC) and placed in ice-cold culture medium containing 15% heat-
inactivated horse serum, 10 mM KCl, 10 mM HEPES, 100 U/ml 
penicillin/streptomycin, 1 mM MEM sodium pyruvate, and 1 mM L-glutamine in 
Neurobasal A (Invitrogen).  Brain tissue was cut in 250 μm thick coronal slices 
using a Vibratome (Vibratome, St. Louis, MO) and incubated for 1 hr at 37oC 
under 5.0% CO2 prior to biolistic transfection. Gold particles (1.6 μm gold 
microcarriers; Bio-Rad, Hercules, CA) were coated with the appropriate DNAs 
(see below) as per manufacturer's instructions and loaded into Tefzel tubing 
(McMaster-Carr, Atlanta, GA) for use with the Helios biolistic device (Bio-Rad), 
which was used at a delivery pressure of 95 psi.  Gold particles were coated with 
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expression constructs encoding YFP as a morphometric marker, cyan 
fluorescent protein CFP-tagged mHDx-1Q-73, and the relevant iAb; for control 
transfections, particles were coated with YFP + CVL, YFP + mHDx-1Q73 and 
vector backbone DNA, or YFP + mHDx-1Q73 + CVL.  For each condition, 
transfections were done on 12 brain slices and using fluorescence microscopy 
the number of healthy MSNs expressing the YFP reporter was assessed 4-5 
days after brain slice preparation and transfection using fluorescence 
microscopy. MSNs with normal-sized cell bodies, even and continuous 
expression of YFP in the cell body and dendrites, and having > 2 discernable 
primary dendrites > 2 cell bodies long were scored as healthy.  P values were 
computed using one-way ANOVA and Bonferroni post-hoc test. 
Immunohistochemical HDx-1 localization. ST14A cells were grown in 6 
well plates containing coverslips and co-transfected with mHDx-1Q103-GFP and 
intrabody in 6 well plates at ~60% confluency.  Each well received 1 μg mHDx-1 
and intrabody DNA at optimal ratios.  Non-transfected wells were used as a 
negative control.  At 48 hours post-transfection, cells were fixed and 
permeabilized as described above.  Intrabodies were then labeled using M2 anti-
Flag for MW7 and 3F10 anti-HA for VL12.3, Happ1 and Happ3. Secondary 
antibodies were conjugated to Alexa fluor 568 (Invitrogen)(S. Hockfield, 1993). 
Cells were processed for microscopy as above.  Mean fluorescence intensity for 
whole cell and nuclear HDx-1 (green channel) and iAb (red channel) was 
measured in 3 microscope fields per well.  The ratio of nuclear HDX-1 or iAb to 
cellular HDx-1 or iAb was determined by (mean intensity of nucleus/mean 
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intensity of whole cell).  P values were computed using one-way ANOVA and 
Bonferroni post-hoc test. 
HDx-1 immunoblot assay.  HEK 293 cells were co-transfected with HDx-
1-GFP and iAb in 10 cm dishes at ~80% confluency.  Each dish received 4 μg of 
mHDx-1Q103 or HDx-1Q25 DNA in pcDNA3.1 vector and iAb DNA in AAV vector 
at the optimal ratio for each iAb (4 μg VL12.3, 16 μg MW7, 8 μg Happ1 and 
Happ3).  A non-transfected dish was used as a negative control.  At 48 hours 
post-transfection, cells were dislodged by mechanical dissociation and pipetting, 
harvested by centrifugation, washed with PBS and lysed by sonication in 500 μl 
lysis buffer (25 mM Hepes, 50 mM NaCl, 1 mM MgCl2, 0.5 % triton) containing 1 
Complete, Mini, EDTA-free Protease Inhibitor Cocktail tablet (Roche) per 7 ml 
buffer.  The soluble protein fraction was collected by centrifugation for 20 min at 
4o C at 20,000x g.  The insoluble pellet was sonicated in 150 μl 6 M urea and 
incubated for 20 min at RT.  Immunoblots were then performed using rabbit anti-
GFP (1:1000 Invitrogen, Carlsbad CA) as primary antibody and HRP-conjugated, 
goat anti-rabbit (1:10,000 Santa Cruz Biotechnology, Santa Cruz, CA.) as 
secondary antibody to detect HDx-1-GFP. For a loading control, membranes 
were stripped using Restore western blot buffer (Pierce) and re-probed with 
mouse anti-β-tubulin (1:1000 Sigma) as primary and HRP-conjugated, goat anti-
mouse (1:10,000 Santa Cruz Biotechnology) as secondary antibody.  Densities 
of HDx-1 and β-tubulin bands were determined.  Each HDx-1 band was 
normalized to the level of the β-tubulin band for that sample.  The ratio of HDx-1 
level in the presence of iAb to HDx-1 level alone was determined by (density of 
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intrabody plus HDX-1/density of iAb plus HDx-1 βtubulin)/(density of HDx-1 
alone/density of HDx-1 alone βtubulin).  The experiment was repeated three 
additional times giving an N of 4.  P values were computed using two-way 
ANOVA and Bonferroni post-hoc test. 
HDx-1 turnover assay.  ST14A cells were grown in 6 well plates 
containing coverslips and co-transfected with HDx-1-SNAP and intrabody at 
~60% confluency.  Each well received 1 μg of either mHDx-1Q97-SNAP (fused 
to the SNAP tag) or HDx-1Q25-SNAP DNA in pSEMXT-26m vector (Covalys 
Witterswil, Switzerland) and iAb DNA in AAV vector at optimal ratios (1 μg 
VL12.3, 4 μg MW7, 2 μg Happ1 and Happ3).  Non-transfected wells were used 
as a negative control, and each condition was performed twice.  To covalently 
label HDx-1 present at 24 hours post-transfection, cells were treated with DAF 
green fluorescent SNAP-substrate (Covalys) according to the manufacturer’s 
protocol.  After labeling, cells were handled in low light conditions to avoid photo 
bleaching the DAF substrate.  One well of each condition was then fixed and 
permeabilized as described above.  For detection of all nuclei, cells were treated 
with blocking solution (3% BSA w/v, 10% NGS, 0.1% Triton X-100 in PBS) 
containing 1:2000 Toto-3 iodide (Invitrogen).  Coverslips were then mounted with 
Prolong gold anti-fade reagent (Invitrogen). The remaining well of each condition 
was incubated for an additional 24 hours (48 hours post-transfection) to allow 
turnover of labeled HDx-1, and then processed for microscopy as above.  Mean 
fluorescence intensity of individual cells was observed in 3 microscope fields per 
well using LCS software (Leica Wetzlar, Germany).  Mean cellular fluorescence 
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intensities were computed for both the 24 and 48 hour conditions.  The 
percentage of labeled HDx-1 at 24 hours and remaining at 48 hours was 
determined by ((mean intensity at 48 hours/mean intensity at 24 hours) x 100).  
The experiment was repeated three additional times giving an N of 4.  P values 
were computed using one-way ANOVA and Bonferroni post-hoc test. 
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FIGURES 
 
Fig 1 
 
Figure 1. The intrabodies bind different epitopes of HDx-1.  (A) The epitopes 
in HDx-1 for the various intrabodies are depicted. (B) To verify binding specificity 
293 cells were transfected with HDx-1 (PQ25) or HDx-1ΔPRR (Q23). After 48 
hours, cell lysates were separated by SDS/PAGE and blotted with intrabodies. 
Non-transfected cells (NEG) were used as a negative control. While VL12.3 binds 
both forms of HDx-1, MW7, Happ1 and Happ3 bind only the form containing the 
PRR. CVL does not bind HDx-1. 
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Fig 2 
 
Figure 2. The anti-Htt intrabodies reduce mHDx-1-induced toxicity and 
aggregation in cell culture.  (A) To quantify mHtt toxicity, 293 cells were co-
transfected with mHDx-1-GFP and intrabody at various intrabody/Htt ratios and 
incubated for 48 hours.  Cells were stained with EthD-2 to identify dead cell 
nuclei, fixed, and stained with DAPI to identify all cell nuclei. The number of dead 
cells was normalized to total cell number. All of the intrabodies reduce mHDx-1-
induced cell death in a saturable, dose-dependent manner, with maximal effects 
at different intrabody/Htt ratios (1:1 for VL12.3, 2:1 for Happ1 and 3, and 4:1 for 
MW7).  (B) Aggregation was determined by counting GFP foci and normalizing to 
total cell number. * = Differ from VL12.3 at p<.05, **=p<.01.  The point labeled as 
0 on the intrabody:Htt axis corresponds to the value for HDX-1 + CVL. 
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Fig 3 
 
Figure 3. Anti-Htt intrabodies protect against mHDx-1-induced 
neurodegeneration in cortico-striatal brain slice explants.  Cortico-striatal 
brain slices were biolistically transfected with plasmid expression constructs 
encoding YFP, mHDx1(N1-66 with 148 Q), and the indicated intrabody. The 
number of healthy medium spiny neurons in the striatal region of each slice was 
scored visually 4-5 days after slice preparation and transfection.  (A) Slices were 
transfected with either YFP + CVL; YFP + CVL + mHDx1; YFP + mHDx1 + 
VL12.3; or YFP + mHDx1 + Happ1. ** = Differ from YFP at p<.01. (B) Slices were 
transfected with YFP + CVL; YFP + vector + mHDx-1; YFP + CVL + mHDx1 or 
YFP + mHDx1 + MW7. ** = p<.01. The data in A and B are from independent 
experiments. 
 
  
51
 
Fig 4 
 
Figure 4. VL12.3 increases the level of nuclear HDx-1.  ST14A cells were co-
transfected with mHDx-1Q103-GFP and intrabody (iAb) at the optimal ratio for 
each iAb.  (A) At 48 hours post-transfection, cells were fixed, stained for the 
appropriate iAb and cell nuclei, and analyzed by confocal microscopy.  (B) Mean 
whole cell fluorescence intensity (int.) and mean nuclear fluorescence intensity of 
HDx-1 are compared. While MW7, Happ1 and Happ3 have no effect on HDx-1 
localization, VL12.3 significantly increases nuclear HDx-1. ** = Differs from HDx-1 
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at p<.01. (C) Mean whole cell fluorescence intensity and mean nuclear 
fluorescence intensity of the iAbs themselves were compared.  MW7 is slightly 
more cytoplasmic than the other iAbs. 
 
Fig 5 
 
Figure 5. All of the anti-Htt intrabodies reduce insoluble mHDx-1, while only 
the anti-PRR intrabodies also reduce soluble mHDx-1. 293 cells were co-
transfected with intrabody and mHDx-1 (76 kD) or wtHDx-1 (40 kD) at the optimal 
ratio for each intrabody.  (A) At 48 hours post-transfection, cells were lysed with 
detergent.  The soluble protein fraction was recovered and the insoluble fraction 
was treated with urea.  Samples were then separated by SDS-PAGE and blotted 
for HDx-1. Non-transfected cells (NEG) were used as a negative control. All of 
the anti-Htt intrabodies reduce insoluble mHDx-1. (B) Quantification of bands 
shows that reduction of soluble HDx-1 by PRR-binding intrabodies is significantly 
greater for the mutant than the WT form of Htt.  VL12.3 does not reduce soluble 
mHDx-1. Chemiluminescence densitometry was used to compare the levels of 
soluble mHDx-1 and wtHDx-1.  Each band was normalized to the level of β-
tubulin (54 kD) in that sample.  Bands for HDx-1 + intrabody (iAb) were then 
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normalized to the level of soluble HDx-1 for that blot.  N = 4 independent 
experiments, and values for each blot were used to compile the mean +/- S.E.M. 
** = p<0.01  
 
Fig 6 
 
Figure 6. Anti-PRR intrabodies increase mHDx-1 turnover.  ST14A cells were 
transfected with mHDx-1-SNAPtag 97Q (A and B) or wtHDx-1-SNAPtag 25Q (C) 
and intrabody at the optimal ratio for each intrabody.  DAF green fluorescent 
SNAP substrate was added to cultures at 24 hrs post-transfection.  Some 
cultures were then fixed and stained with Topro-3 iodide nuclear marker while 
others were incubated an additional 24 hrs to allow turnover of labeled HDx-1. 
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Mean fluorescence intensity of cells at 24 hrs was compared to intensity at 48 hrs 
to determine the percentage of labeled HDx-1 remaining.  VL12.3 has no effect 
on mHDx-1 or wtHDx-1 turnover while MW7, Happ1 and Happ3 significantly 
increase the rate of mHDx-1 turnover. N = 4, ** = p<.01 
 
 
 
 
 
 
  
55
 
Chapter 3  
Intrabody gene therapy ameliorates motor, cognitive and 
neuropathological symptoms in multiple mouse models of 
Huntington's disease  
 
Southwell AL, Ko J, Patterson PH 
 
INTRODUCTION 
Intrabodies are a powerful and diverse therapeutic tool ideally suited to 
treatment of protein mis-folding neurodegenerative diseases.  The potential for 
iAb design is virtually infinite. An example is the targeting of iAbs to different 
epitopes within the same protein.  Intrabodies that recognize expanded 
polyglutamine in mHtt such as MW1 and 2 increase mHtt aggregation and 
toxicity in cultured cells while MW7, which recognizes the adjacent polyP regions, 
has the opposite effects (Khoshnan et al., 2002). Intrabodies can also be 
targeted to specific protein confirmations such as D5, an anti-α-synuclein iAb that 
recognizes only the highly toxic oligomeric form of the protein, and does not bind 
monomeric or fibrillar α-synuclein (Emadi et al., 2007).  
In addition, iAbs can be fused to signaling sequences to alter the 
functional outcome. For example, C4, an iAb that recognizes the N-terminus of 
Htt and reduces aggregation and toxicity in cell culture, brain slice and 
Drosophila HD models (Murphy and Messer, 2004; Wolfgang et al., 2005; 
McLear et al., 2008) has no baseline effects on Htt localization. However, when 
C4 is fused to a nuclear localization sequence (NLS), it directs Htt, normally most 
abundant in the cytoplasmic and perinuclear regions, to the nucleus (Lecerf et 
al., 2001). Similarly, the D10 iAb recognizes α-synuclein, the mis-folded mutant 
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version of which can cause PD, and reduces α-synuclein-induced toxicity and 
aggregation in cell culture. D10 directs α-synuclein to the nucleus when fused to 
an NLS, but not the highly homologous β-synuclein (Zhou et al., 2004). Another 
example is an iAb (sFvβ1) that recognizes an epitope adjacent to the β-secretase 
site of amyloid precursor protein (APP), the precursor to the Aβ peptide, whose 
mis-folded mutant form can cause AD. This iAb shifts APP processing toward the 
more favorable α-secretase cleavage product, reducing Aβ production and 
toxicity in cell culture models of AD with no baseline effects on localization.  
When sFvβ1 is fused to an endoplasmic reticulum retention signal, however, it 
prevents newly generated APP from leaving the endoplasmic recticulum, leading 
to its degradation and virtually abolishing Aβ production (Paganetti et al., 2005).  
Increased clearance of Htt is a common property of anti-Htt iAbs with 
therapeutic potential. Compared to cells infected with HDx-1 plus a control iAb, 
bicistronic adenoviral delivery of HDx-1 plus the C4 iAb dramatically reduces 
levels of both WT and mHDx-1 in infected 293 cells (Miller et al., 2005). EM48, 
an iAb recognizing an epitope C-terminal to the PRR of Htt, preferentially binds 
mHtt and increases its ubiquitination and turnover in EM48-adenovirus-infected 
PC12 cells. Adenoviral delivery of EM48 to the brains of R6/2 and N171-82Q HD 
model mice reduces striatal neuropil aggregates, increases Htt cleavage 
products in brain homogenates, and improves the gait and rotarod performance 
of N171-82Q mice. However, EM48 gene therapy has no effect on intranuclear 
inclusions, body weight or survival (Wang et al., 2008). This adenoviral delivery 
strategy is also limited to the study of short-life span HD models because of the 
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transient transgene expression of the adenoviral vector. The more stably 
expressing adeno-associated virus (AAV) vector is preferable in this regard. 
The AAV vector can yield long-term transgene expression in a wide range of cell 
types, depending on serotype.  The AAV1 capsid, which displays excellent 
spread and transduction efficiency in the central nervous system (CNS), 
preferentially infects neurons, but also infects glial and ependymal cells (Wang et 
al., 2003a). As neuronal death and dysfunction in HD may not occur solely by a 
cell autonomous mechanism, transduction of glia, at least in preclinical studies, is 
preferable (Shin et al., 2005). The AAV2 genome under the control of the chicken 
β-actin promoter plus CMV promoter enhancer regions  (CBA) confers long-term 
stable transgene expression. The combination of these properties in chimeric 
AAV2/1 vectors is ideal for iAb delivery to HD model mice.                                        
 Due to the clear mechanistic differences of VL12.3 and Happ1 as potential 
therapeutics and the lack of a single, ideal mouse HD model (Chapter 1; 
Southwell et al., 2008), we tested both iAbs for therapeutic efficacy in a lentiviral 
model and four transgenic HD mouse lines. 
    
RESULTS 
Widespread striatal transduction is achieved with the lentiviral vector 
in adult mice and with the AAV vector in adult and neonatal mice. A 
schematic outline of the various types of gene therapy experiments is given in 
Fig. 1. In the lentiviral model, adult WT mice were unilaterally injected with a 
mixture of mHDx-1 or GFP lentivirus plus GFP, VL12.3, or Happ1 AAV.  Mice 
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were sacrificed 6 weeks later and coronal sections throughout the striatum were 
stained for mHDx-1 and iAb.  Similar striatal spread is seen with both viruses 
(Fig. 2A).  Co-localization of mHDx-1 and iAb in confocal images shows that 
these viruses co-transduce cells (Fig. 2B).  There are a larger number of iAb-
positive cells than mHDx-1-positive cells, indicating a greater transduction 
efficiency of AAV2/1. Adult injections of AAV2/1 were also used bilaterally in the 
N171-82Q, YAC128 and BACHD HD transgenic mice. Striatal iAb spread in 
these mice is similar to that seen in the lentiviral model (data not shown). The 
R6/2 model has an accelerated time frame that includes Htt inclusions at birth 
and onset of behavioral symptoms at less than 3 weeks of age (Mangiarini et al., 
1996; Stack et al., 2005). Because of this and the 3 week delay before AAV 
delivered transgene expression reaches its peak (Tenenbaum et al., 2004), 
postnatal day 3 injections were used in this line.  Striatal spread equivalent to or 
better than that seen with adult injections is apparent (Fig. 3). 
Treatment with VL12.3 or Happ1 prevents abnormal amphetamine-
induced rotation behavior in the lentiviral HD model. Four-week old C57Bl/6 
mice were injected unilaterally with mHDx-1 or GFP lentivirus plus GFP, VL12.3 
or Happ1 AAV.  Six weeks after surgery, animals were injected with 10 mg/kg 
amphetamine i.p. After 5 min, animals were placed in an open field for 30 min 
and ipsilateral rotations counted (Fig. 4).  Age-matched, un-injected mice were 
also tested as a control for surgery effects.  Naïve mice were randomly assigned 
to right turn or left turn groups for scoring ipsilateral turns. Compared to naïve 
mice, injection of GFP lentivirus along with any of the AAVs does not significantly 
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increase the number of ipsilateral rotations.  In contrast, animals injected with 
mHDx-1 lentivirus plus GFP AAV display a major increase in ipsilateral rotations.  
Co-injection of VL12.3 or Happ1 AAV strongly reduces the number of ipsilateral 
rotations in mHDx-1 lentivirus-injected animals to levels not significantly different 
from GFP lentivirus-injected or naïve animals.   
Happ1 treatment improves rotarod performance in four transgenic 
HD models.  Mice were assessed for accelerating rotarod performance as 
follows: weekly from four weeks of age until death in R6/2 and WT littermates 
(Fig. 5A), every two weeks from six weeks of age until death in N171-82Q and 
WT littermates (B), monthly from 3 until 7 months of age in YAC128 and WT 
littermates (Fig. 5C, D), and monthly from 3 until 6 months of age in BACHD mice 
(Fig. 5E). Compared to WT littermates, R6/2 mice display a deficit in rotarod 
performance from 5 weeks of age. Compared to GFP-treated mutants, Happ1 
treatment ameliorates this deficit between 9 and 12 weeks of age (Fig. 5A). In 
contrast, compared to GFP-treated mutants, VL12.3 treatment reduces latency to 
fall in R6/2 mice between 10 and 12 weeks of age.  Although rotarod 
performance is also impaired below GFP controls at 13 weeks of age, statistics 
cannot be performed, as only one VL12.3-treated mutant remained alive at this 
time point.   
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Compared to WT littermates, N171-82Q mice display a motor deficit on 
the rotarod from 20 weeks of age. From 22 weeks of age performance is 
significantly improved by Happ1 treatment (Fig. 5B). Happ1-treated mutants do 
not differ from WT animals in their performance until 40 weeks of age. 
Happ1 treatment improves rotarod performance in 3, 4 and 7 month old 
YAC128 mice (Fig. 5C, D).  The lack of significant difference at 5 and 6 months 
of age appears to be related to an improvement in the performance of GFP-
treated animals rather than a decline in the performance of Happ1-treated mice.  
YAC128 mice display a learning deficit that includes impaired learning of the 
rotarod task from 2 months of age (Van Raamsdonk et al., 2005). As rotarod 
training was performed at 3 months of age with the same number of training trials 
for all mice, the difference in performance between young GFP- and Happ1-
treated mice could be the result of enhanced learning of the task by Happ1 
treatment. By 7 months of age, the performance of GFP-treated YAC128 mice 
begins to decline, presumably as a result of declining motor ability. Happ1 
treatment also ameliorated the motor deficit in the BACHD line. Compared to 
GFP-treated mice, Happ1 treatment increases the latency to fall from the rotarod 
in 5 and 6 month old BACHD mice (Fig. 5E).   
Happ1 treatment improves beam crossing performance in four 
transgenic HD models.  Mice were assessed for beam crossing performance as 
follows: weekly from four weeks of age until death in R6/2 and WT littermates 
(Fig. 6A-C), every two weeks from six weeks of age until death in N171-82Q and 
WT littermates (Fig. 6D-F), monthly from 3 until 7 months of age in YAC128 and 
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WT littermates (Fig. 6G-I), and monthly from 3 until 6 months of age in BACHD 
mice (Fig. 6J-L). Three widths of square beam were used: 28 mm, 12 mm and 6 
mm. Compared to WT littermates, R6/2 mice display increased time to cross the 
beams from 10, 7 and 5 weeks respectively. Being the easiest to traverse, there 
are no significant effects of iAb treatment on time to cross the 28 mm beam. 
However, compared to GFP-treated mice, Happ1 treatment does reduce the time 
to cross the 12 mm beam in 10 and 11 week old R6/2 mice, and the 6 mm beam 
between 9 and 11 weeks of age. Conversely, compared to GFP-treated 
littermates, VL12.3 treatment increases the time to cross the 12 mm beam at 11 
and 12 weeks of age and the 6 mm beam at 9 and 10 weeks of age.  
N171-82Q mice display increased time to cross the three beams at 22, 16, 
and 12 weeks respectively. Happ1 treatment significanly reduces time to cross 
the 28 mm beam from 22 weeks of age on, the 12 mm beam in 16, 18 and 24 
weeks and older mutants, and the 6 mm beam in 18, 20, and 26 weeks and older 
mutants. Happ1-treated mutants only show a deficit as compared to WT mice in 
time to cross the 12 mm beam at 30 and 40 weeks of age and the 6 mm beam at 
28, 30, 38, and 40 weeks of age.  
Compared to WT littermates, YAC128 mice display impaired beam 
crossing performance at 7 months of age for the 28 mm beam and 3 and 4 
months of age for the 12 mm and 6 mm beams. Compared to GFP-treated mice, 
Happ1 treatment reduces the time to cross the 28 mm beam in 7 month-old 
YAC128 mice and the 12 mm and 6 mm beams at 3 and 4 months. As in the 
rotarod test, the performance of the GFP-treated YAC128 mice appears to 
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improve over the earliest time points, suggesting a motor task learning deficit that 
is restored by Happ1 treatment. In contrast, VL12.3 treatment appears to 
exacerbate this learning deficit in 3 month-old mice. Happ1 treatment of BACHD 
mice reduces the time to cross the beams at 5 and 6 months for the 28 mm 
beam, at 4 and 6 months for the 12 mm beam, and at 6 months for the 6 mm 
beam. 
Happ1 treatment improves climbing performance in YAC128 and 
BACHD mice. Climbing time was assessed in 7 month-old YAC128 and WT 
littermates (Fig. 7A) and in 6 month-old BACHD mice (Fig. 7B).  Mice were 
placed at the bottom of a closed-top wire mesh cylinder and observed for 5 
minutes.  Time spent climbing with all four feet off of the tabletop was scored. 
Compared to WT littermates, GFP- and VL12.3- treated YAC128 mice investigate 
the wire mesh and rear on two or three legs frequently, but climbing time is 
reduced. Happ1 treatment increases climbing time in these mice to a level not 
significantly different from WT mice (Fig. 7A). Compared to GFP-treated mice, 
Happ1 treatment also increases climbing time in BACHD mice (Fig. 7B).   
Happ1 treatment ameliorates clasping in N171-82Q mice. Twenty 
week-old N171-82Q and WT littermates were assayed for clasping. Mice were 
suspended by the tail and observed for 1 minute.  Mice with normal limb 
extension were given a score of 0. Forelimb clasping was scored as 1, and hind 
limb clasping was scored as 2 (Fig. 8). WT mice do not exhibit clasping. All GFP-
treated N171-82Q mice exhibit clasping, with roughly half displaying forelimb-
only clasping and half displaying hind limb clasping. The majority of Happ1-
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treated mutants display forelimb-only clasping, while a few display hind limb 
clasping or no clasping.  
Happ1 treatment normalizes open field behavior in full-length Htt 
transgenic models of HD. Anxiety behavior of 7 month-old YAC128 and WT 
littermates and 6 month old BACHD mice was inferred by studying exploration of 
an open field (Fig. 9) and by investigation of a novel object (Fig. 10). Compared 
to WT littermates, GFP- and VL12.3-treated YAC128 mice display reduced 
entries into, and time spent in, the center of the field.  In contrast, Happ1 
treatment increases center entries and time in the center to levels not 
significantly different from WT mice (Fig. 9A, B). In the BACHD mice, there is a 
trend toward an increased number of center entries as a result of Happ1 
treatment, but it does not reach significance (Fig. 9C). However, compared to 
GFP-treated BACHD mice, Happ1 treatment significantly increases the time 
spent in the center of the open field (Fig. 9D).   
Compared to WT littermates, there is a trend toward reduced investigation 
of a novel object in GFP- and VL12.3-treated YAC128 mice, which is reversed by 
Happ1 treatment, although there are no statistically significant differences 
between any of the groups (Fig. 10A).  Although there is no effect of Happ1 
treatment on investigation of a novel object in male BACHD mice, Happ1 
treatment increases that number in female BACHD mice (Fig. 10B).   
Happ1 treatment improves learning in YAC128 mice. To assess 
hippocampal-dependent learning, 7 month-old YAC128 and WT littermates and 6 
month-old BACHD mice were tested for preference for the novel location of a 
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known object (Fig. 11A)(Mumby et al., 2002). On day 1, mice were habituated to 
an open field. After a five minute inter trial interval (ITI) they were re-introduced to 
the same field now containing two novel objects in the upper corners of the box 
located far enough from the sides to allow free movement around the outer edge. 
Investigations of each object were scored for 5 minutes (trial 1, T1). In trial 2 (T2) 
after another 5 minute ITI, they were re-introduced to the same field with the 
object previously located in the upper right corner moved to the lower right 
corner. Investigations of each object were scored for 5 minutes, and the percent 
of investigations of the target object (the one that was moved) was computed. A 
score of 50% percent represents no preference. As expected, WT mice of the 
YAC128 line display no preference in T1 and a preference for the target object in 
T2 (Fig. 11C).  In contrast, GFP- and VL12.3-treated YAC128 mice display no 
preference in either trial, indicating impaired spatial learning. However, Happ1 
treatment restores significant spatial learning (Fig. 11C). BACHD mice in both 
treatment groups show no preference for the target object, indicating impaired 
spatial learning and no effect of iAb treatment (Fig. 11E).  
To assess cortical-dependent learning, mice were tested for preference for 
a novel object. (Fig. 11B)(Mumby et al., 2007).  On day 2, mice were re-
habituated to the same field and T1 from day 1 was repeated. In T2 they were re-
introduced to the field with the object in the upper right corner replaced with a 
completely novel object. Investigations of each object were scored for 5 minutes, 
and the percent of investigations of the target object (the completely novel object) 
was computed. WT mice of the YAC128 line display no preference in T1 and 
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trended toward a preference for the target object in T2, although the difference is 
not significant. There are no differences between the treatment groups in WT 
mice, and when all WT groups are combined, the preference for the target object 
reaches significance (p<.01)(data not shown) indicating that the lack of significant 
preference is related to small sample size. GFP- and VL12.3-treated YAC128 
mice display no preference for the target object, indicating impaired cortical 
learning. In contrast, Happ1-treated YAC128 mice display a preference for the 
target object, indicating preserved cortical learning (Fig. 11D). In the BACHD line, 
GFP-treated mice display no preference for the target object in T2 while Happ1 
treated-mice trended toward a preference for the target object, although this does 
not reach significance (Fig. 11F).  
Happ1 treatment improves body weight of N171-82Q mice. Body 
weight was assessed as follows: weekly from four weeks of age until death in 
R6/2 and WT littermates (Fig. 12A), every two weeks from six weeks of age until 
death in N171-82Q and WT littermates (Fig. 12B) monthly from 3 until 7 months 
of age in YAC128 and WT littermates (Fig. 12C), and monthly from 3 until 6 
months of age in BACHD mice (Fig. 12D). N171-82Q mice weigh significantly 
less than Wt littermates from 16 weeks of age onward. Happ1-treated mutants 
though still weighing less than WT littermates, display increased weight as 
compared to GFP-treated mutants from 22 weeks of age. Compared to WT 
littermates from 10 weeks of age, R6/2 mice display decreased body weight.  
YAC128 mice trend toward greater body weight than WT littermates.  BACHD 
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males display greater body weight than females. There is no effect of iAb 
treatment on this parameter in any of these three models.  
Happ1 treatment increases survival in N171-82Q mice while VL12.3 
treatment decreases survival in the R6/2 HD model. Lifespan was assessed 
in R6/2 mice (Fig. 13A) and N171-82Q mice (Fig. 13B).  Once mice became 
visibly ill, they were assayed twice daily for loss of the righting reflex.  Mice who 
did not immediately right themselves after being laid on their side were 
euthanized.  Happ1 treatment had no effect on lifespan while VL12.3 treatment 
decreased survival time of R6/2 mice.  However, Happ1 treatment increased 
maximum lifespan of N171-82Q mice 33% from 30 weeks of age in GFP-treated 
mutants to 40 weeks of age in Happ1-treated mutants. 
In the lentiviral HD model, treatment with VL12.3 or Happ1 
ameliorates neuron-specific mHDx-1 toxicity. Four week-old C57Bl/6 mice 
were injected unilaterally with mHDx-1 or GFP lentivirus plus GFP, VL12.3 or 
Happ1 AAV.  Six weeks after surgery, animals were perfused for histology.  Mice 
injected with mHDx-1 lentivirus plus GFP AAV display large areas of strongly 
diminished DARPP-32 immunostaining.  Areas of DARPP-32 loss also display 
loss of NeuN-positive cells, indicating death of striatal neurons (Fig. 14A).  Toto-3 
iodide nuclear staining does, however, show the presence of cells within lesioned 
areas, indicating hypersensitivity of neurons to the toxicity of mHDx-1 lentivirus 
(Fig. 14B).  Lesioned areas also display reactive gliosis, as evidenced by an 
increase in GFAP staining (Fig. 14C).  Co-injection of VL12.3 or Happ1 AAV with 
mHDx-1 lentivirus reduces both the size and intensity of DARPP-32 loss (Fig. 
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14D).  To quantify lesion size, the ratio of the area of total DARPP-32 loss to the 
area of lentivirus transduction was computed (Fig. 14E).  Animals injected with 
GFP lentivirus and any of the AAVs display very small if any lesion areas.  
Injection of mHDx-1 lentivirus with GFP AAV causes a dramatic increase in 
lesion size, which is reduced by co-injection of VL12.3 or Happ1 AAV to a level 
not significantly different from animals injected with GFP lentivirus plus any of the 
AAVs.   
To assess the severity of DARPP-32 staining loss within the lesion, the 
ratio of DARPP-32 intensity in the transduced striatum to DARPP-32 intensity in 
the non-injected side was computed (Fig. 14F).  Injection of mHDx-1 lentivirus 
plus GFP AAV causes a decrease in DARPP-32 intensity of the transduced 
striatum, which is rescued by VL12.3 or Happ1 AAV to the level of animals 
injected with GFP lentivirus.   
In the R6/2 model, Happ1 treatment has no effect while VL12.3 
treatment decreases DARPP-32 staining intensity. DARPP-32 staining of 
coronal sections was measured in 10 week-old R6/2 and WT littermates (Fig. 
15A), 7 month-old YAC128 and WT littermates (Fig. 15B), and 6 month-old 
BACHD mice (Fig. 15C). Compared to WT littermates, R6/2 mice display 
reduced DARPP-32 intensity (Fig. 15A).  Happ1 treatment has no effect while 
VL12.3 treatment further decreases the intensity of DARPP-32 staining. There 
are no differences in the intensity of DARPP-32 between YAC128 and WT 
littermates, and there is no effect of iAb treatment (Fig. 15B).  Similarly, there is 
no effect of Happ1 treatment in DARPP-32 intensity in BACHD mice (Fig. 15C).    
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Treatment with VL12.3 or Happ1 reduces mHtt aggregation in the 
lentiviral and R6/2 HD models. Coronal sections from mHDx-1 lentivirus-
injected animals 6 weeks post-surgery (Fig. 16A) and10 week-old R6/2 mice 
(Fig. 16B) were stained for Htt.  Most of the Htt staining in both models was in the 
form of aggregates, although some diffuse staining in neurons is seen (arrows in 
left panel in Fig. 16A).  VL12.3 or Happ1 treatment reduces aggregates and 
increases the level of diffuse Htt, both in neuronal somas (arrows) and in the 
neuropil (Fig. 16A).  The larger areas of bright staining in both the Happ1- and 
VL12.3-treated R6/2 brains appear to represent neuronal cytoplasm (Fig. 16B). 
Happ1-treated brains appear to display lower overall levels of Htt staining in both 
HD models though this was not quantified.  To quantify aggregation in the 
lentiviral model, 3 sections per animal were stained with MW8, an anti-Htt 
antibody that labels aggregated but not diffuse Htt.  Striatal MW8-positive foci 
were counted and normalized to the area of HDx-1 transduction (Fig. 16C). 
Treatment with VL12.3 or Happ1 dramatically reduces mHDx-1 aggregates. To 
quantify small neuropil aggregates in the R6/2 model, 3 sections per animal were 
stained with MW8 and toto-3 iodide nuclear marker. MW8-positive foci of 2-8 
pixels in size that do not co-localize with toto-3 iodide in a 250 μm2 area of the 
transduced striatum were counted (Fig. 16D).  Treatment with VL12.3 or Happ1 
dramatically reduces the number of these neuropil aggregates. To quantify intra-
nuclear inclusions, MW8-positive foci of 9-15 pixels in size that co-localize with 
toto-3 iodide staining were counted (Fig. 16E). There is a trend toward a 
reduction of intra-nuclear inclusions in VL12.3-treated animals, and a significant 
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reduction in Happ1-treated animals. Htt inclusions are not observed in YAC128 
or BACHD brains.  This is not surprising as inclusion formation has been 
reported to begin at 12 months of age in YAC128 mice (Slow et al., 2005) and 
between 12 and 18 months of age in BACHD mice (Gray et al., 2008). 
Happ1 treatment reduces ventricular enlargement in three transgenic 
HD models. Ventricular enlargement has been reported in R6/2 mice beginning 
at 3 weeks of age (Stack et al., 2005) and in 9 and 12 month-old YAC128 mice 
(Slow et al., 2003). Ventricle size was assessed in 10 week-old R6/2 and WT 
littermates (Fig. 17A, B), in 7 month-old Yac128 and WT littermates (Fig. 17C), 
and in 6 month-old BACHD mice (Fig. 17D). Compared to WT littermates, GFP- 
and VL12.3-treated R6/2 mice display ventricular enlargement.  Happ1 treatment 
reduces ventricle size to a level not significantly different from WT animals (Fig. 
17A, B). Compared to WT littermates, GFP- and VL12.3-treated YAC128 mice 
display ventricular enlargement while Happ1 treatment reduces ventricle size 
(Fig. 17C). In addition, Happ1-treated BACHD mice also display smaller 
ventricles than GFP-treated BACHD mice (Fig. 17D). 
 
DISCUSSION 
 AAV is a very promising candidate vector for gene therapy in humans.  
Wild type AAV is widespread in human populations with 80-85% of adults being 
seropositive reducing the probability of host immune activation complications 
(Chirmule et al., 1999; Peel and Klein, 2000).  It is non-pathogenic in humans 
and unable to replicate in the absence of a helper virus.  Clinical trials using AAV 
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to treat neurodegenerative diseases in the human CNS have demonstrated no 
pathology related to the vector (McPhee et al., 2006; Kaplitt et al., 2007; Marks et 
al., 2008). AAV can infect both dividing and non-dividing cells and is capable of 
eliciting long-term transgene expression, which has been monitored for up to six 
years in primates (Klein et al., 2002; Bankiewicz et al., 2006).  Although wtAAV 
commonly integrates into genomic DNA at specific sites, integration events for 
recombinant AAV (rAAV), which lacks 96% of the viral genome, are rare, 
reducing the probability of oncogenic complications (Schnepp et al., 2003). The 
existence of over 120 different capsid proteins also confers a wide range of 
tropisms allowing customization of rAAV gene therapy vectors (Mueller and 
Flotte, 2008).   
 AAV2 is the most common serotype found in humans.  As a result, most 
early AAV gene therapy studies use this serotype.  Although the AAV2 genome 
is capable of long-term gene expression, due to the AAV2 capsid protein this 
serotype has low transduction efficiency, low viral spread in the CNS as well as 
an inability to transduce non-neuronal cell types (McCown et al., 1996; Bartlett et 
al., 1998; Klein et al., 1998; Tenenbaum et al., 2000).  Due to the similarity 
between inverted terminal repeats (ITRs), the AAV2 genome can be packaged 
into the capsid proteins of other AAV serotypes.  Chimeric AAV2/1, consisting of 
the AAV2 genome and the AAV1 capsid protein, exhibits increased spread, 
transduction efficiency, and the ability to transduce glial and ependymal cells as 
well as neurons, while retaining the long-term expression capabilities of AAV2 
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(Wang et al., 2003a).  Chimeric AAV2/1 also has a decreased lag time between 
infection and transgene expression (Auricchio et al., 2001). 
Traditional AAV gene therapy vectors use the high expressing CMV 
promoter.  However, gene expression from this promoter in AAV infected cells in 
the CNS declines over time (McCown et al., 1996; Klein et al., 1998; Tenenbaum 
et al., 2000).  This decline is attributed to a combination of loss of non-integrated 
vector, death of infected cells, or 5’ CpG methylation of the CMV promoter 
leading to silencing (Prösch et al., 1996).  Use of the CBA promoter stabilizes 
gene expression in AAV infected cells in the CNS (Klein et al., 2002). Therefore, 
for our iAb gene therapy studies we have used a chimeric AAV2/1 vector, 
consisting of the AAV2 genome under the control of the CBA promoter and the 
AAV1 capsid. We observe extensive striatal iAb expression for at least 8 months 
(the longest post-surgical experimental time point). 
VL12.3 treatment results in improved behavior and neuropathology in the 
lentiviral mouse model of HD.  However, in transgenic HD models, VL12.3 either 
has no effect or adverse effects on symptoms.  Perhaps the presence of VL12.3 
prior to or at the same time as the introduction of mHtt is required for beneficial 
effects of this intrabody.  Conversely, the negative effects of VL12.3 i.e. 
stabilizing soluble mHtt and increasing its nuclear localization may have 
detrimental effects in longer term studies such as the gene therapy studies in 
transgenic models.   
Happ1 treatment, while equally beneficial to the lentiviral model, also 
improves motor and cognitive performance as well neuropathology in the 
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transgenic models. In the lentiviral model, Happ1 treatment prevents the 
amphetamine-induced rotation phenotype and reduces striatal lesion size and 
intensity as well as aggregation. Happ1 treatment increases body weight and 
survival of N171-82Q but not R6/2 mice. The lack of effect in the R6/2 may be 
related to the extremely early onset and severity of symptoms in this model. Body 
weight was not affected by iAb treatment in YAC128 or BACHD mice though 
these mice exhibit progressive weight gain uncharacteristic of human HD. Happ1 
treatment improves rotarod and beam crossing performance in all four transgenic 
models. Unlike the other three models, the improvement to YAC128 motor 
performance is most significant at the earliest time points. Indicating a beneficial 
effect of Happ1 on the motor task learning deficit of this model. A climbing test 
was performed on the full-length transgenic models as a way to test motor 
performance independent of learning ability as this behavior is spontaneous and 
does not require training. Happ1 treatment increased climbing time of both 
YAC128 and BACHD mice. Both full-length transgenic models exhibit anxiety in 
the open field and deficits in spatial and cortical learning tasks. Happ1 treatment 
normalizes open field exploration in both models as well as learning in the 
YAC128 model.  
Like VL12.3 treatment, Happ1 treatment reduces mHDx-1 aggregates and 
inclusions in the R6/2 model. The similar effect of these iAbs on aggregation is 
particularly interesting as Happ1 ameliorates and VL12.3 exacerbates the HD like 
phenotype in these mice. This indicates that simply preventing aggregation is not 
predictive of therapeutic benefit. Striatal atrophy resulting from neuronal 
  
73
 
shrinkage and/or death and concomitant ventricular enlargement is common to 
human HD patients as well as all four transgenic models used in this study. 
Happ1 treatment decreases ventricle enlargement in R6/2, YAC128 and BACHD 
mice. DARPP-32 intensity, aggregation and ventricle size were not assessed in 
N171-82Q mice as they were used to study survival and thus euthanized at the 
same disease stage rather than the same age. 
The overwhelmingly beneficial effects of Happ1 treatment on all five 
mouse models of HD supports the idea that therapies directed at the specific 
degradation of mHtt represent a direct and effective strategy for the treatment of 
HD with a low probability of off-target effects.   
 
MATERIALS AND METHODS 
Lentivirus production and purification. Ten 15 cm plates of ~80% 
confluent 293 GPG cells (Ory et al., 1996) were triple transfected by calcium 
phosphate with 20 μg pFugW lentiviral genome encoding either mHDx-1Q103-
GFP or GFP, 15 μg Δ8.9 and 10 μg VSV-G plasmids (Naldini et al., 1996).  
Sixteen hrs post-transfection, medium was removed and replaced with medium 
supplemented with 2% FBS.  Medium containing lentivirus was collected at 48 
and 72 hrs post-transfection, filtered at .45 μm and centrifuged for 90 min at 
25,000 RPM at 4oC to pellet lentivirus.  Pellets were then dissolved overnight at 
4oC in sterile PBS.  Viral solutions were buffer exchanged into sterile saline 
(0.9% NaCl) and concentrated using Amicon ultra 4 ml tubes (MWCO 
100,000)(Millipore, Billerica, MA) until a final volume of 150-250 μl was reached, 
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aliquotted, and stored at –80oC until use. Viral titer was determined by infection 
of HEK 293 cells with a dilution series and counting colonies of GFP-positive 
cells.  Before injection, all lentiviruses were adjusted to a titer of 5x108 pfu/ml. 
AAV production and purification. Fifty 15 cm plates of ~80% confluent 
HEK 293 cells were triple transfected by calcium phosphate with 12.5 μg AAV 
serotype 2 genome (Stratagene, La Jolla, CA) with a modified CBA promoter 
encoding GFP, VL12.3 or Happ1, 25 μg pHelper (Stratagene) and 37.5 μg AAV 
serotype 1 rep/cap (University of Pennsylvania viral vector core) plasmids per 
plate.  Medium was replaced 16 hrs post-transfection.  At 48 hrs post-
transfection, medium was removed and cells were dislodged by pipetting, 
collected by centrifugation, washed with and re-suspended in 10 mM tris buffer.  
Cells were lysed by two rounds of freeze/thaw with vortexing and treated with 
DNAse I for 30 min. at 37oC.  The viral fraction was then isolated by 
ultracentrifucation at 40,000 RPM for 2 hr at 4oC in an optiprep gradient (15-
60%)(Sigma).  The fraction containing the virus  (40-60% interface) was collected 
by syringe, diluted 1:5 in 20mM tris buffer, pH 8.0 and further purified by 
Mustang-Q membrane ion exchange (Acrodisc, Pall corporation, East Hills, NY). 
Virus was eluted in 500 μl 20mM tris buffer, pH8.0 with 400 mM NaCl and stored 
at –80oC in 50μl aliquots.  Before use each aliquot was dialyzed in a slide-a-lyzer 
mini dialysis unit (MWCO 7000, Pierce) for 1 hr at 4oC in 1 L sterile saline with 
gentle stirring.  Viral titer was determined by qPCR of a dilution series using 
primers that recognize the inverted terminal repeats and comparison to AAV of a 
known titer obtained from the University of Iowa viral vector core.  Prior to 
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injection, all AAVs were adjusted with sterile saline to a titer of 1x1013 viral 
particles/ml.   
Animals. Mice were obtained from the Jackson laboratory (C57Bl/6 and 
BACHD (through W. Yang lab)) or bred in the Caltech facility from breeding pairs 
obtained from the Jackson laboratory (R6/2, N171-82Q and YAC128).  Due to 
the infertility of the R6/2 line, ovarian transplant hemizygote females and WT 
males were used. Wild type females and hemizygote males were used for mating 
in the N171-82Q and YAC128 lines.  Genotyping PCR was performed as 
specified on the Jackson laboratory website. Mice were housed in ventilated 
cages and all surgical and experimental procedures were carried out according 
to Institute Animal Care and Use Committee specifications.   
Surgeries. Adult mice were anesthetized with 500 mg/kg ketamine and 
100 mg/kg xylazine and placed in a sterotaxic frame. After shaving and 
disinfecting the scalp, an incision was made along the midline.  A dental drill was 
used to make a burr hole at 0.75 mm anterior and 2 mm lateral to bregma.  
Injections were done at a depth of 3.5 mm from the dura using a 5 μl Hamilton 
syringe and removable 30-gauge needle with a 20o bevel tip attached to an ultra 
micropump III and micro4 controller (World Precision Instruments, FL). After 
injection, the needle was left in place for five minutes and withdrawn slowly.  
Incisions were closed using vet bond glue (3M, St Paul, MN) and mice were 
allowed to recover on a heating pad.  Mice were checked for general health daily 
for three days following surgery.  
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For the lentiviral model, four week-old C57Bl/6 mice were injected 
unilaterally in the striatum on alternating sides with 4 μl mHDx-1 or GFP lentivirus 
plus 1 μl GFP, VL12.3 or Happ1 AAV at a rate of .5 μl/min (10 mice per group).  
Four week old male N171-82Q and WT littermates were injected bilaterally in the 
striatum with 1 μl of GFP or Happ1 AAV followed by 4 μl sterile saline at a rate of 
0.5 μl/min (10 mice per group). The needle was loaded first with saline and then 
with virus so that saline is injected after the virus and serves to push virus into 
the brain, increasing spread. Two month-old male YAC128 and WT littermates 
were injected bilaterally in the striatum with 1μl GFP, VL12.3 or Happ1 AAV 
followed by 4 μl sterile saline at a rate of 0.5 μl/min (10 mice per group).  Two 
month-old male and female BACHD mice were injected bilaterally in the striatum 
with 1 μl of either GFP or Happ1 AAV followed by 4 μl sterile saline at a rate of 
0.5 μl/min (5 females and 4 males per group).   
Postnatal day 3 male R6/2 and WT littermates were anesthetized by 
hypothermia by submersion in ice water inside a latex glove for five minutes.  
Pups were then placed on an ice pack with their heads stabilized in a putty mold 
for the duration of the surgery.  After disinfecting the scalp, a 5 μl Hamilton 
syringe with a removable 33-gauge needle with a 20o bevel tip was pushed 
through the skin and skull at approximately the center of each forebrain 
hemisphere to a depth of 2.5 mm.  Bilateral injections of 1 μl GFP, VL12.3 or 
Happ1 AAV at a rate of 0.1 μl/min were performed using an ultra micropump III 
and micro4 controller. The needle was left in place for an additional five minutes 
and withdrawn slowly. Pups were allowed to recover on a 37o water circulating 
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heating pad, and a small amount of the dam’s urine was rubbed on their rump to 
prevent subsequent cannibalism.  Pups were checked for the presence of a milk 
spot two hours after surgery and for general health daily for three subsequent 
days.  After weaning, genotyping was performed to determine how many mice 
from each of the 6 groups had been injected until a minimum of 20 per group was 
reached. Ten mice per group were sacrificed for histology at 10 weeks of age 
while the remaining mice were studied until the point of mortality.   
Behavioral assays. All behavioral experiments were conducted during 
the light cycle by a researcher blind to genotype and treatment group.  Repeated 
tests were conducted at approximately the same time of day.  Single time point 
behaviors were compared using ANOVA.  Repeated behavior tests were 
compared using repeated measures ANOVA for lines where all animals were 
sacrificed at the same age (YAC128 and BACHD) and 2 way ANOVA at 
individual time points for lines where animals were tested until a disease related 
endpoint was reached and therefore not sacrificed at the same age (R6/2 and 
N171-82Q).  Bonferroni post-hoc tests were used to determine significance. 
Amphetamine-induced rotation. Mice were injected i.p. with 10 mg/Kg 
amphetamine in sterile saline and placed in a 50x50 cm open white plexiglass 
box with 16 cm sides.  Activity was recorded for 30 minutes beginning 5 minutes 
after amphetamine injection by a ceiling-mounted video camera.  The number of 
ipsilateral rotations was counted.  Only rotations with a diameter similar to the 
animal’s body length or smaller (as opposed to large circles around the edge of 
the box) were scored.   
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Rotarod. The latency to fall from an accelerating rotarod (Ugo Basile,Italy) 
beginning at 5 RPM and accelerating to 40 RPM over 240 seconds was scored.  
Mice were allowed to stay on the rotarod for a maximum of 300 seconds. Mice 
were trained prior to the initial test for 2 consecutive days for R6/2, N171-82Q 
and YAC128 lines, and 3 consecutive days for the BACHD line.  Two trials were 
performed per training day with a 10 minute ITI.  On testing days, 2 trials were 
performed separated by a 10 minute ITI.  Only the second trial was scored.   
Beam Crossing. The time to cross the center 80 cm of a 1 m beam was 
scored.  Three square beams of different widths were used (28 mm, 12 mm, and 
6 mm). The beams were mounted atop poles (50 cm above the tabletop) with a 
bright light at the starting end and a dark box containing the animal’s home cage 
nest material at the far end.  A nylon hammock 7.5 cm above the tabletop was 
used to prevent injury to mice falling from the beam.  Mice were placed at the 
end of the beam with the bright light and the time from when the entire body of 
the mouse entered to the time that the nose of the mouse exited the center 80 
cm was measured using an electronic infrared interrupt sensor. The 80 cm 
section is used because the mice sometimes hesitate before starting and before 
entering the dark box. Mice were trained prior to the initial test for 3 consecutive 
days on all beams with a 10 minute ITI between beams.  During training, mice 
were encouraged to keep moving across the beam by nudging and tail pinching.  
Training trials were repeated until each animal crossed the beam 3 times without 
stopping or turning around.  On testing days, 3 trials were performed per mouse 
for each beam with a 10 minute ITI between beams.  Trials in which the animal 
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took longer than 60 s to cross or fell off the beam were scored as 60 s.  Trials in 
which the animal stopped or turned around were repeated.  The average of the 
trials was scored.   
Climbing. Mice were placed at the bottom end of a closed topped wire 
mesh cylinder (10x15 cm) on the tabletop and recorded with a video camera for 5 
minutes.  The time from when a mouse’s fourth foot left the tabletop to the time 
when the first foot was replaced on the tabletop was scored as time spent 
climbing.  The sum of climbing time for the 5 minute trial was compared.  
Clasping. Animals were suspended by the tail approximately 30 cm 
above the tabletop for 1 min and recorded with a video camera.  No clasping was 
scored as 0, front limb clasping was scored as 1, and hind limb clasping was 
scored as 2.  
Open field, novel object, novel object location and novel object 
preference. Mice were placed in the lower left corner of a 50x50 cm open white 
plexiglass box with 16 cm sides in a room brightly lit by fluorescent ceiling lights. 
Open field activity was recorded for 10 minutes by a ceiling-mounted video 
camera. Center entries and time spent in the center were scored.  Mice were 
then removed from the box for a 5 minute ITI and two different novel objects 
were placed in the upper two corners of the box, far enough from the sides so as 
to not impede movement around the outer edge (approximately 7 cm).  The 
mouse was re-introduced to the box in the lower left corner and recorded for 5 
minutes during which the number of investigations of the novel objects was 
scored.  Episodes involving the mouse in close proximity to the objects but not 
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facing or sniffing them were not considered investigations.  Circling or rearing on 
the objects with continued sniffing was considered a single investigation while 
episodes in which the mouse sniffed the object, turned away or reared against 
the wall and subsequently turned back to sniff the object again were considered 
separate investigations.  Combined investigations of both objects were scored for 
novel object testing. Mice were then removed from the box a 5 minute ITI and the 
object at the top right corner of the box was moved to the lower right corner of 
the box.  Mice were re-introduced to the box and recorded for 5 minutes, and the 
number of investigations of the objects was scored. For novel object location 
testing, the percent of investigations of the target object (the one in the new 
location) was computed. For novel object preference testing, the experiment was 
repeated on the subsequent day with the exception that rather than moving the 
position of the object in the top right corner, it was replaced by a different, 
unfamiliar object in the same location.  The percent of investigations of the target 
object (the unfamiliar one) was computed. 
Survival. When animals became obviously ill, they were assessed twice 
daily for the loss of righting reflex.  If animals failed to right themselves 
immediately after being laid on their side in the home cage they were euthanized.   
Histology. Brain tissue was fixed by transcardiac perfusion of 4% PFA in 
PBS.  Brains were post-fixed in ice cold 4% PFA in PBS for 45 minutes and then 
placed in 30% sucrose at 4oC overnight until they sunk. Brains were then 
embedded in optimal cutting temperature (OCT) embedding medium and cut in 
16 μm slide mounted coronal sections.  Sections were stored at –20oC until 
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immunohistochemistry (IHC).  For IHC, sections were blocked for 30 minutes at 
room temperature in 3% BSA, 10% normal goat serum, 0.1% triton-X100 and 
.02% sodium azide in PBS.  Antibodies were diluted in the blocking solution.  
Primary antibodies were incubated on sections overnight or for 48 hrs (anti-HA) 
at 4oC.  Secondary antibodies were incubated on sections for 2 hrs at room 
temperature. Primary antibodies used include rabbit anti-DARPP-32 (1:500, 
Chemicon, Billerica, MA), mouse anti-Htt MW8 (Ko et al., 2001),mouse anti-Htt 
EM48 (1:1000, Chemicon), rabbit anti-GFP (1:400, Invitrogen), mouse anti-NeuN 
(1:500, DAKO, Carpinteria CA), rabbit anti-GFAP (1:500 Chemicon) and mouse 
anti-HA (1:200, Covance, Princeton, NJ).  Secondary antibodies used include 
Alexa-fluor 350 (blue)-, 488 (green)- and 568 (red)-labeled goat anti-mouse or 
anti-rabbit (1:250, Invitrogen).  Topro-3 iodide nuclear stain (Invitrogen) was 
incubated at 1:5000 in PBS for 5 min at RT after secondary antibody. Animals 
with less than 50% of the striatal area transduced at 0.75 mm anterior to bregma 
were eliminated from all behavioral and histological analyses. Quantification of 
IHC was compared using 2 way ANOVA and Bonferroni post-hoc tests for 
significance.   
Lentiviral HD model. Three sections per mouse selected from the 
anterior region of the forebrain (1.7-2 mm anterior to bregma), the injection site 
(0.75 mm anterior to bregma), and the posterior region of the forebrain (0.8-1 mm 
posterior to bregma) were stained for GFP (green) and HA (iAb, red) to 
determine the extent of viral transgene spread.  In the case of the iAb-treated 
groups, these sections were also used to determine the similarity of spread and 
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co-transduction efficiency of the mHDx-1 lentivirus and iAb AAV.  Three sections 
per mouse selected near the injection site were stained for Htt inclusions (MW8, 
green), DARPP-32 (red) and all nuclei (blue).  Striatal Htt inclusions were 
quantified by counting green foci larger than 2 pixels at 40X magnification for 
each section.  Striatal DARPP-32 staining was assessed both for the area of the 
lesion and for the intensity of staining within the lesion.  For lesion area, the ratio 
of the area of total DARPP-32 loss to the area of striatal lentiviral transgene 
spread was calculated.  For staining intensity, the ratio of DARPP-32 (red 
fluorescence) staining in the transduced area of the injected striatum to DARPP-
32 staining in the same area of the contralateral, un-injected striatum was 
calculated.  Image J was used for all three quantifications. To further characterize 
lesions, 2 sections per mouse were stained for DARPP-32 (red), GFAP (green), 
and NeuN (blue) or all nuclei (topro-3 iodide, blue).   
R6/2 HD model. Three sections per mouse selected from the anterior 
region of the forebrain, the injection site (~0.75 mm anterior to bregma), and the 
posterior region of the forebrain from both the group sacrificed at 10 weeks of 
age and the group used to assess survival were stained for GFP (green), and HA 
(red) to determine the extent of viral transgene spread.  Three sections per 
mouse at approximately bregma from the group sacrificed at 10 weeks of age 
were stained for Htt inclusions (MW8, green), DARPP-32 (red), and all nuclei 
(topro-3-iodide, blue).  Small Htt aggregates were quantified by counting green 
foci 2-8 pixels in size within a 250 μm2 area of the transduced striatum.  
Intranuclear inclusions were quantified by counting green foci 9-15 pixels in size 
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that co-localized with topro-3-iodide staining. DARPP-32 was quantified by mean 
red fluorescence intensity of the entire striatal area of both hemispheres.  
Ventricle area was also measured for both hemispheres of these sections by 
tracing its outline (area computed in arbitrary units).  Image J was used for all 
three of these measures.   
N171-82Q HD model. Three sections per mouse selected from the 
anterior region of the forebrain, the injection site (0.75 mm anterior to bregma), 
and the posterior region of the forebrain were stained for GFP (green), and HA 
(red) to determine the extent of viral transgene spread.  Neuropathological 
markers were not assessed for these animals as they were used to assess 
survival and were therefore not euthanized at the same age but at the same 
disease stage.   
YAC128 and BACHD HD models. Three sections per mouse selected 
from the anterior region of the forebrain, the injection site (0.75 mm anterior to 
bregma), and the posterior region of the forebrain were stained for GFP (green), 
and HA (red) to determine the extent of viral transgene spread.  Three sections 
per mouse at approximately bregma were stained for Htt inclusions (EM48, 
green), DARPP-32 (red), and all nuclei (blue).  DARPP-32 was quantified by 
mean red fluorescence intensity of the entire striatal area of both hemispheres.  
Ventricle size was also measured for both hemispheres of these sections.  Image 
J was used for these measures. 
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FIGURES 
 
Fig 1 
 
Figure 1. Schematic of intrabody gene therapy experiment in HD mice. Viral 
vectors used in each case are listed below model names. Abbreviations used: 
AIR, amphetamine-induced rotation; BC, beam crossing; C, climbing; CL, 
clasping; NO, novel object; NOL, novel object location; NOP, novel object 
preference; OF, open field; RR, rotarod; S, survival. Dotted line indicates that RR 
and BC were continued until death.  
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Fig 2 
 
 
Figure 2. Lentivirus and AAV2/1 vectors co-transduce cells and display 
similar spread. Coronal sections from a mouse injected unilaterally with a 
mixture of mHDx-1 lentivirus and VL12.3 AAV were stained for Htt  (green) and 
intrabody (red). (A) Three different anterior/posterior levels show a similar spread 
between the two viruses. Numbers indicate mm from bregma. (B) Confocal 
images show co-localization of mHDx-1 and VL12.3 with more cells being VL12.3 
positive than mHDx-1 positive, indicating co-transduction of cells and greater 
transduction efficiency for AAV. scale bar = 50 μm  
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Fig 3 
 
Figure 3. Spread of GFP AAV injected on postnatal day 3.  Coronal sections 
from an R6/2 mouse injected with AAV-GFP on postnatal day 3 and sacrificed at 
10 weeks of age. Three different anterior/posterior levels show striatal spread 
equivalent to, or better than, that seen for adult injections. Numbers indicate mm 
from bregma. 
 
Fig 4 
 
Figure 4. Co-injection of VL12.3 or Happ1 AAV prevents the amphetamine-
induced rotation phenotype caused by mHDx-1 lentivirus.  Wild type mice 
were injected unilaterally at 4 weeks of age with mHDx-1 or GFP lentivirus plus 
GFP, VL12.3 or Happ1 AAV.  At 10 weeks of age mice were assayed for 
amphetamine-induced rotation. Un-injected (naïve) animals were tested as a 
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negative control. Animals injected with mHDx-1 lentivirus and GFP AAV exhibit 
many ipsilateral rotations in response to amphetamine.  VL12.3 or Happ1 
prevents this phenotype. ***=p<.001 
 
Fig 5 
 
Figure 5. Happ1 treatment improves rotarod performance in four HD mouse 
models. Mice were tested on an accelerating rotarod for a maximum of 300 
seconds. (A) Male R6/2 and WT littermates were tested weekly and Happ1 
treatment significantly improves performance during weeks 9-12 while VL12.3 
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treatment degrades performance during weeks 10-12.  (B) Male N171-82Q and 
WT littermates were tested every other week. Happ1 treatment improves 
performance to a level not different from WT animals from 22 weeks until 38 
weeks. (C) Male YAC128 and WT littermates were tested monthly and Happ1 
(but not VL12.3) treatment significantly improves performance at months 3, 4 and 
7. (D) YAC128 rotarod performance showing only GFP- and Happ1-treated 
groups. (E) Male and female BACHD mice were tested monthly and Happ1 
treatment significantly improves performance at months 5 and 6.  Asterisks 
indicate difference between GFP- and iAb-treated mutants. *=p<.05, **=p<.01, 
***=p<.001 
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Fig 6 
 
Figure 6. Happ1 treatment improves beam crossing performance in four HD 
mouse models. Time to cross the center 80 cm of a square 1 m long, 28 mm, 12 
mm or 6 mm wide (indicated by the different sizes of open boxes in each panel) 
beam was measured. (A-C) Male R6/2 and WT littermates were tested weekly, 
and Happ1 treatment improved while VL12.3 treatment degraded performance.  
(D-F) Male N171-82Q and WT littermates were tested every other week and 
Happ1 treatment improved performance. (G-I) Male YAC128 and WT littermates 
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were tested monthly, and Happ1 treatment improved performance. (J-L) Male 
and female BACHD mice were tested monthly, and Happ1 treatment improved 
performance.  Asterisks indicate difference between GFP- and iAb-treated 
mutants. *=p<.05, **=p<.01, ***=p<.001  
 
 
Fig 7 
 
Figure 7. Happ1 treatment improves climbing performance in HD 
transgenic mice. To assay climbing performance, mice were placed at the 
bottom of a vertical wire mesh tube and observed for 5 minutes.  Time when all 
four feet were off the ground was scored as climbing time.  (A) 7 month old GFP- 
and VL12.3-treated YAC128 mice have impaired climbing compared to WT mice.  
This is rescued by Happ1 treatment. (B) Happ1 treatment improves climbing time 
in 6 month old BACHD mice. *=p<.05, **=p<.01 
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Fig 8 
 
Figure 8. Happ1 treatment reduces clasping in N171-82Q HD mice. (A) The 
GFP-treated N171-82Q mouse (left) displays forelimb and hind limb clasping and 
reduced body weight while the Happ1-treated N171-82Q mouse (right) displays 
normal limb extension and body weight. (B) 20 week old male N171-82Q and WT 
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littermates were tested for clasping.  Mice were suspended by the tail, observed 
for 1 minute, and given a clasping score as follows: no clasping=0, forelimb 
clasping=1, hind limb clasping=2. *=p<.05 
Fig 9 
 
Figure 9. Happ1 treatment normalizes open field behavior in full-length 
transgenic models of HD. Mice were observed for 10 minutes during 
exploration of an open field.  Anxiety was inferred by scoring entries into, and 
time spent in, the center of the open field. (A, C) There was a trend toward 
increased center entries for both models in response to Happ1 treatment, but it 
was not significant. (B, D) Happ1 treatment increases time spent in the center of 
the open field in (B) 7 month old YAC128 mice and (D) 6 month old BACHD 
mice.  *=p<.05, **=P<.01 
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Fig 10 
 
Figure 10. Happ1 treatment increases investigation of a novel object in 
female BACHD mice.  Mice were habituated to an open field for 10 min, 
removed for 5 min, and then re-introduced to the same field now containing a 
novel object in each upper corner.  Investigation of the novel objects was scored 
for 5 min.  (A) There is a trend toward increased investigation of the novel objects 
as a result of Happ1 treatment in 7 month old YAC128 mice. (B) Happ1 
treatment increases investigation of the novel objects in female but not male 6 
month old BACHD mice. **=p<.01 
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Fig 11 
 
Figure 11. Happ1 treatment improves the learning deficit of YAC128 mice.  
(A) To assay for preference of a known object in a novel location mice were 
habituated to an open field for 10 min.  After a 5 min inter-trial interval (ITI), they 
were exposed for 5 min to novel objects in the upper corners of the open field 
(T1).  Investigation of the novel objects was scored. After another 5 min ITI, the 
mice were re-introduced to the same field with the object previously in the upper 
right corner moved to the lower right corner (T2) for 5 min.  The percent of 
investigations of the target object (the one in the new location) was scored.  A 
score of 50% would indicate no preference. (B) On the next day mice were tested 
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for preference for a novel object. Mice were re-habituated to the open field for 10 
min. After a 5 min ITI, they were exposed for 5 min to 2 objects in the upper 
corners of the open field (T1).  Investigation of the objects was scored. After 
another 5 min ITI the mice were re-introduced to the same field with the object in 
the upper right corner replaced with a completely novel object in the same 
location. The percent of investigation of the target object (the completely novel 
one) was scored.  A score of 50% would indicate no preference. (C, D) 7 month 
old YAC128 and WT littermates were tested.  WT mice display a preference for 
the novel object location (C) and a trend toward a preference for the novel object 
(D). This does not reach significance, but when data from the 3 WT treatment 
groups is pooled, the preference is significant (p<.01). GFP- and VL12.3-treated 
YAC128 mice show no preference for either object in either paradigm, indicating 
a learning deficit.  Happ1 treatment improves this deficit. (E, F) GFP- and Happ1-
treated BACHD mice show no preference for either object in either paradigm. 
There is a trend toward a preference for the novel object in Happ1 treated 
BACHD mice, but it does not reach significance. *=p<.05, ***=p<.001 
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Fig 12 
 
Figure 12. Happ1 treatment improves body weight of N171-82Q mice. (A) 
While R6/2 mice weigh significantly less than WT mice from 10 weeks of age 
until death, there is no effect of intrabody treatment.  Asterisks indicate difference 
between GFP-treated WT and R6/2 mice. (B) While Happ1 treated N171-82Q 
mice weigh less than WT littermates, they also weigh more than GFP treated 
mutants. Asterisks indicate difference between GFP- and Happ1-treated N171-
82Q mice. (C) While YAC128 mice trend toward weighing more than WT mice, 
there is no effect of intrabody treatment. (D) While male BACHD mice weigh 
more than female mice, there is no effect of intrabody treatment. Asterisks 
indicate difference between GFP-treated male and female mice. *=p<.05, 
**=p<.01, ***=p<.001 
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Fig 13 
 
Figure 13. Happ1 treatment increases survival of N171-82Q mice. (A) Happ1 
treatment has no effect on while VL12.3 decreases survival of R6/2 mice. (B) 
Happ1 treatment increases maximum survival of N171-82Q mice 33% from 30 
weeks to 40 weeks of age (p<.05). 
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Fig 14 
 
Figure 14. mHDx-1 lentivirus causes neuron-specific toxicity in the 
striatum, which is reduced by VL12.3 or Happ1. Mice were injected unilaterally 
with mHDx-1 or GFP lentivirus plus GFP, VL12.3 or Happ1 AAV. Areas with loss 
of DARPP-32 staining were analyzed. (A) Areas of DARPP-32 loss (lower 
panels) also show loss of NeuN-positive cells, indicating death of neurons in 
these areas. (B) Topro-3 iodide nuclear stain shows the presence of cells in 
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lesioned areas, indicating that toxicity is neuron-specific. (C) Areas of DARPP-32 
loss show increased GFAP staining, indicating increased inflammation in 
lesioned areas. (D-F) Co-injection of either Happ1 or VL12.3 with mHDx-1 
reduces the area and intensity of DARPP-32 loss. (D) Adjacent coronal sections 
stained either for mHDx-1 (green) or DARPP-32 (red).  DARPP-32 loss is 
reduced in the presence of either intrabody.  (E) The ratio of the area of total 
DARPP-32 loss to the transduced area was compared to assess lesion size.  
Lesions are significantly smaller in the presence of either intrabody. Three 
sections per mouse were analyzed. (F) The ratio of DARPP-32 staining 
fluorescence intensity in the transduced area of the striatum to DARPP-32 
staining fluorescence intensity in the same sized area of the un-injected striatum 
was compared to assess the severity of the lesion.  Lesions are more severe in 
the absence of intrabody. Three sections per mouse were analyzed. *=p<.05 
**=p<.01, scale bar = 50 μm 
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Fig15
 
Figure 15. VL12.3 treatment decreases DARPP-32 staining in R6/2 mice. 
DARPP-32 staining intensity of the entire striatum in 3 sections each at 
approximately bregma was measured in (A) 10 week old R6/2 and WT 
littermates, (B) 7 month old YAC128 and WT littermates, and (C) 6 month old 
BACHD mice. (A) Compared to WT littermates, R6/2 mice display decreased 
DARPP-32 staining, which is exacerbated by VL12.3 treatment.  There is no 
significant loss of DARPP-32 staining and no effect of iAb treatment in (B) 
YAC128 or (C) BACHD mice. ***=p<.001 
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Fig 16 
 
Figure 16. VL12.3 or Happ1 decreases Htt aggregation in the lentiviral and 
R6/2 HD models. Three sections each of (A) mHDx-1 lentivirus-injected and (B) 
10 week old R6/2 brains were stained for Htt. Following GFP-AAV injection in 
both models, the majority of the Htt is aggregated although some diffuse staining 
in neurons is seen (arrows in left panel A).  With injection of VL12.3 or Happ1 
there is a reduction in aggregated Htt and an increase in diffuse Htt staining.  In 
the presence of Happ1, total Htt staining appears reduced. (C) The ratio of 
  
109
 
striatal aggregates to transduced area is reduced by both intrabodies.  (D) The 
number of small Htt aggregates per 250 μm2 is reduced by both intrabodies.  (E) 
Happ1 treatment reduces the number of intranuclear inclusions per 250 μm2. 
*=p<.05, **=P<.01, ***=p<.001, scale bars = 50 μm 
 
Fig 17 
 
Figure 17. Happ1 treatment reduces ventricular enlargement in three HD 
mouse models. Ventricle area was measured at approximately bregma in 3 
sections each from (A, B) 10 week old male R6/2 and WT littermates, (C) 7 
month old male YAC128 and WT littermates, and (D) 6 month old male and 
female BACHD mice.  Both R6/2 and YAC128 mice display increased ventricle 
size compared to WT littermates.  (B) There is a trend toward reduced ventricular 
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enlargement in response to Happ1 treatment. (C) Happ1 treatment reduces 
ventricular enlargement in YAC128 mice. (D) Happ1 treatment reduces 
ventricular enlargement in BACHD mice. *=p<.05, **=p<.01, ***=p<.001 
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Appendix A  
 
Recombinant Intrabodies as Molecular Tools and Potential  
Therapeutics for Huntington's Disease 
 
 
Ali Khoshnan, Amber Southwell, Charles Bugg, Jan Ko and Paul H. Patterson 
"New therapeutics in Huntington’s disease", eds. RE Hughes and DC Lo. Taylor & Francis 
group, in press. 
 
 The therapeutic potential of intracellularly expressed, recombinant 
or single-chain fragment variable (scFv) antibodies (intrabodies) is being 
explored for several diseases including cancer, HIV and neurodegenerative 
disorders.  Intrabodies can bind and inactivate toxic intracellular proteins, prevent 
misfolding, promote degradation and block aberrant protein-protein interactions 
with extreme molecular specificity.  Neurodegenerative disorders are particularly 
attractive candidates for these reagents, since many of these diseases involve 
protein misfolding, oligomerization and aggregation (1).  In particular, intrabodies 
have shown efficacy in blocking the toxicity of the amyloidogenic protein 
fragment Aβ in cell culture and mouse models of Alzheimer's disease, paving the 
way for clinical trials of these reagents in brain disorders (2).  In addition to their 
therapeutic potential, intrabodies are also useful molecular tools to identify the 
pathogenic epitopes in toxic proteins, which can be targets for other types of 
therapy.  In this chapter, we will review the strategies that have been used to 
develop intrabodies specific for the huntingtin (htt) protein, and describe their 
testing in models of Huntington’s disease (HD) and their development as 
potential therapeutics for clinical use in HD.  
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STRATEGIES FOR INTRABODY CONSTRUCTION  
Intrabodies are recombinant antibody molecules usually derived from a 
monoclonal antibody of interest by cDNA cloning of the antigen binding domain; 
the variable heavy and light chains (VH and VL) from the monoclonal antibody are 
then joined together by a synthetic cDNA encoding a flexible polypeptide linker 
(Fig. 1A). Alternatively, naïve intrabody libraries have been constructed and 
cloned in phage or displayed on yeast for selection and binding to specific 
antigens (Fig 1B). 
A major problem with intracellular expression of intrabodies is, however, 
proper folding and low solubility in the reducing cytoplasmic environment 
((Biocca et al., 1995).  This is due to the presence of disulfide bonds in both the 
VH and VL, which are required for efficient folding.  While some intrabodies are 
inherently stable in the cytoplasm, selection of stable intrabody frameworks, 
which fold efficiently in the absence of disulfide bonds, has also been achieved 
(4).   Additionally, a process known as in vitro maturation or re-engineering, 
where the disulfide bonds are removed, can be used to correct low solubility 
through several rounds of random mutagenesis and antigen binding selection (5). 
Single domain intrabodies.  Recently, functional single domain (VH or 
VL) intrabodies have also been developed and selected for specific targets.  
These single domain intrabodies can block protein-protein interaction and are 
favored for their stability and better folding (6).  Moreover, in vitro maturation of 
single domain intrabodies can further enhance their folding, specificity and 
solubility (5).  
  
113
 
DEVELOPMENT OF EPITOPE-SPECIFIC INTRABODIES AGAINST HTT 
 Epitopes in mutant huntingtin for intrabody development.  
Intrabodies recognizing a variety of epitopes within mutant huntingtin (Htt) exon-1 
(HDx1) have been isolated and tested for their ability to block toxicity and 
aggregation (Fig. 2).  Lecerf and colleagues have isolated an intrabody 
recognizing the 17 N-terminal AA of Htt (C4) from a synthetic phage library and 
tested this intrabody for efficacy in cell culture (7).  C4 was found to block 
aggregation and interfere with malonate-enhanced toxicity of mutant HDx1 
(Murphy and Messer, 2004).  Due to its modest efficacy, C4 was further matured 
and examined in a fly model of HD, where it was found to protect against the 
toxicity of HDx1 during the larval stage and significantly increase life span 
(Wolfgang et al., 2005). 
Surprisingly, C4 increased the level of soluble mutant HDx1 in both fly and 
culture models (9).  This property of C4 raises the possibility that long-term 
exposure to this intrabody could lead to buildup of soluble HDx1 and promote 
oligomerization and toxicity.  Recent studies suggest that mutant HDx1 
monomers can acquire a toxic conformation by switching from an α-helical to a β-
sheet conformation (10).  Furthermore, blocking the 17 N-terminal AA of Htt may 
also have other undesirable consequences; for example, this motif is essential 
for vesicle localization as well as Htt cytoplasmic retention and turnover (11, 12) 
and removal of the N-terminal domain results in nuclear localization of HDx1, 
which has been associated with enhanced toxicity (11, 12).  Therefore, long-term 
expression studies in transgenic HD mice will be important to examine if binding 
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of C4 to the 17 N-terminal AA of Htt has any detrimental effects in a therapeutic 
setting. 
Another intrabody that binds the N1-17 domain of Htt (VL12.3) was 
isolated from a yeast surface display library as a single domain light chain and 
matured in vitro through random mutagenesis and selection by yeast surface 
display (5).  VL12.3, engineered for efficient intracellular expression and folding 
by removal of its disulfide bond, is a more potent inhibitor of mutant HDx1 
aggregation and toxicity in cell culture than C4 (13).  However, like C4, VL12.3 
increases the level of soluble mutant HDx1; moreover, VL12.3 promotes nuclear 
localization of mutant HDx1 (14). This paradoxical inhibition of toxicity and 
aggregation together with enhancement of nuclear localization of Htt may 
eventually shed light on the role of nuclear Htt in toxicity.  In fact, intrabodies 
such as VL12.3 may have important research and clinical potential in blocking 
association of soluble mutant HDx1 with nuclear targets. Examination of VL12.3 
in animal models of HD is crucial for validating its protective effects and further 
understanding of the role of N-17 AA in mutant Htt toxicity.  
The polyglutamine and polyproline domains of Htt.  Intrabodies 
recognizing the polyglutamine (polyQ) and proline-rich motifs of HDx1 have also 
been shown to influence toxicity.  We generated a number of monoclonal 
antibodies using either polyQ peptides or HDx1 recombinant proteins as antigens 
(15).  The intrabodies cloned from these antibodies display striking, epitope-
specific differences in their effects on mutant HDx1 toxicity.  The MW7 intrabody, 
which recognizes the polyproline (polyp) motifs of mutant HDx1, protects against 
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toxicity in several models of HD, including cell culture (Fig. 3), acute brain slice 
culture, and Drosophila models (16, 17, Reinhart et al., unpublished data).  This 
protection is correlated with reduced aggregation and increased turnover of 
mutant HDx1 (14, 16). 
In contrast, intrabodies that bind the expanded polyQ domain exacerbate 
the toxicity and aggregation of mutant HDx1 in cell culture (16).  One possible 
explanation for this effect is that the MW1 and MW2 intrabodies may bind and 
stabilize a novel confirmation in HDx1 with expanded polyQ.  In fact, several anti-
polyQ antibodies bind Htt in different cellular compartments, supporting the 
presence of distinct conformations of expanded polyQ (15).  On the other hand, 
anti-polyQ intrabody binding could aid in nucleation of monomeric mutant HDx1 
and accelerate oligomerization.  In a study of the crystal structure of MW1 bound 
to polyQ, the polyQ domain adopts an extended, coil-like structure with short 
sections of polyproline type II helix and β-strand.  Consistent with the linear 
lattice model (18) for polyQ, linking MW1 intrabodies together in a multimeric 
form results in tighter binding to longer compared to shorter polyQ domains and, 
compared with monomeric Fv, binds expanded polyQ with higher apparent 
affinity (19).  Whether the affinity of the monomeric vs. multimeric form of MW1 
could influence the oligomerization of mutant Htt, remains unknown.  
Clearly, a unified view on the role of aggregates in HD pathology will be 
required to understand better how anti-polyQ intrabodies could be used to 
regulate mutant htt toxicity.  The initial studies of the effects of MW1 and MW2 on 
HDx1 toxicity and aggregation were done in non-neuronal cells and with 103 
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polyQ HDx1, which may require a high concentrations of intrabody to counteract 
its toxicity.  Thus, reevaluation of anti-polyQ intrabodies is worthy of investigation, 
possibly with shorter polyQ repeats or a multimeric form of MW1 (18).  Indeed, in 
light of recent findings that mutant HDx1 aggregation can be neuroprotective, 
anti-polyQ intrabodies will be ideal tools to dissect the role of aggregation and 
toxicity in neuronal models (20).     
The proline-rich domain of Htt.  Finally, we have recently isolated two VL 
domain intrabodies from a human scFv phage display library (24) that specifically 
bind to the proline-rich epitope in HDx1 (which is between the two pure polyP 
domains discussed above)(14).  These single-domain intrabodies (Happ1 and 3, 
Fig. 1) are efficient in reducing HDx1 toxicity and aggregation.  A novel feature of 
these intrabodies, and of the anti-polyP intrabody MW7, is their reduction of 
soluble mutant HDx1 levels by increasing its turnover.  It is intriguing that 
although the proline-rich epitope is identical in mutant and wild-type (WT) Htt, the 
Happ intrabodies have a greater effect on turnover of the mutant versus WT Htt 
(14).  In addition, the inhibitory effects of Happ1 and 3 suggest that the proline-
rich domain of Htt also contributes to Htt toxicity and may be involved in the 
misfolding of mutant HDx1 or in its binding to partners critical for toxicity.   
Conformation-specific intrabodies.  Isolation of conformation specific 
polyQ intrabodies may help in determining whether expanded polyQ can be a 
potential target for intrabody therapy.  This approach has recently been reported 
for α-synuclein oligomers (21). These oligomer-specific intrabodies inhibit both 
aggregation and toxicity of α-synuclein and have been useful tools for identifying 
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the pathogenic epitopes.  Our laboratory, in collaboration with Ron Wetzel's 
group, isolated a panel of monoclonal antibodies that specifically recognize 
oligomeric forms of polyQ proteins. Interestingly, some of these antibodies also 
react with fibrils formed by prion proteins and Aβ amyloid (22).  This cross-
reactivity suggests the presence of common structural motifs in the fibrils of 
misfolded proteins that cause neurodegeneration.  A similar antiserum that also 
reacts with amyloid fibrils of various misfolded proteins has been reported by 
Glabe's laboratory (23).  It will be interesting to see if intrabodies derived from 
these antibodies can block oligomerization and the toxicity of these diverse 
proteins in vivo.  
 
INTRABODIES AS RESEARCH TOOLS TO DISSECT MECHANISMS OF HTT DISEASE 
PATHOGENESIS.  
While the therapeutic potential of intrabodies in mouse HD models 
remains to be explored, anti-Htt intrabodies are powerful molecular tools that can 
be used to identify and characterize the pathogenic epitopes in HDx1 that 
regulate oligomerization, toxicity, and interactions with other disease 
mechanisms and pathways.  The findings that intrabodies directed against 
various epitopes of HDx1 can either block or enhance aggregation and toxicity 
underscore the importance of these domains. 
For example, it is known that the first 17 amino acids of HDx1 regulate not 
only its nuclear targeting but also its endoplasmic reticulum and mitochondrial 
localization (11, 12).  One hypothesis is thus that VL12.3 reduces toxicity by 
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blocking the localization of mutant HDx1 to mitochondria and thereby reducing 
mitochondrial permeability.  On the other hand, consistent with the role of the first 
17 AA in cytoplasmic retention of HDx1, co-expression of VL12.3 with HDx1 also 
promotes HDx1 nuclear localization (14).  Thus, as noted above, while studies 
with VL12.3 confirm the importance of 17 N-terminal AA in cellular distribution of 
Htt and the contribution of this motif to aggregation and toxicity (11, 12), they also 
raise questions regarding whether and how nuclear localization contributes to 
toxicity.  One possibility is that although VL12.3 promotes nuclear localization of 
HDx1, it may also prevent its association with the transcriptional apparatus. 
Similarly, the ability of anti-polyQ intrabodies to promote aggregation and 
toxicity of mutant HDx1 (16) may be relevant for understanding the mechanism of 
in vivo oligomerization.  One theory is that anti-polyQ intrabodies function as 
nucleating centers and recruit soluble HDx1, which then forms oligomers and 
eventually aggregates.  Alternatively, binding of anti-polyQ intrabodies may 
induce or stabilize a conformation in the expanded polyQ domain that enhances 
oligomerization.  If so, this raises the question of whether there are endogenous 
cellular modifiers that induce such conformation changes in this domain.  
Understanding how MW1 and 2 promote aggregation may thus shed light on this 
process in vivo and enable discovery of modifiers of polyQ oligomerization.  In 
this context, it is intriguing that intracellular expression of a polyQ binding peptide 
(PQBP1) blocks the toxicity of mutant HDx1 in tissue culture (25); this peptide 
interferes with conversion of a non-toxic α-helical structure of polyQ to a toxic β-
sheet conformation (10).  While this conformation switch occurs in vitro with 
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purified protein, the existence of an endogenous modifier of polyQ toxicity is an 
attractive area of investigation and intrabodies will help with the identification of 
these potential regulators of toxicity.   
 The MW7 intrabody, on the other hand, was instrumental in identifying the 
HDx1 polyP domain as a pathogenic epitope (16, 26).  Several important 
signaling proteins including NEMO /IKKγ, CBP, WW domain proteins, dynamin 
and FIP-2 require the HDx1 polyP domain for binding to HDx1 (26-29).  
Therefore, the protective mechanism of the MW7 intrabody may work through its 
reducing the sequestration of important cellular proteins by mutant HDx1.  In fact, 
we have shown that MW7 blocks binding of the IκB-kinase (IKK) complex to the 
proline-rich domain of mutant HDx1 and subsequently reduces HDx1-induced 
NF-κB activation (26; Fig. 4).  Moreover, both MW7 and genetic inhibitors of the 
IKK complex have similar inhibitory effects on mutant HDx1 in cell and brain slice 
cultures (26).  These findings underscore the importance of intrabodies as 
molecular tools that can lead to the identification of novel pathogenic epitopes 
and therapeutic targets.  
 
NOVEL TARGETS FOR INTRABODY THERAPY IN HD 
To date, most of the intrabodies developed to perturb Htt function have 
been targeted to HDx1, which is generated by proteolytic processing of full-length 
Htt.  However, a more upstream, primary therapeutic goal would be to prevent 
proteolytic processing of mutant Htt using specific intrabodies.  Htt is cleaved by 
several proteases, including caspases 3 and 6, and the calpains (30, 31).  
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Cleaved mutant Htt fragments are precursors to oligomers, and the species that 
accumulate in the nucleus likely contribute to transcriptional dysregulation (2).  
Therefore, blocking the cleavage of full length Htt by intrabodies may be an 
effective strategy to reduce the generation of fragments that misfold and induce 
toxicity. 
Indeed, such inhibition of Htt cleavage by intrabody binding to cleavage 
sites may be preferred over small molecule inhibitors of the relevant proteases 
because of the target specificity of antibody binding, and because small molecule 
inhibitors can have systemic side effects.  This technology has already been 
applied to reduce production of β-amyloid in AD models.  Intracellular expression 
of an intrabody that binds an epitope in close proximity to the β-secretase 
cleavage site of amyloid precursor protein (APP) blocks production of 
amyloidogenic fragments and promotes cleavage with α-secretase, which 
generates non-amyloidogenic Aβ (32).  For HD, intrabodies specific to Htt 
cleavage sites can readily be isolated from phage display libraries and tested in 
tissue culture for their effects on Htt processing.  This approach could be used to 
validate the role of these caspases on Htt processing and toxicity and, 
importantly, would generate potential therapeutics for HD.   
DELIVERY OF INTRABODIES TO THE HD BRAIN. 
In principle, viral vector-based gene therapy is the ideal method for the 
delivery of therapeutic intrabodies to the brain.  Optimal delivery of gene therapy 
vectors into the diseased brain remains an important research area and 
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represents the best mode of delivery for long-term expression.  Among these, 
adeno-associated viruses (AAV) are the most promising vectors, since they are 
largely non-pathogenic and the virus is already widespread and non-toxic in 
human populations.  AAV is capable of infecting both dividing and non-dividing 
cells and generating long-term expression of transgenes.  The existence of 
several serotypes offers varied tropism allowing expression in a wide range of 
cell and tissue types.  Delivery of AAV vectors also appears to be safe and well 
tolerated, as no obvious side effects have been reported following a phase 1 
clinical trial of AAV mediated delivery of glutamic acid decoarboxylase (GAD) to 
the brains of human Parkinson’s disease patients (33)(2); intracerebral delivery 
may also avoid systemic complications outside of the CNS. 
In animal models of AD, several successful approaches have been 
reported for delivery of anti-Aβ intrabodies (2, 34).  Intracranial delivery of AAV 
encoding anti-Aβ scFvs, which can be secreted and enter the circulation, has 
been effective in reducing amyloid plaque loads, neurotoxicity and correcting 
behavioral abnormalities (2).  Viral injections in this model were performed at P0, 
which allowed widespread distribution and expression.  Intrabody delivery to HD 
models may be more challenging, since the toxic protein remains intracellular, in 
contrast to Aβ, which is secreted.  Nonetheless, success has been obtained with 
systemic vaccination approaches in mouse models of Parkinson's disease, in 
which the targeted antigen, -synuclein, is also thought to be intracellular (35).  
Moreover, we find that anti-Htt antibodies display specific binding to the surfaces 
of live cells expressing mutant HDx1, suggesting that systemic and/or 
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extracellular delivery of intrabodies may also be beneficial in combating Htt 
toxicity (Fig. 5).    
Direct viral delivery to the striatum has also proven to be effective.  A 
single injection of an AAV vector encoding an RNAi targeted against Htt results in 
extensive spread, reduced HDx1 oligomerization, enhanced DARPP-32 
expression in striatal neurons, and amelioration of HD neuropathology (36, 37).  
Significant neuroprotection by AAV-mediated delivery of the neurotrophins GDNF 
and BDNF to striatum has also been demonstrated in the quinolinic acid model of 
HD (38).  Thus, direct delivery of intrabody viral vectors to the striatum may be 
realistic and it is expected that intrabodies will have fewer off-target effects than 
either RNAi or neurotrophins, due to the high degree of specificity of antibodies.  
In fact, an intrabody constructed from the EM48 monoclonal antibody, which 
targets the C-terminus of HDx1, has been tested in an HD mouse model and 
preliminary data suggest that expression of this intrabody provides significant 
protection against mutant HDx1 (38).  Injection of an adenvovirus expressing 
EM48 intrabody in the striatum of N-171-82Q HD mice reduces the overall 
toxicity and decreases the aggregation of mutant Htt in the neuropils. Moreover, 
expression of EM48 in the striatum improves some of the behavioral deficits of 
these mice. EM48 however, does not extend the life span of these mice (39). In a 
lentiviral model of HDx1, intrastriatal injection of adeno-associated virus (AAV) 
expressing VL12.3- or Happ1 reduces aggregation of mutant Htt in the adult mice 
and ameliorates the loss of DARPP-32 expression caused by injection of mHtt-
lentivirus.  AAV-VL12.3 and AAV-HAPP1 also improve the amphetamine-induced 
  
123
 
rotation bias seen with unilateral mHtt lentivirus injection.  
 
FUTURE DIRECTIONS FOR INTRABODIES IN HD THERAPY 
 
Development of intrabodies for therapeutic purposes and as novel 
molecular tools to perturb protein function in vivo is an exciting emerging field.  
Some intrabodies have already reached clinical trials and others have been used 
as novel diagnostic tools (40).  As optimization of delivery vehicles progresses, 
anti-Htt intrabodies will hold great promise for HD therapy in the future.  
However, many milestones, including the identification of the best targets, the 
most potent and effective intrabodies, and the most effective methods to ensure 
a safe, widespread delivery to the CNS must first be achieved.  With rapid 
progress in proteomics, intrabodies can also serve as excellent tools for in vivo 
functional knock-down, for inactivating specific protein domains, and for inhibiting 
interactions between particular proteins.  The HD field can also benefit from 
intrabody technology for inactivating other intracellular targets that enhance Htt 
toxicity such as caspases, p53, and IKKs.   
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Figure 1. Intrabody construction strategies. (A) Cloning of scFv from 
monoclonal parental antibodies. (B) selection of intrabodies from phage display 
library. 
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Figure 2. Binding domains of different intrabodies that have been developed 
against the HDx-1 peptide sequence. 
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Fig 3 
C MW2 MW7
 
Figure 3. MW7 prevents while MW2 promotes aggregation of mutant HDx1-EGFP 
in PC12 cells. MW7 and MW2 cDNAs were cloned into ecdysone-inducible vectors and 
transfected into PC12 cells that were engineered to express HDx1 in response to 
ecdysone (26).  Selected PC12 cell clones were then treated with ecdysone to induce 
simultaneous expression of HDx1 and the scFv.  A luciferase construct was used as 
control (far left panel). 
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Figure 4 Blocking the interaction of mutant HDx1 with the IKK complex 
reduces the toxicity in a brain slice culture model of HD. Binding of MW7 
intrabodies to the poly-P domains of Htt also prevents IKK–HDx1 interaction and 
  
132
 
thereby reduces the toxicity of mutant HDx1. Binding of HDx1 to the IKK complex 
requires the polyP domain of Htt and the N-terminus of IKKγ.   
Fig 5 
 
Figure 5.  The anti-huntingtin antibodies/intrabodies, anti-N1-17, MW7 and 
MW8, stain living striatal cells with a punctate pattern (red) similar to an 
anti-dopamine D2 receptor (D2R) antibody.  The striatal ST-14 cell line was 
transduced with PQ103-EGFP lentivirus and live cells were incubated with either 
control antibodies (mouse Ig2b, and a non-neuronal anti-CD9 (ROCA)), or anti-
Htt antibodies/intrabodies as indicated.  A polyclonal antibody against D2R was 
used as positive control for cell surface staining.  Alexa 568-conjugated 
secondary antibody was used to visualize staining (red); the green fluorescence 
is native HDx1-EGFP.  
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Appendix B 
 
GABA transporter deficiency causes tremor, ataxia, 
nervousness, and increased GABA-induced tonic conductance 
in cerebellum 
 
Chiu CS, Brickley S, Jensen K, Southwell A, Mckinney S, Cull-Candy S, Mody I, 
Lester HA. J Neurosci. 25:3234-45, 2005.  
ABSTRACT  
GABA transporter subtype 1 (GAT1) knock-out (KO) mice display normal 
reproduction and life span but have reduced body weight (female, -10%; male, -
20%) and higher body temperature fluctuations in the 0.2-1.5/h frequency range. 
Mouse GAT1 (mGAT1) KO mice exhibit motor disorders, including gait 
abnormality, constant 25-32 Hz tremor, which is aggravated by flunitrazepam, 
reduced rotarod performance, and reduced locomotor activity in the home cage. 
Open-field tests show delayed exploratory activity, reduced rearing, and reduced 
visits to the central area, with no change in the total distance traveled. The 
mGAT1 KO mice display no difference in acoustic startle response but exhibit a 
deficiency in prepulse inhibition. These open-field and prepulse inhibition results 
suggest that the mGAT1 KO mice display mild anxiety or nervousness. The 
compromised GABA uptake in mGAT1 KO mice results in an increased GABA(A) 
receptor-mediated tonic conductance in both cerebellar granule and Purkinje 
cells. The reduced rate of GABA clearance from the synaptic cleft is probably 
responsible for the slower decay of spontaneous IPSCs in cerebellar granule 
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cells. There is little or no compensatory change in other proteins or structures 
related to GABA transmission in the mGAT1 KO mice, including GAT1-
independent GABA uptake, number of GABAergic interneurons, and GABA(A)-, 
vesicular GABA transporter-, GAD65-, and GAT3-immunoreactive structures in 
cerebellum or hippocampus. Therefore, the excessive extracellular GABA 
present in mGAT1 KO mice results in behaviors that partially phenocopy the 
clinical side effects of tiagabine, suggesting that these side effects are inherent to 
a therapeutic strategy that targets the widely expressed GAT1 transporter 
system. 
INTRODUCTION 
GABA is the principal inhibitory neurotransmitter in the mammalian brain, 
where it activates GABAA, GABAB, and GABAC receptors. GABA released from 
presynaptic terminals is removed from the vicinity of the synaptic cleft by GABA 
transporters, and this action is believed to be a key event in terminating synaptic 
currents. GABA transporters are also involved in maintaining a low extracellular 
GABA concentration throughout the brain, preventing excessive tonic activation 
of synaptic and extrasynaptic receptors. GABA transporters may also play a role 
in replenishing the supply of presynaptic transmitter. Furthermore, GABA 
transporters may reverse, under both normal and pathological circumstances, to 
release GABA (Richerson and Wu, 2003, 2004) 
Of the three GABA transporters identified in the CNS, GABA transporter 
subtype 1 (GAT1) is highly expressed in the olfactory bulb, neocortex, 
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cerebellum, superior colliculus, and substantia nigra, where it is predominantly 
found in axons, presynaptic terminals, and glial cells. GAT2 is weakly expressed 
throughout the brain, primarily in arachnoid and ependymal cells. GAT3 
expression is densest in the olfactory bulb, midbrain regions, and deep cerebellar 
nuclei, where it is found predominantly on glial cells (Radian et al., 1990; Ikegaki 
et al., 1994; Itouji et al., 1996; Yan et al., 1997; Engel and Wu, 1998; Barakat and 
Bordey, 2002; Chiu et al., 2002). 
The GAT1 inhibitor tiagabine is a clinically useful antiepileptic drug with few 
cognitive side effects (Aldenkamp et al., 2003),but it also causes tremor (its 
major side effect), ataxia, dizziness, asthenia, somnolence (sedation), and 
nonspecific nervousness (Adkins and Noble, 1998; Pellock, 2001; Schachter, 
2001). It is important to know whether these side effects arise directly from 
increased extracellular concentration of GABA in the CNS or, instead, from 
actions on unintended targets. For instance, GAT1 inhibitors may also inhibit 
GABAA receptors (Overstreet et al., 2000; Jensen et al., 2003). If the latter 
mechanism holds, then a more selective GAT1 inhibitor could be a more effective 
antiepileptic.  
To address this question, we examined the phenotype of the ultimate 
GAT1-specific inhibitor: genetic interruption of GAT1 function. The homozygous 
and heterozygous mouse GAT1 (mGAT1) knock-out (KO) strain is viable and 
fertile, with a normal life span. Its hippocampal electrophysiology has been 
studied previously (Jensen et al., 2003), but this is the first report of several other 
phenotypes, including motor behavior, general mood, cerebellar 
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electrophysiology, and thermoregulation. We emphasize measurements on the 
cerebellum, where GAT1 is heavily expressed and has been quantified (Chiu et 
al., 2002).  
GABA influences circadian rhythm (Liu and Reppert, 2000). Because 
tiagabine-treated patients show dizziness, asthenia, and somnolence, we 
determined whether the GAT1 KO mice display altered activity in their habituated 
home cage. We also monitored body temperature rhythm, which is synchronized 
with daily activity (Weinert and Waterhouse, 1999). We found that the mGAT1 
KO mouse does phenocopy some effects of tiagabine, which, in turn, suggests 
that the various clinical side effects of this drug result, directly or indirectly, from 
its blockade of GAT1. We measure altered synaptic physiology, deriving from 
increased and prolonged extracellular [GABA], which provides a plausible 
physiological basis for these effects. 
 
MATERIALS AND METHODS 
 
 
 GAT1 knock-out strain. The mGAT1 KO strain, previously termed "intron-
14-neo-mGAT1," carries an intact neomycin selection marker in intron 14. The 
details of the targeting construct, homologous recombination, and genotyping 
were described previously (Chiu et al., 2002).  
Synaptosomal GABA uptake assay. Details of synaptosomal preparation and 
GABA uptake assay were described previously (Chiu et al., 2002). Briefly, mice 
were anesthetized with halothane (2-bromo-2-chloro-1,1,1-trifluorothane), and 
brains were dissected and collected on ice. The cerebellum ( 50 mg) was 
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homogenized in 20x (w/v) medium I (0.32 M sucrose, 0.1 mM EDTA, and 5 mM 
HEPES, pH 7.5; 1 ml) (Nagy and Delgado-Escueta, 1984). The P2 fraction 
(synaptosome fraction) was suspended with 1 ml of medium I. Protein 
concentrations were analyzed by using the Coomassie Plus kit (Pierce, Rockford, 
IL).  
GABA uptake assays were performed by mixing 20 µl of the suspension 
with 280 µl of uptake buffer (in mM: 128 NaCl, 2.4 KCl, 3.2 CaCl2, 1.2 MgSO4, 
1.2 KH2PO4, 10 glucose, 25 HEPES, pH 7.5) and then incubated at 37°C for 10 
min (Lu et al., 19980). GABA and [3H]GABA in various concentrations (100 µl) 
were added to the synaptosome suspension and incubated for 10 min (final 
radioactive concentrations were 2.2-8.8 µCi/ml). Uptake was terminated by 
placing the samples in an ice-cold bath, followed by two washes with uptake 
buffer containing the same concentration of cold GABA at 10,000 x g. The GABA 
uptake inhibitor 1-[2-[[(diphenylmethylene)imino]oxy]ethyl]-1,2,5,6-tetrahydro-3-
pyridinecarboxylic acid hydrochloride (NO711) (final concentration, 30 µM) was 
included to measure the non-GAT1 uptake activity; the NO711-sensitive fraction 
accounted for 75-85% of wild-type (WT) activity.  
Tremor measurements. The mouse was placed in a 2 L polyethylene 
freezer container. A piezoelectric transducer (LDT0 - 028K; Measurement 
Specialties, Fairfield, NJ) was taped to the bottom of a 7.5 x 10 cm plastic board 
(8 g), and this board was loosely attached to the bottom of the container with a 
loop of paper tape. The mice were placed directly on the board. The signal from 
the sensor was low-pass filtered at 200 Hz, amplified by 100 (model 902; 
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Frequency Devices, Haverhill, MA), and led to the analog-to-digital inputs on an 
Axon DigiData 1200 interface (Axon Instruments, Union City, CA). The signals 
were collected using Clampex Gap-Free recording, and power spectra were 
computed in ClampFit. We verified that the resonant frequency of this instrument 
was far from the tremor frequency by replacing the mouse with 20 g of mass, and 
the response of the instrument to constant-frequency mechanical stimulation 
varied, with frequency, by <40% between 20 and 32 Hz.  
Benzodiazepine modulation of the tremor. Mice were tested for baseline 
tremor as described previously. They were then injected intraperitoneally with 
either flunitrazepam in 20% FreAmine HBC (B Braun Medical, Bethlehem, PA) or 
vehicle. After 15 min, the tremor was measured.  
Footprint. Hindpaws were painted with black India ink, and mice were 
placed in a cardboard box (90 x 12 x 12 cm) with a 75-cm-long white paper floor. 
Paw angle is the hindpaw central axis relative to its walking direction.  
Rotarod. Mice were tested on a motorized rotarod (Ugo Basile, Comerio, 
Italy) consisting of a grooved metal roller (3 cm in diameter) and separated 11-
cm-wide compartments elevated 16 cm. The acceleration rate was set at 0.15 
rpm/s. Mice were placed on the roller, and the time they remained on it during 
rotation was measured. The rotarod has an increment of 4 rpm/step. Tests were 
performed for fixed speed at either 12 or 20 rpm and for accelerating speed. A 
maximum of 120 s was allowed per animal for fixed speed tests.  
Exploratory locomotor activity. An individual mouse was placed in a novel 
environment of a square open field (50 x 50 cm), the floor of which was divided 
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into 25 smaller squares (5 x 5) by painted lines. Within 10 cm of the chamber 
walls is termed the periphery (16 squares), and the central region indicates the 
central nine squares. The animal behavior in the open field was recorded by 
videotaping for 10 min and analyzed subsequently. The measurements include 
delayed exploratory activity (measuring the time required for mice to walk the first 
50 cm), frequency of visits to the central area, dwell time in the inner field, 
number of rearing events, total distance traveled, and walking speed. Mice 
usually made short walks interrupted by brief stops. To make meaningful walking-
speed measurements, we chose uninterrupted walking for >25 cm and averaged 
3-12 such walking-speed measurements for each animal. All animals were tested 
in a particular behavioral assay on the same day during the light part of the 
light/dark cycle.  
Elevated plus maze. Mice were allowed to habituate to the testing room for 
2 h. The maze consisted of two opposing open arms (40 x 10 cm) and two 
opposing closed arms (40 x 10 cm, with 40 cm walls) on a platform 50 cm above 
the ground. Mice were placed in the center square (10 x 10 cm) facing an open 
arm and videotaped during a 5 min exploration. Arm entries and duration were 
scored when all four paws entered the arm. Partial arm entries were scored when 
one to three paws entered the arm. Head dipping was scored when the head was 
dipped over the edge of the maze. All animals were tested on the same day 
during the light part of the light/dark cycle.  
Home-cage activity. Mice were housed individually in cages with bedding, food, 
and water. To assess activity, beam breaks were collected for 42 h with a photo 
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beam system (San Diego Instruments, San Diego, CA). Plots show the number of 
beam breaks for each 5 min interval.  
Benzodiazepine hyperlocomotor activity. Mice were allowed to habituate to 
activity cages for 2 h. They were then injected intraperitoneally with either 
flunitrazepam in 20% FreAmine HBC (5 or 15 mg/kg) or vehicle. Activity (single 
beam breaks) and ambulation (successive beam breaks) data were then 
collected for 1 h and plotted for each 5 min interval.  
Acoustic startle and prepulse inhibition. Animals were tested in a Startle 
Response system (SR-LAB; San Diego Instruments) consisting of a 5 cm 
Plexiglas cylinder mounted on a Plexiglas platform in a ventilated, lighted, sound-
attenuated chamber. Acoustic stimuli were presented by a high-frequency 
loudspeaker mounted 28 cm above the cylinder. A piezoelectric accelerometer 
attached to the Plexiglas base was used to detect movement of the animals 
within the cylinder. Animal movement was scored in arbitrary numbers between 0 
and 1000. Ambient background noise of 68 dB was maintained throughout each 
testing session. Each session was initiated with a 5 min acclimation period 
followed by six 120 dB trials and concluded with another six 120 dB trials. These 
first and last sets of six 120 dB pulses were not included in the analysis. For 
acoustic startle-response (ASR) testing, seven different levels of acoustic startle 
pulse (73, 78, 83, 85, 100, 110, and 120 dB) were presented along with a trial 
containing only the background noise for 40 ms each in random order with 
variable intertrial intervals of 10-20 s. At the onset of stimulus, 65 startle-
amplitude readings were taken for 1 ms each. Ten trials of each decibel level 
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were performed, and the average startle amplitude was determined. The session 
used for prepulse inhibition (PPI) testing consisted of five different trials 
presented 10 times each in random order. These include 120 dB startle pulse 
alone, 120 dB startle pulse preceded by a prepulse of 73, 78, or 83 dB (5, 10, 
and 15 dB above background), and a trial containing only the background noise. 
The percentage of prepulse inhibition was calculated as follows: 100 x [(average 
120 dB startle pulse - average prepulse + 120 dB startle pulse)/average 120 dB 
startle pulse].  
Temperature measurements. Mini Mitter (Sunriver, OR) ER-4000 
telemetric temperature probes were used in 3- to 6-month-old male mGAT1 KO 
mice. For implantation, mice were anesthetized with halothane, and a 1 cm 
incision was made at the back of the neck. Probes were inserted subcutaneously 
into the back. The incision was sealed with surgical glue. The mice were housed 
with ad libitum water and food at 24 ± 2.5°C. Lights were on between 6:00 A.M. 
and 6:00 P.M. for 7-10 d after implantations and then off for the period of data 
collection. Temperature and activity data were acquired using Vital View software 
(Mini-Mitter) and analyzed (including fast Fourier transforms) in Origin.  
Seizure tests. Pentylenetetrazole (PTZ) was solubilized in 0.9% NaCl saline 
solution, and bicuculline was dissolved in 0.1N HCl, pH adjusted to 5.5 with 0.1N 
NaOH (Pericic and Bujas, 1997). Animals were injected intraperitoneally with 
either PTZ or bicuculline. For PTZ, animals were injected with either subthreshold 
(40 mg/kg) or suprathreshold (70 mg/kg) doses. For bicuculline, animals were 
injected with 3, 4, or 5 mg/kg.  
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Brain slice electrophysiology. Cerebellar slices were prepared using 
standard procedures (Brickley et al., 1996). The brain was rapidly dissected and 
submerged in cold slicing solution ( 4°C), which contained the following (in mM): 
125 NaCl, 2.5 KCl, 1 CaCl2, 4 MgCl2, 25 NaHCO3, 1.25 NaH2PO4, and 25 
glucose. All extracellular solutions were bubbled with 95% O2 and 5% CO2, pH 
7.4. After cutting on a moving-blade microtome, slices were maintained at 32°C 
for 60 min before transfer to a recording chamber. For granule cell recordings, 
slices were constantly perfused (1.5 ml/min) with recording solution containing the 
following (in mM): 125 NaCl, 2.5 KCl, 2 CaCl2, 1 MgCl2, 26 NaHCO3, 1.25 
NaH2PO4, and 25 glucose. For Purkinje cell recordings, slices were perfused with 
the following (in mM): 126 NaCl, 2.5 KCl, 2 CaCl2, 2 MgCl2, 26 NaHCO3, 1.25 
NaH2PO4, 10 glucose, 0.2 L-ascorbic acid, 1 pyruvic acid, and 3 kynurenic acid. 
All experiments were performed at room temperature, and whole-cell voltage-
clamp recordings were made using Axopatch 1D or 200B amplifiers (Axon 
Instruments). The pipette solution contained the following (in mM): 140 CsCl, 4 
NaCl, 0.5 CaCl2, 10 HEPES, 5 EGTA, 2 Mg-ATP, adjusted to pH 7.3 with CsOH.  
Currents were filtered at 2-3 kHz and digitized at 10 kHz. The tonic GABAA 
receptor-mediated conductance (GGABA) was measured from the reduction in 
holding current recorded in the presence of the GABAA receptorantagonist2-(3-
carboxypropyl)-3-amino-6-(4-methoxyphenyl)-pyridazinium bromide (SR95531) 
(>100 µM). All-points histograms were constructed from sections of data not 
containing synaptic currents and mean values calculated from a Gaussian fit to 
the histogram. Spontaneous IPSCs (sIPSCs) were detected with amplitude- and 
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kinetics-based criteria (events were accepted when they exceeded a threshold of 
6-8 pA for 0.5 ms) using custom-written LabView-5.1-based software (National 
Instruments, Austin, TX). All IPSCs were also inspected visually, and sweeps 
were rejected or accepted manually. Individual spontaneously occurring IPSCs 
were then aligned on their initial rising phase, and average IPSC waveforms were 
constructed from those events that exhibited a clear monotonic rise and returned 
to baseline before the occurrence of later sIPSCs. The decay of average sIPSC 
waveforms was quantified as a weighted value calculated from the charge 
transfer of normalized averages ( integral).  
Immunocytochemistry. Detailed procedures for immunocytochemistry were 
described previously (Chiu et al., 2002; Jensen et al., 2003). Mice were 
anesthetized with halothane and perfused with 4% paraformaldehyde in PBS, pH 
adjusted to 7.6 with Na2HPO4. Brains were dissected and kept in 4% 
paraformaldehyde for 1 h in 4°C and then incubated in 30% sucrose in PBS for 
20 h. The brains were embedded in OCT medium (Tissue-Tek; Miles, Elkhart, IN) 
for either horizontal or sagittal sections and sliced by cryostat at 35 µm. Brain 
slices were stored in a solution containing the following (in mM): 11 NaH2PO4, 20 
Na2HPO4, 30% ethylene glycol, and 30% glycerol, pH 7.5, at -20°C.  
Sections were incubated for 2 h at room temperature in a blocking solution (10% 
normal goat serum and 0.3% Triton X-100 in PBS, pH 7.6), followed by 
incubation with the primary antibody for 2 d at 4°C with rotational mixing. Primary 
antibodies and their dilutions were rabbit anti-GAT3 (1:200 dilution; Chemicon, 
Temecula, CA), rabbit anti-GABAA receptor 1 (1:100; Upstate Biotechnology, 
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Lake Placid, NY), rabbit anti-glutamate decarboxylase 65 (GAD65) (1:1000; 
Chemicon), and rabbit anti-vesicular GABA transporter (vGAT) (1:100; Synaptic 
Systems, Goettingen, Germany). The brain slices were first washed with PBS 
containing 0.5% Triton X-100 followed by two additional washes with PBS. The 
slices were then incubated in solutions containing the appropriate rhodamine red-
x-conjugated secondary antibodies. These secondary antibodies include goat 
anti-rabbit, goat anti-guinea pig, or donkey anti-goat secondary antibodies (1:200; 
Jackson ImmunoResearch, West Grove, PA). After three washes with PBS, 
slices were rinsed with PBS, mounted with Vectashield (Vector Laboratories, 
Burlingame, CA), and subjected to confocal microscope imaging. 
 
RESULTS 
Evidence for functional knock-out of GAT1. The knock-in mouse strain 
studied here, previously termed intron-14-neo-intact-mGAT1, harbors a neomycin 
resistance cassette (neo) in intron 14 as well as a green fluorescent protein 
(GFP) moiety fused to the C terminus of the mGAT1 coding region in exon 14 
(Jensen et al., 2003). This strain was originally constructed as a genetic 
intermediate in the eventual construction of a neo-deleted mGAT1-GFP knock-in 
strain that has also been described previously (Chiu et al., 2002). However, we 
found that the present strain appears to have essentially no functional mGAT1 
(Jensen et al., 2003), presumably because the neo sequences interfere with 
mRNA or protein. Figure 1 shows additional evidence on this point in the 
cerebellum, for which we later provide electrophysiological data. First, the GFP 
  
145
 
moiety at the C terminus of the GAT1 construct provides a fluorescent label for 
the level of GAT1 expression (Chiu et al., 2002). The mGAT1 KO strain shows 
<2% as much fluorescence as the mGAT1-GFP strain (Chiu et al., 2002) and no 
more fluorescence than WT mice (Fig. 1A-C). Second, to measure mGAT1 
function, we performed GABA uptake assays on cerebellar synaptosomes. The 
NO711-sensitive GABA uptake activity from mutant mice synaptosomes was 
<2% of that of WT littermates, whereas heterozygotes displayed intermediate 
GABA uptake activity (Fig. 1E), indicating that mutant mice have little or no 
functional presynaptic GAT1 activity. mGAT1-deficient mice also display reduced 
body weight, 20 and 10% less than WT for males and females, respectively 
(Fig. 1F). 
Cerebellar immunocytochemistry. To test whether the mGAT1 KO 
mouse has abnormalities in the GABAergic system, we performed 
immunocytochemistry on several proteins related to GABA function. 
Immunocytochemistry using antibodies against GAD65, the GABAA 1 subunit 
and the vGAT indicated that mGAT1 KO mice do not change GABAergic synapse 
densities and related receptor expression in the molecular layer of the cerebellum 
(summarized in Fig. 1D) (based on images in the supplemental figure, available 
at www.jneurosci.org as supplemental material). We also found no qualitative 
differences in GABAA 1 subunit staining in the granule cell layer (data not 
shown). These data agree with previous data on the hippocampus (Jensen et al., 
2003). Also, the expression pattern for GAT3 is not changed, suggesting that no 
compensatory changes occurred because of the GAT1 deficit (see supplemental 
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figure, available at www.jneurosci.org as supplemental material). 
Immunocytochemistry using antibodies against GABAergic, interneuron-specific, 
calcium-binding proteins showed no changes in GABAergic interneuron density in 
the hippocampus and in the cerebellum.  
Behavioral characterizations of GAT1 KO mice 
Tremor. The mGAT1 KO mice display readily observable, nearly 
continuous tremor in the limbs and tail. Measured by a simple instrument (Fig. 
2A) (see Materials and Methods), the tremor frequency is 25-32 Hz (Fig. 2B). In 
addition, KO and WT share an additional lower amplitude tremor at 80 Hz (Fig. 
2B) (n = 6). Vibrations in both frequency ranges are highest during rearing 
episodes (Fig. 2A, arrows). Acute high-dose NO711 treatment caused complete 
sedation in WT mice, vitiating any observations on tremor in NO711-treated WT 
mice. Flunitrazepam treatment decreased the frequency and increased the 
amplitude of the tremor in mGAT1 KO mice (Fig. 2C) but had very little effect on 
the power spectrum of WT mice (data not shown). These effects in KO mice were 
both significant for 15 mg/kg flunitrazepam; both effects were intermediate for 10 
mg/kg flunitrazepam, but only the frequency change was significant for 10 mg/kg 
flunitrazepam.  
Ataxia. Ataxia is associated with cerebellar defects in many strains of mice 
(Mullen et al., 1976; Watanabe et al., 1998; Rico et al., 2002). The mGAT1 KO 
mice walk with an abnormally large paw angle relative to the direction of walking: 
23 ± 0.7 versus 12.5 ± 1.4° for KO and WT, respectively (Fig. 3E, F). In another 
indication of ataxia, mGAT1 KO mice display flattened stance and lowered hip on 
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the rotarod (Fig. 3B). The mGAT1 KO mice show reduced time on the rotarod in 
both fixed speed (Fig. 3C) and accelerating speed (Fig. 3D) tests, indicating 
ataxia. Both WT and mutant mice improved performance on the rotarod after 
training; however, the difference of latency to fall remained significant between 
WT and KO mice (data not shown). The mGAT1 KO and WT mice displayed 
equal muscle strength in hanging-wire activity tests (data not shown). 
Mild anxiety: flexor contraction, exploratory activity, elevated plus 
maze, and startle.When suspended by the tail, the mGAT1-deficient mice 
display trembling and flexor contraction (front paws held together and rear paws 
flexed) (Fig. 3A). This gesture resembles typical mouse models for anxiety. WT 
littermates displayed normal extension without trembling (Fig. 3A). The flexor 
contraction was also observed in WT mice treated with a high dose of NO711 
(10-40 mg/kg; data not shown).  
The open field was used as an additional test of anxiety-like behavior (Fig. 
4) (Prut and Belzung, 2003). Because an open field is a novel environment, 
rodents tend to prefer the periphery of the apparatus, later exploring the central 
parts of the open field. We observed several aspects of behavior in this 
apparatus. The mGAT1 KO mice tend to remain longer in the corner of the open 
field (Fig. 4A) and then tend to walk slowly along the wall; thus, there was 
markedly reduced frequency of visits to the central area (Fig. 4B), reduced dwell 
time in the central area (Fig. 4C), and reduced rearing activity (Fig. 4D). These 
results may signify anxiety of the mGAT1 KO mice. There was modestly reduced 
walking speed (Fig. 4E). Although WT and heterozygotes walk faster than KO 
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mice, they spend more time in rearing; as a consequence, all three genotypes 
traveled about the same distance (Fig. 4F). Several of the observations in the 
open-field test suggest that the heterozygote is the least anxious phenotype; we 
did not explore this observation systemically. 
We observed the mGAT1 KO mice in the elevated plus maze, another test 
of anxiety (Fig. 5A, B). The mGAT1 KO mice displayed increased partial arm 
entries (Fig. 5A) and time spent in the central square (Fig. 5B) compared with WT 
mice. Homozygous mutant mice showed reduced open-arm entries and reduced 
total time spent in the open arms (data not shown). There was a trend toward 
reduced closed-arm entries; however, this difference was not statistically 
significant compared with WT. Mutant mice spent the majority of the testing time 
in the central square engaging in partial-arm entries, indicating no reduction in 
locomotor activity. No difference was seen in head dipping. Thus, the elevated 
plus maze provided some additional evidence for anxiety. 
Startle is a fast twitch of facial and body muscles evoked by sudden and 
intense tactile, visual, or acoustic stimulations. Many anxious mouse strains 
display both enhanced ASR and reduced PPI. The mGAT1-deficient mice display 
normal ASR (Fig. 5C) but reduced PPI (Fig. 5D), compared with their WT 
littermates. The baseline movement of the mGAT1 mutant in the absence of 
acoustic stimulation was elevated above the WT. This most likely reflects the 
constant tremor of these mice.  
Ambulation activity. The mGAT1 KO mice show reduced ambulation in 
their cages; as a consequence, the 24 h activity cycle becomes less obvious (Fig. 
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6A). The total ambulation activities were 2425 ± 395 versus 965 ± 146 times 
during 42 h for WT and mGAT1 KO mice, respectively (Fig. 6B) (mean ± SEM). 
Flunitrazepam treatment caused hyperlocomotor activity in KO animals and 
sedation in WT animals (data not shown). 
Autonomic regulation: body temperature fluctuations. The mGAT1 
KO mice display a striking pattern of abnormal temperature regulation (Fig. 
7A,B). There is a normal circadian temperature rhythm, but in addition, there are 
many fluctuations, primarily hyperthermic episodes on a time scale of several 
minutes to 2 h. To quantify these fluctuations, we computed and averaged the 
power spectral density of temperature fluctuations in WT or KO mice (Fig. 7C). 
The data have been normalized to the peak at 0.0416 h-1 (corresponding to the 
circadian rhythm). It is clear that mGAT1 KO mice display increased relative 
noise power in the frequency range from 0.2 to 1.5 h-1. The mGAT1 hyperthermic 
episodes are larger, especially during high activity (i.e., higher body temperature), 
but no more frequent than in WT mice (Fig. 7B). Two additional animals in each 
group provided similar data, but these animals were not included in the averaged 
power spectra because of differences in sample rate. 
Sensitivity to convulsants. The mGAT1 KO mouse is slightly more 
sensitive than the WT mouse to PTZ-induced seizures, but there is no obvious 
change in bicuculline-induced seizure susceptibility. Bicuculline (i.p.) at 5 mg/kg 
kills WT and mGAT1 KO mice, whereas at 3 and 4 mg/kg, both WT and KO mice 
survived with moderate seizure (n = 2 each). PTZ at a subthreshold dose (40 
mg/kg, i.p.) decreased observable activity in WT and heterozygotes while causing 
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preconvulsive states and mild seizures in mGAT1 KO mice (n = 3 each). At a 
suprathreshold dose (70 mg/kg), all WT and heterozygotes survived with severe 
seizures, whereas mGAT1 KO mice showed severe seizures, and one of three 
died (n = 3 each).  
Cerebellar slice electrophysiology. GABAA receptor-mediated currents, 
recorded from wild-type mice, are similar to those reported previously (Brickley et 
al., 2001) (Fig. 8). Granule cells dialyzed with high-internal Cl- and voltage 
clamped at -70 mV (see Materials and Methods) exhibit sIPSCs, with a frequency 
of 0.8 ± 0.6 Hz (n = 4). In addition, a tonic GABAA receptor-mediated 
conductance (GGABA) is clearly present in all recordings. The phasic and tonic 
conductances are both blocked by the GABAA receptor antagonist SR95531 
(>100 µM) (Fig. 8A). The magnitude of GGABA (84.2 ± 50.4 pS/pF) is similar to 
previous reports for animals of this age, as are the peak amplitude (388.5 ± 143.3 
pS/pF) and kinetics ( integral = 17.6 ± 3.3 ms) of average sIPSCs (Brickley et al., 
2001). 
Recordings from mGAT1 KO cerebellar granule cells reveal marked 
differences in both the tonic and phasic conductances, consistent with the 
removal of a GABA transporter. In all seven recordings from mGAT1 KO mice, 
GGABA is significantly increased (Fig. 8B) to an average value of 318.9 ± 65.6 
pS/pF (p < 0.05) (Fig. 8C). Conventional sIPSCs (Fig. 8D,E) are still detectable 
within the current record, albeit at an apparently lower average frequency (0.4 ± 
0.2 Hz). The increased current variance associated with GGABA (Fig. 8E, 
histogram) made resolution of small sIPSCs more difficult. Nevertheless, it 
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appears that the average peak amplitude is not significantly different in the 
mGAT1 KO recordings (270.5 ± 31.5 pS/pF). However, as shown in Figure 8F, 
the decay of sIPSCs is slower in the mGAT1 KO cells ( integral = 36.9 ± 5.7 ms 
compared with 17.6 ± 3.3 ms in wild-type granule cells). Therefore, in mature 
cerebellar granule cells, we observed an 300% increase in the magnitude of 
GGABA and a 100% increase in the decay time of sIPSCs after the removal of 
GAT1.  
In Purkinje cell recordings, a standing inward GABAA receptor-mediated 
conductance, defined by sensitivity to the GABAA receptor antagonist SR95531 
(>100 µM), was observed in mGAT1 KO mice, which is much larger than in WT 
mice (75 ± 19 pS/pF, n = 10 vs 13 ± 5 pS/pF, n = 9, respectively) (Fig. 9). 
However, the high frequency of sIPSCs consistently observed in Purkinje cells 
(>10 Hz) indicates that a comparison of sIPSC kinetics between WT and mGAT 
KO mice is not possible in this cell type because of the considerable 
superimposition of events. Moreover, it is not feasible to selectively analyze the 
tonic and phasic components of the GABAA-mediated conductance in a similar 
manner to the granule cell recordings. Nonetheless, as shown in Figure 9, it is 
clear that in Purkinje cell recordings, the magnitude of a standing inward GABAA 
receptor-mediated conductance is significantly increased in mGAT1 KO mice. 
 
DISCUSSION 
 The mGAT1 KO mouse as a model for tiagabine side effects. The 
distinct phenotype of mGAT1 KO mice includes ataxia, tremor, sedation, 
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nervousness (mild anxiety), increased frequency and amplitude of body 
temperature fluctuations, and reduced body weight. Similar behavioral patterns 
were also observed in WT mice treated with either tiagabine or NO711, both 
GAT1 inhibitors (Nielsen et al., 1991; Suzdak et al., 1992; Suzdak, 1994). 
Epileptic patients treated with Tiagabine display similar side effects, including 
dizziness, asthenia, somnolence (sedation), nonspecific nervousness, tremor, 
and ataxia (Adkins and Noble, 1998). The fact that the mGAT1 KO mice 
phenocopy many effects of both mice and humans treated with GAT1 inhibitors 
suggests that the clinical side effects might be expected from any systemically 
administered drug that targets GAT1, no matter how selective.  
Synaptic basis of the tremor. GAT1 inhibition causes elevated 
extracellular [GABA] and therefore generates an increased tonic GABAA-
mediated conductance, perhaps primarily by acting at areas that typically express 
high-affinity, nondesensitizing GABAA receptors (Brickley et al., 1996; Wall and 
Usowicz, 1997; Hamann et al., 2002; Jensen et al., 2003). Our data for cerebellar 
granule (Fig. 8) and Purkinje (Fig. 9) cells support these ideas. Previous studies 
also report a prolongation of the evoked GABAA receptor-mediated synaptic 
decay after block of GABA transporters (Dingledine and Korn, 1985; Roepstorff 
and Lambert, 1992, 1994; Thompson and Gahwiler, 1992; Draguhn and 
Heinemann, 1996; Rossi and Hamann, 1998; Overstreet et al., 2000). This 
phenomenon is not observed after action potential-independent release 
(Thompson and Gahwiler, 1992; Isaacson et al., 1993), suggesting that GAT1 
transporters are likely to be more important in limiting the GABA profile after 
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multivesicular release. However, the use of GABA transport blockers in previous 
assays may be complicated by the fact that GAT1 inhibitors are also competitive 
antagonists of GABAA receptors (Overstreet et al., 2000; Jensen et al., 2003).  
The cerebellar glomerulus, like the basket cell-Purkinje cell pinceau 
synapse and the chandelier cell-pyramidal cell cartridge of cortex, is a highly 
organized synaptic structure that contains many synaptic contacts produced by 
just a few presynaptic inhibitory axons (Jakab and Hamori, 1988) and features a 
dense level of GAT1 expression (Chiu et al., 2002). The dramatically prolonged 
granule cell IPSC waveforms in mGAT1 KO mice are certainly consistent with the 
idea that GAT1 plays a more important role in clearing GABA after multivesicular 
release in structures such as the glomerulus, where diffusion is limited (Nielsen et 
al., 2004). This may explain the greater prolongation of sIPSCs we observe in 
mGAT1 KO granule cells (Fig. 8) than previously observed in hippocampus 
(Jensen et al., 2003). The unchanged level of GAD65 (Fig. 1D), vGAT (Fig. 1D), 
the GABA receptor 1 subunit (Fig. 1D), GABAB receptors (Jensen et al., 2003), 
and GAT3 (see supplemental figure, available at www.jneurosci.org as 
supplemental material) in the mGAT1 KO mice argues against some classes of 
compensatory changes in response to the chronically elevated [GABA]. 
Furthermore, the NO711-insensitive cerebellar synaptosomal GABA uptake was 
only 15-25% of the total activity in WT, and the absolute value of NO711-
insensitive GABA uptake activity showed no difference between WT and mGAT1 
KO. However, we cannot rule out other changes such as altered subunit 
composition of GABAA receptors or an altered waveform of synaptically released 
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[GABA]. Whatever the underlying synaptic mechanisms, the distorted inhibitory 
waveform observed in granule cells suggests that inhibition in one or more motor 
control nuclei provides a reasonable, although not quantitative, explanation for 
the tremor that we observed in the mGAT1 KO mouse. An oscillation between 
excitation and inhibition underlies many neuronal pacemakers, and in mGAT KO 
mice, this oscillation is apparently timed in part by the accentuated inhibitory 
phase that results from increased and prolonged [GABA]. Flunitrazepam, an 
allosteric activator of GABAA receptors, increased the period and increased the 
amplitude of the tremor (Fig. 2C), consistent with the idea that one phase of the 
oscillation is governed by the waveform of GABAA-mediated inhibition.  
Which inhibitory synapse(s) dominates the tremor? We do not imply that 
the oscillation is solely determined by the timing of a cerebellar inhibitory synapse 
such as the Golgi cell-granule cell contact. The removal of GAT1 presumably 
alters characteristics of GABA-mediated transmission in many nuclei. GABAA 
receptor 1 subunit knock-out mice tremble at 18 Hz (Kralic et al., 2002), 
suggesting that a tremor can arise from either too little or too much GABAergic 
transmission throughout the brain. However, the tremor in mGAT1 KO mice is 
inconsistent with the low-frequency tremors generally associated with basal 
ganglia and midbrain pathology. The tremor also has a higher frequency (25-32 
Hz) (Fig. 2) than most previously reported mouse tremors but equal to that of 
mice expressing the hypofunctional glycine receptor (GlyR) oscillator 1 subunit 
(Simon, 1997) or a human hyperekplexia-related GlyR mutant (Becker et al., 
2002). Glycine transporter 2 knock-out mice also display 15-25 Hz tremor 
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(Gomeza et al., 2003). These observations on the glycinergic system suggest 
that the tremor is primarily spinal in origin. 
Ataxia. The ataxia exhibited by mGAT1-deficient mice (i.e., rotarod 
deficits) (Fig. 3C,D; broader paw angle in E,F) is more likely to originate from a 
specific cerebellar defect, because ablation of GABAergic neurons in the 
cerebellum also causes ataxia in several classic mouse mutants. Overall, these 
results illustrate that normal motor control depends on maintaining appropriate 
levels of both phasic and tonic GABAA receptor-mediated inhibition in the 
cerebellum. 
Nervousness versus anxiety. Nervousness describes the clinical side 
effects of tiagabine (Dodrill et al., 1997, 1998, 2000; Adkins and Noble, 1998). In 
the absence of an accepted test for nervousness in rodents, we assumed that it 
can be assessed as a mild form of anxiety. The GAT1 KO mice show such a 
phenotype. In the open-field test, mGAT1-deficient mice display delayed 
exploratory activity and decreased frequency of visits to the central area (Fig. 4A-
C). However, the reduced rearing (Fig. 4D) could be caused by simply the 
decreased motor ability that leads to the lowered stance (Fig. 3B); there was only 
moderately reduced walking speed (Fig. 4E) and no reduction in total distance 
traveled (Fig. 4F). Furthermore, mutant mice show no difference in acoustic 
startle response compared with WT (Fig. 5C), but they display a dramatic 
decrease in prepulse inhibition of the acoustic startle response (Fig. 5D). The 
mGAT1 KO displays reduced home-cage activity, but the modest decrement in 
open-field walking speed suggests that mutant mice remain active when 
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encountering novel environments, whereas they display reduced activity in a 
habituated environment (Fig. 5A,B). In contrast, 5-HT transporter null mice exhibit 
a classical pattern of increased anxiety-like behavior in the elevated plus maze, in 
light-dark exploration and emergence tests, and in open-field tests (Holmes et al., 
2003). 
It is also true that many classical anxiolytic drugs operate by increasing the 
activity of GABAA receptors. Likewise, reduced GABA also causes anxiety; for 
example, GAD65 knock-out mice exhibit increased anxiety-like behavior in both 
the open-field and elevated-zero maze assays (Kash et al., 1999). 
Reduced body weight. The reduced body weight of mGAT1 KO mice 
(Fig. 1F) contrasts with obesity of transgenic mice overexpressing mGAT1 under 
nonspecific or pan-neuronal promoters (Ma et al., 2000). GABA-related 
regulatory mechanism of feeding behavior in the ventro-medial hypothalamus 
may be responsible for impaired responses to glucoprivation in genetically obese 
rats (Tsujii and Bray, 1991). Benzodiazepine-treated rats lose body weight, 
presumably via activation of GABAA receptors (Blasi, 2000). Excess GABA in the 
anterior piriform cortex region reduces feeding (Truong et al., 2002). We believe 
that the reduced body weight and tremor is not related to delayed (or retarded) 
development, because mGAT1 KO mice are reproductive at the same time as 
WT and display muscle strength and balance similar to WT. Additional detailed 
studies are required. 
Thermoregulation and circadian rhythm. Thermoregulation is controlled 
by several brain regions, including the horizontal limb of the diagonal band of 
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Broca (HDB), the basal forebrain, the preoptic area (POA), and the rostral part of 
the raphe pallidus nucleus (rRPa). Many neurons in these areas are GABAergic. 
In the HDB, muscimol reduces thermosensitivity (Hays et al., 1999) and, in the 
rRPa, muscimol to rRPa blocks fever and thermogenesis in brown adipose tissue 
induced by intra-POA as well as by intracerebroventricular prostaglandin E2 
applications (Nakamura et al., 2002). 
We know of no clinical studies on temperature effects of tiagabine. However, the 
higher amplitude of hyperthermic episodes in the mGAT1 KO mouse (Fig. 7) 
clearly does not phenocopy the acute hypothermic effects of tiagabine in rodents 
(Inglefield et al., 1995). Interestingly, GABAB activation leads to hypothermia 
(Schuler et al., 2001), but we found previously that the presynaptic GABAB 
response is diminished or lost in mGAT1 KO mice (Jensen et al., 2003), which 
may explain the discrepancy. 
Although GABA has been related to circadian rhythm in many publications (Liu 
and Reppert, 2000; Wagner et al., 2001), the mGAT1-deficient mice did not 
display obvious changes in circadian rhythm during 5 d of testing either in 
constant dark or in a 12 h light/dark cycle environment. These results suggest 
that excess GABA does not affect circadian rhythm. 
An additional use for knock-out mice strains. To the other useful 
information obtained from knock-out mouse strains, we may add the decision 
regarding whether the clinical side effects of a drug (in this case, tiagabine) arise 
from either widespread expression of its target or nonselective actions on other 
targets. Such information is particularly valuable when the pleiotropic effects 
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cannot readily be predicted from, but are certainly consistent with, the 
widespread and varied roles of the target molecule. Of course, such a study is 
rather straightforward when it is believed that the effects are mostly acute and 
subject to straightforward neurological tests (as in the present case), rather than 
delayed and primarily psychiatric (as for serotonin and perhaps dopaminergic and 
noradrenergic transporters). 
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FIGURES 
 
Fig 1 
 
Figure 1. mGAT1 KO cerebellar images, synaptosomal GABA uptake, and body 
weight. A, Fluorescent image of an mGAT1-GFP knock-in mouse cerebellar 
cortex, showing typical GAT1 expression pattern. B, Fluorescent image of GAT1 
KO showing no obvious GAT1 expression pattern. C,WT mouse shows no 
obvious fluorescence. B and C were exposed to_20-fold greater photo power 
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than A. GL, Granule cell layer; ML, molecular layer; P, Purkinje cell. Scale bar, 
50_m.D, Quantification of GAD65, vGAT, and GABAA receptor-containing 
boutons in WT and KO mice based on the immunocytochemical staining (see 
supplemental figure for the actual images, available at www.jneurosci.org as 
supplemental material). E, The NO711-sensitive synaptosomal [ 3H]GABA 
uptake activities among the three genotypes (mean_SEM; triplicate assays from 
each of two experiments with all three genotypes). E, Decreased body weight of 
the GAT1 KO mouse. Data measured from 11 litters of het/het matings between 
the ages of 50 and 66 d are shown. Compared with WT littermates, male 
homozygotes weigh_20% less, whereas female homozygotes weigh _10% less. 
M, Male; F, female. WT, Het, KO: n_8, 17, 15 for males; n_11, 14, 8 for females. 
Differences fromWTat *p_0.05 and **p_0.01. 
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Fig 2 
 
Figure 2. Characterization of mGAT1 KO tremor. A, Recordings from the 
vibration transducer. Arrows (higher amplitude) indicate activities when forepaws 
were raised. B, Power spectrum of the transducer signal for all genotypes. All 
genotypes shared a minor peak at 80 Hz; however, only the KO showed a 
significant tremor at 25-32 Hz. C, Modulation of tremor frequency and amplitude 
by flunitrazepam. Error bars represent SEM. 
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Fig 3 
 
Figure 3. mGAT1 KO displays abnormal motor behavior. A, WT (left) and 
mGAT1 KO (right) mice showed different gestures when hung by their tails. WT 
mice showed a typical extensor gesture, whereas KO mice showed flexor 
contraction. B, Stance of WT and KO mice on the rotarod. The KO mice show 
flattened and lowered hips, and their paws move more slowly than WT mice. C, 
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Mice were tested at fixed speed (either 12 or 20 rpm) on the rotarod. n = 6, 5, 
and 8 (WT, Het, and KO, respectively). D, Mice were tested at accelerating 
speeds. KO mice fell significantly sooner than WT mice. E, Abnormal gait. 
Hindpaw footprint pattern of WT, heterozygotes, and homozygotes is shown. The 
hindpaws of mGAT1 KO mice show a wider angle with respect to the direction of 
walking. The KO mouse seems to waddle. F, Comparison of the average paw 
angles among WT (n = 8), Het (n = 9), and KO (n = 17) mice. The paw angle of 
the KO mouse is approximately twice as large as that of WT and heterozygotes 
(23 ± 1 vs 12.5 ± 1°). Differences from WT at *p < 0.05 and **p < 0.01. 
 
Fig 4 
 
Figure 4. Characterization of mGAT1 KO exploratory activity in the open field. A, 
The time required for mice to walk the first 50 cm in open field. Most WT and Het 
mice take <10 s, whereas KO mice spend 13-240 s. Points show mean ± SEM. 
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B, C, The KO mouse shows reduced frequency (B) and reduced duration (C) 
visiting the central area in the open-field test. Total visits to the central area were 
15 ± 2, 25 ± 3, and 7 ± 3, and total time to stay in the central area were 67 ± 11, 
106 ± 23, and 21 ± 7s for WT, Het, and KO, respectively. D, The GAT1 KO 
mouse showed reduced frequencies of rearing (73 ± 2, 87 ± 9, and 29 ± 10 for 
WT, Het, and KO, respectively). E, The average walking speeds for WT, Het, and 
KO mice were 16.2 ± 0.5, 19.4 ± 0.6, and 12.3 ± 0.6 cm/s, respectively. F, 
mGAT1 KO mice showed no obvious difference in total walking distance within 
10 min (2000 ± 210, 2840 ± 320, and 2190 ± 300 for WT, Het, and KO, 
respectively). E, n = 7, 12, and 10 (WT, Het, and KO, respectively). For all other 
panels, n = 6, 8, and 8 (WT, Het, and KO, respectively). *p < 0.05; **p < 0.01. 
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Fig 5 
  
Figure 5. Additional anxiety-related behaviors: elevated plus maze and acoustic 
startle. mGAT1 KO mice display increased partial arm entries (A) and time spent 
in the central square (B) compared with WT mice. *p < 0.01; n = 4 mice in each 
group. C, Acoustic startle response of mutant (open circle; n = 4) and WT (filled 
square; n = 4) measured in arbitrary units. D, Prepulse inhibition of mutant (open 
column; n = 7) and WT (filled column; n = 7). The 5, 10, and 15 under the x-axis 
refer to prepulses at 5, 10, and 15 dB, respectively, above the background level 
of 68 dB. The difference between KO and WT is significant at *p < 0.05 and **p < 
0.01. Error bars represent SEM. 
 
  
174
 
Fig 6 
  
Figure 6. GAT1 KO mice showed reduced ambulation in home cages. A, Profiles 
of ambulation activity of WT (top) and KO (bottom) mice over a 42 h recording 
period. WT displays a 24 h rhythm, whereas KO shows lower activity. B, Total 
ambulation activity of KO and WT mice (2425 ± 395 and 965 ± 146 counts). Error 
bars represent SEM. 
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Fig 7 
 
Figure 7. mGAT1-deficient mice display more body temperature fluctuations in 
the 0.2-1.5/h frequency range than WT mice. A, Raw traces of body temperature 
fluctuation from one WT (top) and one mutant (bottom) mouse. Mutant mice 
display multiple hyperthermic episodes, especially during periods of higher 
activity (i.e., higher body temperature). B, Expanded traces from A. C, Power 
spectrum analysis. The y-axis represents the average power (n = 4 KO, 3 WT) 
normalized to the peak at 24 h cycle as 100%. The x-axis represents the 
frequency (inverse hours). 
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Fig 8 
 
Figure 8. mGAT1 KO cerebellar granule cells are characterized by an increased 
tonic GABAA-mediated conductance and prolonged IPSCs. A, B, Continuous 
current records from typical wild-type (A) and mGAT1 KO (B) internal granule 
cells voltage clamped at -70 mV. The horizontal line indicates the 0 current level 
in each recording. There is an increased inward current in mGAT1 KO cells and 
a substantial increase in the current variance associated with this conductance. 
This increased tonic conductance is completely blocked by the GABAA receptor 
antagonist SR95531 (gabazine). C, The bar graph illustrates that, on average, 
GGABA in GAT1 KO granule cells was 319 ± 65 pS/pF (n = 7) compared with 84 ± 
50 pS/pF (n = 4) in control littermates. This resembles the 98 ± 20 pS/pF GGABA 
recorded previously in the C57BL/6 strain (Brickley et al., 2001 ). Therefore, the 
tonic conductance tripled after the removal of GAT1, indicating a raised 
concentration of ambient GABA in the slice preparation. D, E, Two average 
sIPSC waveforms recorded from a wild-type (D) and an mGAT1 KO (E) granule 
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cell are shown on the same scale. The waveforms have similar peak amplitudes 
but very different decays. The histograms also illustrate the peak amplitude 
distribution of all sIPSCs recorded in these cells. The open histograms were 
constructed from periods of baseline noise. As shown by the increase in the 
width of the baseline histogram for mGAT1 KO, the increased current variance 
associated with mGAT1 KO recordings does complicate interpretation of peak 
amplitude measurements. It is possible that we are missing a significant fraction 
of small events in the mGAT1 KO, because they would be unresolved in the 
noisy mGAT1 KO recordings. However, this possible artifact does not affect the 
decay estimates, because the decay of sIPSCs is not correlated with peak 
amplitude in granule cells (data not shown). F, The significant increase in the 
decay of sIPSC recorded from mGAT1 KO granule cells. The decay was defined 
as integral (see Materials and Methods). The integral of control littermates was 13 ± 
5 ms (n = 4) compared with 37 ± 6 ms (n = 5) in the mGAT1 KO animals. In 
contrast, there was no significant difference between the average peak 
amplitudes recorded in the two strains. Error bars represent SEM. 
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Fig 9 
 
  
 
Figure 9. mGAT1 KO mice display higher tonic currents in cerebellar Purkinje 
cells. In both WT and mGAT1 KO slices, sIPSCs were recorded in Purkinje cells 
by holding at -70 mV. Zero current levels are shown in the light trace. Injection of 
SR95531 into the bath (>100 µM; heavy trace) blocked tonic current and sIPSCs. 
Average tonic currents in mGAT1 KO cells are approximately six times larger 
than in WT cells [75 ± 19 and 13 ± 5 pS/pF for KO (n = 10) and WT (n = 9), 
respectively]. Error bars represent SEM. 
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Appendix C 
 
Atypical expansion in mice of the sensory neuron-specific Mrg G 
protein-coupled receptor family. 
 
 Zylka MJ, Dong X, Southwell AL, Anderson DJ.  
PNAS. 2003,100(17):10043-8. 
 
 
ABSTRACT 
The Mas-related genes (Mrgs) comprise a family of >50 G protein-coupled 
receptors (GPCRs), many of which are expressed in specific subsets of 
nociceptive sensory neurons in mice. In contrast, humans contain a related but 
nonorthologous family of genes, called MrgXs or sensory neuron-specific 
receptors, of which many fewer appear to be expressed in sensory neurons. To 
determine whether the diversity of murine Mrgs is generic to rodents or is an 
atypical feature of mice, we characterized MrgA, MrgB, MrgC, and MrgD 
subfamilies in rat and gerbil. Surprisingly, although mice have approximately 22 
MrgA and approximately 14 MrgC genes, rats and gerbils have just a single 
MrgA and MrgC gene. This murine-specific expansion likely reflects recent 
retrotransposon-mediated unequal crossover events. The expression of Mrgs in 
rat sensory ganglia suggests that the extensive cellular diversity in mice can be 
simplified to a core subset of approximately four different genes (MrgA, MrgB, 
MrgC, and MrgD), defining a similar number of neuronal subpopulations. Our 
results suggest more generally that mouse-human genomic comparisons may 
sometimes reveal differences atypical of rodents. 
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INTRODUCTION 
 In many sensory systems, including taste, olfaction, and vision, primary 
sensory neurons express diverse families of seven transmembrane domain G 
protein-coupled receptors (GPCRs) to detect and discriminate among various 
chemical and visual stimuli (1–3). The expansion of diverse GPCR families is 
enabled by the fact that functional receptors and their transcriptional controls 
often reside within small (≈10-kb) segments of DNA present in tandem arrays (4–
6). The success of this molecular unit is reflected in the fact that GPCRs 
constitute the largest single gene family in all metazoan genomes (7–10).  
Recent studies have identified a novel family of GPCRs specifically 
expressed in primary nociceptive sensory neurons in mice and humans (11, 12). 
In vitro studies suggest that some of these receptors can be activated by 
neuropeptides that contain C-terminal -RF(Y)amide or -RF(Y)G motifs (11–13). 
Members of this family have been referred to as Mas-related genes (Mrgs) (11, 
14, 15). Alternatively, in humans they have been called sensory neuron-specific 
receptors (SNSRs) (12). In mice, the Mrg family is comprised of six single-copy 
genes (MrgD, MrgE, MrgF/RTA, MrgG, MrgH/GPR90, and MAS1), as well as 
three large clades or subfamilies (MrgA, MrgB, and MrgC) that together comprise 
≈50 distinct sequences. The differential expression of various mouse (m)Mrgs 
defines a surprisingly diverse axis of cellular heterogeneity among murine 
nociceptive sensory neurons, the functional significance of which is currently 
unclear (11).  
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In contrast to the extensive sequence diversity exhibited by mMrgA, 
mMrgB, and mMrgC subfamilies, in humans there are only four functional 
hMrgX/SNSR genes. Although some of these genes are specifically expressed in 
nociceptive sensory neurons like their murine counterparts, none of the human 
and mouse genes are strictly orthologous (11). This difference raises the 
question of whether the extensive Mrg sequence diversity characteristic of mice 
is generic to rodents, perhaps reflecting differences with humans in nociceptive 
physiology, or rather reflects genomic expansion events unique to mice.  
To address this question, we have characterized the complement of Mrg 
genes in two other rodent species, rat and gerbil.  
Our results indicate that the extreme diversity of murine Mrgs is an 
atypical feature of mice. These findings simplify the problem of understanding the 
functional significance of Mrg sequence diversity in rodents to a core set of 
approximately four different genes (MrgA, MrgB, MrgC, and MrgD), defining a 
similar number of neuronal cell populations.  
 
METHODS 
 Distance Calculations. Representative nucleotide sequences from the 
coding regions of MrgA (mMrgA1-A8, rMrgA), MrgB (mMrgB1-B5, mMrgB7-B8, 
rMrgB1, rMrgB2, rMrgB5-B6, rMrgB8), and MrgC (mMrgC1, mMrgC2, mMrgC7, 
mMrgC11, rMrgC) subfamilies were aligned with clustalw and then manually 
aligned on a codon-by-codon basis. Nucleotides that introduced gaps within a 
codon were removed from the analysis (complete-deletion option). The program 
  
182
 
diverge was then used to calculate the number of pairwise synonymous (K s) and 
nonsynonymous (K a) nucleotide substitutions between mMrgAs, mMrgBs, 
rMrgBs, and mMrgCs by using the method described by Li et al. (16–18) with 
recent modifications. A neutral substitution rate of 4.5 = 10– 9 substitutions per 
synonymous site (K s) per year was used to calculate evolutionary distance 
between each pair of sequences (10). This rate was based on the assumption 
that humans and rodents last shared a common ancestor 75 million years ago 
(MYA), and it is similar to the neutral substitution rate for rodents calculated by 
others (19).  
The details describing how rat and gerbil Mrgs were cloned as well as 
methods for in situ hybridizations and Southern blot hybridizations can be found 
in Supporting Methods, which is published as supporting information on the 
PNAS web site, www.pnas.org.  
 
RESULTS 
 Identification of the Rat Mrg Family. Searches of the January 21, 2003, 
release of the rat genome using mouse Mrgs as query sequences revealed that 
the rat has a single copy each of rat (r)MrgA and rMrgC (Fig. 1A). These two rat 
genes have been previously characterized as an adenine receptor and rSNSR, 
respectively (12, 20). However, the total number of rat Mrgs was not 
systematically examined in these previous studies. Our searches also identified 
10 rMrgBs, many of which are orthologous to at least one of the mouse MrgB 
genes (Fig. 6, which is published as supporting information on the PNAS web 
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site). The mouse and rat MrgB subfamily was divided further into phylogenetically 
defined B2, B4, and B8 subdivisions (Figs. 1 A and 6). 
The rat genomic dataset also contained complete sequences of rMrgD, 
rMrgE, rMrgF/RTA, rMrgG, rMrgH/GPR90, and rMAS1. With the exception of 
MrgH, which has not been identified in humans, these genes all have orthologs in 
mice and humans. As in mice, we were unable to identify rat genes that are 
orthologous to the human MrgX subfamily or to hMrg, the first Mas-related gene 
identified in humans (14). Taken together, these data indicate that rats and mice 
contain orthologous sets of the MrgA, MrgB, MrgC, and MrgD genes, albeit in 
different numbers, and that neither species contains genes orthologous to human 
MrgX/SNSRs. 
Because our bioinformatic analysis was based on draft genomic 
sequence, we performed Southern blot experiments to confirm the copy number 
of rat Mrg genes. We used probes that covered most of the coding regions of 
rMrgA, rMrgB2, rMrgB4, rMrgB8, rMrgC, and rMrgD. Because the coding region 
of each Mrg is contained within a single exon (11), the number of bands of 
equivalent intensity on a Southern blot approximates the number of genes. 
Control experiments using mouse genomic DNA indicated that the rat Mrg 
probes were capable of hybridizing to at least 10 genes in the mMrgA and 
mMrgC subfamilies [Fig. 1B, lanes rMrgA (M) and rMrgC (M)]. Analysis of rat 
genomic DNA [Fig. 1B (R)] revealed one band each for rMrgA, rMrgC, rMrgB8 
(B8 subdivision), and rMrgD; at least four strong bands for rMrgB2 (B2 
subdivision), and two strong bands for rMrgB4 (B4 subdivision). The weaker 
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bands detected by the rMrgB4 probe are likely due to cross-hybridization with 
other rMrgB2-like genes (note size similarities between MrgB2 and MrgB4 lanes). 
The number of bands detected by Southern blot analysis was therefore well 
correlated with the number of genes identified by our database searches.  
Identification of Gerbil Mrg Family Members. The contrasting results in 
rat and mouse raised the question of whether the diversity of murine Mrgs 
represents the exception, or rather the rule, among rodents. To address this 
question, we characterized Mrgs from a third murid rodent, the Mongolian gerbil 
(Meriones unguiculatus). Because genomic sequence data are currently not 
available for this species, our approach was restricted to experimental analysis.  
First, using degenerate PCR primers and gerbil liver genomic DNA as the 
template, we identified gerbil orthologs of MrgB1, MrgB4, and MrgD. On the 
basis of a phylogenetic analysis, gerbil (g)MrgB1 and gMrgB4 are located in the 
B2 and B4 subdivisions, respectively (Fig. 6). Despite numerous attempts, we 
were unable to amplify gerbil MrgA or MrgC sequences with degenerate primers.  
We therefore conducted a Southern blot analysis of gerbil genomic DNA 
using rat MrgA and MrgC probes. That these rat probes strongly cross-hybridized 
to their murine orthologs under our hybridization conditions (Fig. 1B) suggested 
they would likely cross-hybridize to their gerbil orthologs as well. Consistent with 
this expectation, the rat MrgA and MrgC as well as the MrgD probes cross-
hybridized to gerbil DNA, revealing single intense bands of 7.5, 1.5, and 8 kb, 
respectively (Fig. 1B, lanes G). The two additional weak bands revealed by the 
rMrgC probe likely represent cross-hybridization to gMrgA and/or a restriction 
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fragment of gMrgC. These data suggest that, like the rat, the gerbil has a single 
copy of MrgA and MrgC and a single copy of MrgD, like all mammals thus far 
examined.  
Gerbil DNA was also probed with rMrgB probes. We detected a total of 
three bands that cross-hybridized to both the rMrgB2 and rMrgB4 probes, albeit 
with different intensities to each (Fig. 1B). The 3.5- and 11-kb bands correspond 
to gMrgB1 and gMrgB4, respectively, as determined by probing duplicate blots 
with gerbil MrgB1 and MrgB4 DNA probes (data not shown). The 1.1-kb band did 
not hybridize to the rMrgB8 probe, and its identity is unknown. It could represent 
an additional gerbil MrgB gene or a restriction fragment of gMrgB1 or gMrgB4. 
Taken together, these data suggest that gerbil has at least two, and possibly 
three, MrgB genes, a number significantly less than mouse or rat (Fig. 1C).  
Expansion of the MrgA, MrgB, and MrgC Subfamilies Occurred at 
Different Times During Rodent Evolution. The foregoing data suggested that 
the murine genome contains a far greater number of Mrgs than either the rat or 
the gerbil. This difference could reflect an evolutionary contraction of the family 
that occurred in the latter two species or a selective expansion in the mouse. To 
distinguish between these alternatives, we determined the evolutionary times at 
which expansions of the different Mrg subfamilies occurred in mice, in relation to 
the times of speciation of rat, mouse, and gerbil (see Methods). These 
calculations suggested that the mouse MrgA and MrgC subfamilies each 
diverged from their respective common ancestors 10–25 MYA (Fig. 2), 
corresponding to a time shortly after, or coincident with, the speciation of rats and 
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mice, and ≈25–45 million years after the speciation of gerbils from the rat–mouse 
lineage (21–23). Thus the larger sizes of the MrgA and MrgC subfamilies in 
mouse are consistent with an evolutionarily late selective expansion in that 
species.  
In contrast to the results for the MrgA and MrgC subfamilies, the 
divergence times for MrgB gene pairs generally occurred before rat–mouse 
speciation but fell over a much broader window of evolutionary time spanning 
10–80 MYA (Fig. 2). Pairwise (rat–rat and mouse–mouse) comparisons between 
members of the three different MrgB subdivisions (B2, B4, and B8) yielded 
average divergence times of 71 ± 6, 66 ± 4, and 70 ± 3 MYA (±SD) for B2–B4, 
B2–B8, and B4–B8 comparisons, respectively. The small variability in these 
numbers, combined with their similar absolute values, suggests that the B2, B4, 
and B8 subdivisions originated from a single ancestral MrgB gene ≈65–70 MYA. 
That this divergence occurred shortly before or during the time that rats and mice 
were predicted to have speciated from gerbils is consistent with our identification 
of one gerbil MrgB gene in each of the B2 and B4 subdivisions. The average 
divergence time calculated for rat or mouse MrgB members within each 
subdivision was 34 ± 17 MYA, consistent with the idea that these subdivisions 
expanded after the divergence of rats and mice from the gerbil lineage. Thus, it 
appears that at least two subdivisions of the MrgB family are likely present in all 
rodents but differ in size due to additional expansion events (Fig. 1C).  
Mrgs Expressed in Sensory Neurons Are Positioned Adjacent to One 
Another in the Genome. To determine whether rat Mrgs are expressed in 
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sensory neurons like their murine counterparts, we performed in situ 
hybridization experiments with tissue from newborn and adult rats. These 
experiments indicated that rMrgA, rMrgB4, rMrgB5, rMrgC, and rMrgD were all 
expressed strongly in newborn dorsal root ganglia (DRGs), adult DRGs, and 
trigeminal ganglia (gV; Figs. 3 and 4; data not shown). Others have similarly 
reported expression of rMrgA and rMrgC exclusively in adult rat DRG neurons 
(12, 20). In contrast, we did not detect expression of rMrgB1, rMrgB2, rMrgB3, 
rMrgB6, or rMrgB8 in sensory neurons. Although we have not looked 
exhaustively, none of our rMrg probes clearly hybridized to any other tissues or 
organs in postnatal day 0 animals. As in the rat, mMrgB4 and mMrgB5 were 
likewise expressed in adult mouse DRG neurons (see below), although not in 
newborn DRG neurons (11). Taken together, these data indicate that genes 
within the MrgB B4 subdivision, but not the B2 or B8 subdivisions, are expressed 
in sensory neurons like MrgA, MrgC, and MrgD.  
The sensory neuron-specific expression of rat Mrgs raised the possibility 
that they might be clustered together within the genome, like olfactory and 
vomeronasal GPCRs (6, 24, 25). Using the draft rat genome assembly as a 
guide, we found that most of the rMrg family members map to rat chromosome 1 
(Fig. 3B, Rn). The rMrgA, rMrgB, and rMrgC genes are found together within a 
760-kb cluster (the MrgABC cluster), and the rMrgD, rMrgE, rMrgF, and rMrgG 
genes are found together within a 1.9-Mb cluster (the MrgDEFG cluster). All of 
the Mrgs from the MrgABC cluster expressed in sensory neurons are adjacent to 
one another in the rat genome. Within this cluster, the MrgBs are arranged along 
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the chromosome in a centromeric to telomeric orientation, within phylogenetically 
defined B4, B8, and B2 subdivisions.  
Analysis of the assembled mouse genome revealed a similar arrangement 
of mMrgs into phylogenetically segregated mMrgABC and mMrgDEFG clusters 
on syntenic regions of mouse chromosome 7 (Fig. 3B, Mm). Furthermore, the 
murine mMrgA and mMrgC genes were generally found as a repeat of (A-A-C)n. 
This arrangement may explain why there are roughly twice as many mMrgAs (n = 
22) as mMrgCs (n = 14) (11). The clustering of Mrgs with sensory neuron-specific 
expression suggests the presence of a locus control region and/or that the gene 
duplication events expanding these subfamilies included local cell type-specific 
transcriptional regulatory elements.  
To obtain more clues about how the MrgABC cluster could have evolved, 
we searched assembled genomic sequences surrounding the rat and mouse 
MrgABC cluster for repetitive elements with the repeatmasker program 
(http://ftp.genome.washington.edu). For comparison, we searched a similar 
stretch of assembled genomic DNA surrounding the rat and mouse MrgD and 
MrgF cluster. This search revealed that the mouse and rat MrgABC clusters are 
intercalated with very large amounts of LINE1/L1 retrotransposon sequences 
(mouse MrgABC cluster = 43.2% L1; rat MrgABC cluster = 48.3% L1) (Figs. 7 
and 8, which are published as supporting information on the PNAS web site). In 
contrast, the rat and mouse MrgD and MrgF cluster contains very few L1 
elements or other repeats (mouse MrgDF cluster = 0.76% L1; rat MrgDF cluster 
= 0.58% L1). We also noticed that L1 retrotransposon sequences were found 
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only at the 5′ end of the rMrgA coding exon but were found at the 5′ and 3′ ends 
of the coding exon of most mMrgAs (Figs. 7 and 8). These repeat elements may 
have played a role in the expansion of the MrgABC cluster (see Discussion).  
Similar Subpopulations of Nociceptive Sensory Neurons Are Defined 
by Mrg Receptor Expression in Rat and Mouse. Nociceptive primary sensory 
neurons fall into many different subclasses. These subclasses can be 
distinguished on the basis of their function, neurotrophin dependence, and 
expression of molecular markers (26, 27). One such subclass expresses the glial 
cell line-derived neurotrophic factor (GDNF) receptor c-Ret and binds Griffonia 
simplicifolia isolectin IB4 (28). This GDNF-dependent subset has been implicated 
in neuropathic and inflammatory pain, conditions for which current analgesics are 
inadequate (29–34). In the mouse, Mrgs are expressed exclusively within this 
subset of nociceptors (11). We therefore wished to determine whether the 
restriction of Mrg expression to this neuronal subclass was conserved in the rat.  
As in the mouse, we found that all rMrgB4 +, rMrgC +, and rMrgD + (all of 
which are rMrgA +; see below) neurons were also IB4 binding+ and c-Ret+ (Fig. 
4A; Table 1, which is published as supporting information on the PNAS web site). 
Within this population, rMrgD + cells were approximately two and three to four 
times more numerous than rMrgB4 + or MrgC + cells, respectively, similar to the 
situation in mouse (Table 1). As in the mouse, the MrgD + subset of c-Ret+ cells 
coexpressed the purinergic receptor P2X3 (11). The main difference between rat 
and mouse was that in the rat, all rMrgD + cells [as well as a minority (7%) of 
rMrgC + cells] express the capsaicin receptor VR1 (Fig. 4A and Table 1), 
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whereas most or all Mrg-expressing cells are VR1– in the mouse (11). In addition, 
in the mouse, only mMrgD + neurons coexpress the purinergic receptor P2X3, 
whereas in the rat, all Mrg + neurons are P2X3+ (Fig. 4A). Taken together, these 
studies indicate that in rats, as in mice, Mrgs are restricted to the GDNF-
dependent subset of nociceptive sensory neurons but display subtle differences 
in the other signaling molecules that they coexpress (Fig. 4B).  
In the mouse, Mrg expression defines multiple subsets of neurons within 
the IB4+/Ret+ population (11). Because rats have a much smaller number of 
Mrgs, we next performed a series of double-label in situ hybridization 
experiments to determine how many adult DRG cell types they distinguish (Fig. 9 
and Table 2, which are published as supporting information on the PNAS web 
site, for quantification). Briefly, we found that rMrgD and rMrgA are 100% 
coexpressed and define a single cell type that does not express rMrgB4 or 
rMrgC. A second nonoverlapping cell type was defined by coexpression of 
rMrgB4 and rMrgB5 (Table 2) and a third by unique expression of rMrgC. A 
fourth cell type was defined by coexpression of rMrgC and rMrgB4 in 27% of the 
MrgC + cells (Fig. 4B and Table 2). Thus, the number of distinct neuronal 
subtypes defined by the combinatorial expression of rMrgA, rMrgB, rMrgC, and 
rMrgD is on the same order as the number of genes (Fig. 4B).  
Because we had not previously detected expression of mMrgB4 or 
mMrgB5 in newborn mouse DRG (11), these rat data prompted us to reexamine 
the coexpression of Mrgs in adult mouse DRG. These experiments revealed 
subtle differences between mouse and rat in the relative distribution of these 
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receptors. For example, in the rat, rMrgB4 and rMrgC are partially coexpressed; 
however, the mouse orthologs mark two nonoverlapping populations of murine 
DRG neurons (Fig. 9). Furthermore, unlike the rat, where rMrgD is coexpressed 
with rMrgA, mMrgD is not coexpressed with any mMrgA genes thus far examined 
in the adult mouse (Fig. 4B). Conversely, whereas rMrgC never overlaps with 
rMrgA in the rat, all mMrgC11 + cells coexpress mMrgA3 in mouse (although 
some mMrgA3 + cells are mMrgC11 –). We used the mMrgA3 probe as 
representative of the murine MrgA family, because it gave the strongest signal in 
adult mouse DRG tissue. However, these observations were confirmed by using 
mixed probes containing mMrgA1, mMrgA2, mMrgA3, and mMrgA4 (data not 
shown). These data therefore suggest that MrgA genes are always coexpressed 
with another Mrg, but that the companion gene differs in rat and mouse (Fig. 4B).  
 
DISCUSSION 
 Expression of the Mrg family of GPCRs revealed a previously 
unanticipated degree of molecular diversity among murine nociceptive sensory 
neurons (11). Humans, in contrast, express a smaller number of related genes 
(12). On the one hand, Mrg diversity in mice could reflect aspects of sensory 
physiology and/or neuronal connectivity that are generic to rodents but different 
from that in humans. On the other hand, it could reflect genomic expansion 
events that are an atypical feature of mice. In an effort to distinguish these 
possibilities, we characterized the complement of Mrgs expressed in two related 
rodent species. Surprisingly, our data suggest that rats and gerbils each have a 
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single MrgA and MrgC gene, and that these subfamilies underwent a relatively 
recent expansion in mice, primarily via local gene duplication events. However, 
like mice, rats and gerbils contain several MrgB genes and one MrgD gene. 
These and other findings suggest that Mrg diversity and function in rodents can 
be reduced to a core set of approximately four different genes, defining a 
comparable number of nociceptive neuron subtypes. These observations reduce 
the complexity of Mrg diversity in rodents to a level more closely approximating 
the limited Mrg diversity in humans.  
The Localized Expansion of Murine MrgA and MrgC Genes May Be 
Driven by Interspersed Retrotransposons and Nonhomologous 
Recombination Events. What mechanism(s) underlie the selective and 
localized expansion of the mMrgA and mMrgC subfamilies in mice? The high 
frequency of interspersed L1 retrotransposons in the mouse MrgA-C cluster 
(>40% L1 sequence) suggests that such repeats could have facilitated unequal 
crossover events that expanded these subfamilies (Fig. 5). Consistent with this 
idea, Mrgs are generally arranged in a head-to-tail (5′ to 3′) fashion. This gene 
arrangement, coupled with the fact that phylogenetically related genes are 
adjacent, strongly supports an unequal crossover mechanism for expansion (24, 
25, 35). However, such a mechanism by itself would not explain why a similar 
MrgA-C expansion did not occur in rat, because the rat also contains a similarly 
high frequency of L1 retrotransposons surrounding the rMrgA and rMrgC genes 
(≈48%). One possibility is that the expansion of the murine genes could be due to 
local L1 retrotransposition of the mMrg sequence, which seems unlikely, 
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however, because the average mMrgA transcriptional unit (first and second exon 
≈14 kb; Fig. 8) is significantly larger than the average length of extraneous DNA 
transposed by L1 elements (36).  
A more likely explanation is that expansion of the murine MrgA-C cluster 
was initiated by de novo L1 retrotransposition into the ancestral MrgA-C cluster 
during murine evolution, followed by unequal crossover with preexisting L1 
sequences to duplicate the ancestral mMrgA gene and create an (A-A-C) repeat 
(Fig. 5A) (37). Additional rounds of localized unequal crossover could have 
created the present day (A-A-C)n repeats, explaining why there are roughly twice 
as many mMrgAs (n = 22) as mMrgCs (n = 14) (11). Our observation that mouse 
MrgAs have L1 sequences at the 5′ and 3′ ends of their coding exons, but that rat 
MrgA has an L1 sequence only at the 5′ end of its coding exon, supports the idea 
that a unique retrotransposition event took place during murine evolution. 
Furthermore, the broader clustering of divergence times calculated for mMrgAs 
versus the more recent and compact clustering of divergence times for mMrgCs 
(Fig. 2) is consistent with the idea that the ancestral mMrgA duplicated first, 
followed by duplication of the (A-A-C) repeat. This model therefore takes into 
account the high level of ongoing retrotransposition as well as the large number 
of local gene family expansions observed in the mouse genome (10).  
Such an expansion mechanism could also explain, in principle, why all of 
the murine MrgC genes except mMrgC11 are pseudogenes, whereas numerous 
mMrgA sequences are maintained as expressed ORFs (11, 13). Because the 
initial (A-A-C) cluster contained the ancestral mMrgA gene, each additional 
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duplication of the (A-A-C) cluster should have included at least one expressed 
mMrgA. In contrast, the first exon of mMrgC11 is located at the boundary of the 
(A-A-C) cluster, thus transcriptional regulatory elements in the mMrgC11 gene 
could have been damaged or eliminated after additional duplications of the (A-A-
C) cluster. This would prevent duplicated mMrgCs from being expressed and 
thereby eliminate selection pressure to maintain functional genes. Consistent 
with this idea, mMrgC11 is the only mouse MrgC that encodes a functional and 
expressed receptor, is more similar to rMrgC than to any other mouse MrgC (Fig. 
6), and is located in the same “ancestral” chromosomal location as rMrgC (11, 
13).  
An unequal crossover mechanism could also account for why humans 
have MrgX genes rather than orthologs of rodent MrgAs, MrgBs, and MrgCs. 
After such nonhomologous meiotic recombination events, one homologous 
chromosome gains a gene (or genes), whereas the other loses a gene (or genes) 
(35). It is tempting to speculate that a nonreciprocal crossover event within a 
primordial MrgX-MrgB cluster yielded recombination products differentially 
preserved by unique selective pressures in the rodent and primate lineages (Fig. 
5B). In a similar fashion, red and green cone opsins, which arose from an 
unequal crossover event, were selectively maintained on the X chromosome of 
Old World primates, because trichromacy provides a selective advantage (3). 
Despite this nonorthologous conservation of coding sequence, members of the 
human MrgX subfamily and rodent MrgA, MrgB, and MrgC subfamilies are all 
expressed in nociceptive sensory neurons, supporting the idea that common 
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promoter and/or enhancer elements were preserved during the evolution of these 
families.  
The Functional Significance of mMrgA Sequence Diversity in Mice. 
Does the fact that mice express more MrgAs than rats or gerbils imply that this 
diversity has a physiological significance unique to mice? Our analysis indicates 
that most intact MrgA coding sequences are under neutral or weak negative 
selection pressure (K a/K s ≤ 1; Fig. 2), arguing against the idea that expansion of 
the mMrgA family was driven by positive selection for diversification of receptor 
coding sequences. However, this expansion could reflect positive selection for 
differential transcription of duplicated MrgA genes. Evidence for such selection, 
however, is difficult to glean from inspection of noncoding sequences, because 
calculations based on third-position changes do not apply. The relative 
conservation of coding sequences among the expanded family of mMrgAs, taken 
together with the fact that other rodent species examined retain a single MrgA 
gene, suggests that the various murine MrgA receptors may have similar or 
equivalent functions in vivo. In support of this view, both mMrgA1 and mMrgA4 
can be activated by related RF-amide neuropeptides (11).  
If the murine MrgAs have similar functions, the problem of Mrg diversity in 
mice would reduce to a core group of approximately four receptors (MrgA, MrgB, 
MrgC, and MrgD). In rats as in mice, these four receptors define a similar number 
of distinct neuronal subtypes (Fig. 4B). Because these receptors all are restricted 
to the GDNF-dependent subset of small-diameter nociceptive neurons in both 
rodent species, they are likely to play a conserved functional role in rodent 
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nociception. In humans, the related hMrgXs/SNSRs are also specifically 
expressed in subsets of small-diameter sensory neurons (12), although whether 
they are restricted to the GDNF-dependent subset is not yet clear. Furthermore, 
like mMrgAs and mMrgC11, these human receptors are activated by RF/Y-
(G)/amide-containing neuropeptides (11–13). Thus, despite the evolutionary 
divergence of the rodent MrgABC and human MrgX/SNSR subfamilies, some 
aspects of Mrg function in nociceptive neurons are likely to be conserved 
between these mammalian species. A better understanding of these conserved 
functions may aid in the development of Mrg-specific agonists or antagonists as 
novel pain therapeutics.  
Finally, although the mouse has been the mammalian genetic model of 
choice for humans, our results highlight the importance of comparing and 
analyzing additional rodent genomes before drawing evolutionary and functional 
inferences based on mouse–human differences in the size of particular gene 
families. This note of caution may be especially true for comparative studies of 
gene families, like the GPCRs, which have the potential to rapidly expand. 
Although such expansion may facilitate rapid functional adaptation and 
reproductive isolation (10, 24), it may also reflect genomic expansion events 
atypical of rodents, perhaps due to unique retrotransposition events occurring 
during evolution. Our data suggest that analysis of the completed rat genome 
may reveal additional instances of atypical expansions of murine gene families 
and argue for the sequencing of at least one additional rodent genome to serve 
as an outgroup for mouse–rat comparisons.  
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FIGURES 
 
Fig 1 
  
 
Fig. 1. Analysis of the rat and gerbil Mrg families. (A) Phylogenetic analysis of 
the rat Mrg family. The program clustalw was used to align rat MRG protein 
sequences and assemble them into a dendrogram by using the neighbor-joining 
method. The mouse formyl peptide receptor 1 (mFMLP) was used as the 
outgroup. Genes that fall into the B2, B4, and B8 subdivisions are bracketed. Ψ, 
predicted pseudogenes. (B) Southern blot analysis of rodent Mrgs. Each lane 
contains 9 μgof BglII digested liver genomic DNA from mouse (M), rat (R), or 
gerbil (G). Blots were probed and washed under high stringency conditions with 
the designated rat Mrg probes. For all lanes, no bands were visible below 1 kb. 
(C) Summary of rodent MrgA, MrgB, MrgC, and MrgD subfamilies based on data 
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obtained from Southern blots, degenerate PCR, and genomic analyses. For 
mouse and rat, the number of bands detected by Southern blotting is similar to 
the number of genes predicted from the draft genomic sequences. 
 
 
 
 
 
 
Fig 2 
 
Fig. 2. Pairwise synonymous (Ks) and nonsynonymous (Ka) nucleotide 
substitutions per 100 sites between mouse and rat Mrg subfamily members. 
Each point represents a single pairwise comparison between Mrgs of the mMrgA 
(green diamonds), mMrgB (dark blue squares), rMrgB (light blue triangles), or 
mMrgC (red circles) subfamily. The dashed line marks a Ka/Ks ratio of 1.0 or 
neutral selection. Points below the line are considered to be under negative 
selection (Ka/Ks ratio <1.0) and points above, under positive selection (Ka/Ks ratio 
>1.0). The scale at the top of the graph relates Ks values to evolutionary 
divergence time in MYA. a, The shaded bar marks the approximate time when 
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rats last shared a common ancestor with mice 20–41 MYA (21–23). B, The 
shaded bar indicates the approximate time when gerbils last shared a common 
ancestor with rats and mice 66 MYA (21, 22). C, The shaded bar indicates the 
approximate time when rodents and primates last shared a common ancestor 
75–115 MYA (21–23). 
 
Fig 3 
 
Fig. 3. Correlated expression and chromosomal localization of rodent Mrgs. (A) 
Expression analysis of rat Mrgs in adult trigeminal ganglia (gV). In situ 
hybridization was performed with antisense digoxigenin-labeled riboprobes. (B) 
Chromosomal arrangement of rat and mouse Mrgs. Analyses of the January 21, 
2003, assembly of the rat genome and the February 24, 2003 (National Center 
for Biotechnology Information mouse build 30), assembly of the mouse genome 
revealed that most of the Mrg family members were located within two discrete 
regions of rat chromosome 1 and mouse chromosome 7. These two regions 
encompass the MrgABC cluster (760 kb in size from rat assembly NW_043369; 
1.2 Mb in size from mouse assemblies NT_039420-NT_039423) and the 
MrgDEFG cluster (1.9 Mb in size from rat assemblies NW_043404-NW_043405; 
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1.6 Mb in size from mouse assembly NT_039437). The circle marks the relative 
position of the centromere. Triangles denote the direction of transcription and 
indicate the relative position of each gene on the chromosome. This figure is not 
drawn to scale. Brackets indicate the location of the three MrgB subdivisions. 
Several of the mouse A-A-C repeats are also highlighted. The mouse A-C cluster 
begins with MrgA6 and ends with a misassembled fragment of MrgC11. We did 
not plot all of the mMrgA and mMrgC genes because of obvious inaccuracies in 
the mouse assembly. 
 
Fig 4 
  
Fig. 4. Analysis of Mrg expression in adult rat and mouse DRG neurons. (A) 
Coexpression of rat Mrgs with various sensory neuron markers. With the 
exception of IB4, all gene combinations were detected by double-label in situ 
hybridization (ISH) with the indicated antisense cRNA probe. Fluorescein-
conjugated G. simplicifolia IB4-lectin was applied to sections after the ISH 
procedure to detect IB4-binding cells. (B) Summary of the rat and mouse Mrg 
expression domains in adult DRG sensory neurons. The sizes of the circles in 
the Venn diagrams are proportional to the sizes of the cell populations. Our 
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results of double-label ISH among mMrgAs, mMrgB4, mMrgC11, mMrgD, and 
several nociceptive sensory neuron markers are also indicated (11, 13). 
 
Fig 5 
 
Fig. 5. Possible mechanisms for Mrg expansion. (A) Idealized mechanism for the 
expansion of the mouse MrgA and MrgC (-A-C-) gene cluster. First, an L1 
retrotransposon inserts into the 3′ end of the ancestral murine MrgA gene (L1*). 
At a later date, an unequal crossover event occurs between this new L1* and 
preexisting intergenic L1 sequences, creating the initial (A-A-C) repeat. Last, 
additional rounds of unequal crossover take place due to the large amount of 
homologous L1 sequence in the local genomic environment. (B)An unequal 
crossover event could explain why rodent and primate Mrg families are related 
but not orthologous. Assume that the common ancestor of primates and rodents 
contained single MrgX and MrgB genes. Unequal crossover could resolve into -
X-B-B- and -X-containing chromosomes. In the rodent lineage, the -X-gene may 
have evolved into MrgA and MrgC genes, because they appear to be more 
closely related to human MrgXs than to rodent MrgBs (Fig. 6 and ref. 11). In 
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humans, the -X-gene likely underwent additional rounds of unequal crossover to 
create the clustered MrgX/SNSR subfamily. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The End : ) 
